var title_f29_15_29936="Triple phase CT HCC diagnosis";
var content_f29_15_29936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Triple phase CT scanning of hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 127px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAB/AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwhmI6Z6A9hViw+ytPm/kYQIpOxDlpD2UHtn17U2yjhmuokmlSGE/fkwTgDrgdz6e9JP8AvZiYUKR9FAXGRjr9fWkSV3fc+5dqAngBScCrGmW4uryGJ3aNJGCl9v3QT1x3qWw0ya9WV40cwwKGmkLfLGM4GT2z0FfQvwP8A6Nb6FB4o1SNZpjukhEv+rhVSRv56njOT0ppAaug+FPD3gfwwdUfRr7Vbhl3KZoAJTkHop+4PrXjevfED+17x1t9G0TT4nlJXdF5jLz3PT68V2Hxi+Lo1qCfRPDDOLBvlnu8EGYei+i/XrXnngzwRq3ii4QW0UyWe/ZJc7flXP8AOnfsN+Q7w34tbw7qS3dlDBNOrYCrart9xk844HTFdDefEXxh4ovI4LPT4WnjzJGIrYF4z13DdnB969k8H/DfRPD0OFsxdz53G4nAZuvTHQfhXbQ6fBFIZEjiTIILIqjj0z6UWGj5NuvCvjnVbpI76z1K4mkfP76Qtgk9T2FaLfBzxUBHmOxDucbTJyM+tfVKsxZXkXbu5CZFQyrG6MWVBkfwjOKLAfJPivwJ4m0xHvLvTozaRIFaazVTGAvGT3z6nFcRg4XIc/8AAgPWvuL5xEYtm5WX7sgByvHXPWvONa+EngSEzXdxPLpsRznzJgI1Zs7QCfftmiwbHzK8u9ixVFJH94AfkKYZOmDH+AJr0j4l/DSfwY+nSQX3220vMqJViC7Wx079c5FYb+C5/sKzJO0sr52Irj5sDJPB4AwaVgucqk8inKs2f9lPb3pQ7A7juyDnlgKS6tms52guojFMmNySZyPqKiBXoqjp2Wga8j0PwXrV3HpXk6P58eoRODJPHdsoWMkAKEyQxJ9h7mvYdEs5vHfgWWW21WG+vGlaO5gvbcCLA6IFHMZ6EODzXz34Q1ybRbi6dEkYSxFCEOxvwPb/AAqfwx4q1jwtrI1HTrh4nY/PHI2Y5R6Mvf8ApTQPzLPjbwJrnhzUJRdabOtty6PFiSMJ/vgduOuK5zFjLpxyFt72Dn5nytwpP6MPyI9+v1b4J+IGi/EXS5tNuEEF+8ZWa0Z871xyyHuP1FeIfFvwJLoGpT3dhaGPTt2MIMqnTGCTk5/TmgR5jn7uNg+i5r2/9kX/AJKNqB7f2XJ/Dj/lrFXkM9mtxpv2u33b4SFuYgcBBwFcex5z7/WvXv2RgB8R9SAI/wCQZJ3z/wAtY6AM39phiPi5qAycfZoP/QK8rLZHGP516j+04f8Ai7uodMi3t/f+CvKgN5HBPbk4FITJEJOM5ZsdzUqrheGGPYYFMGV+VTn1Kj+tWLOzlupRHCm5iO/OPegRFAJJ5UjgXe7cBVGc10SeCtUa2EsuxRjOGOMexrsvBngm8W1MtzOlijgkuUzIV7f7opNd1JdJR7Se8N3D/BEBzjvkinYDiD4U1RWAjhU7u6nNXLfwPfyJ5lxNDEvfJJP6Ct221BpDCuj2Mju6/wDLRiAnbBqYaR4m1OdoZLlLK3AyTEMZ9s0CMCbwrYWbkXmsQoRxhV5/WqLw+HoHZUlur1s8FFxn866iH4ayG7BuLwSRnktySTW/o3wntJy8janOiKcAIBmiw7M89utMiSza4iszGi43LJLk+3AFHhtbm8vWjsTHbkKSW8sYxjpXa+LPBOuTXbW41CKaCPG3Me1jx+prh7fQNci1cwWNtcNdxnIZMkH+lArHSTajbaNCq3CxXgDASRMoDqT3Wr9te+H9QiaRbSIkYyGjANcZr+g65a3M0uq2k8bBgruRhQSMjkVSGhX8Nv57Ws3l9dwU/wA6Auej2EmkrdCOKxthGrYJKrk56kA1p+JbPws9kFlKrIwwGWPp+VeaeEH2X6Fly56ZHTFemahfWsNk5k6Feijr+NMaeh5jd6Cpikl0qZLpE+8irhgPUZ61z7KBIQwBPp1Ir0vwRrehzGfS9XREdpcwTNgde24dDVrxl8Pn86S706XeCNxXA5/EfzpWFbqeUFs4yuAfXApVKgHaNx/2Vp11bSQTOkiCNlJBGMkVGDuHUn1yf6CkB9u/AX/kkPh7j/llJ/6Nevi68YfbJ8kDErjk57mvs/4A/wDJHvDvT/UydP8Arq9fFl5n7XcHcf8AWt6f3qBshLcNyT0PAp8KPJ93KqByxwBTraFZWDSFjEOuD94+gqw43FcRjA7AHFArjoljRfus5z1dsfoKvabp93fSMlnDv7nYDgfjVzw3od1fzxf6O8iMwwqJgt+J7e9evW2lX+jWiER2MaHhYlHCjHU+tNAlc8jPh3VYdrPayYwQSqg0230LVbiTENpOTnvgcV3o1y0kvLkS3MgZVOPLOFbHXHoaWDVryW2ebTNPnkRRhXkJ/kKB2OXh8D6rK2JBBFwDh5Mn9PpU0vg1LVS99qlpGO3y+ldJP4d8WazapJNcR20bjIiiGD+NQQ/C69lt1luL7Ep6qcn9aY7GBb6NpDTCG3vLm5l5AMUIA/M1n61pr6LemC80+VG4YGaQAEHnPFeq+GfB+p+FIrqayTTL+SZADHcggpg9Qa4fx3pfiCZpNT1gLNuYAmMhlT0A56UAzT8GeG7vX7O1nWz06HT9zKs7rubK8nI71ZvtL0Wy1afTtXsbeK7QBvk/1cinoVPaua8O+K9Y0zQrrTLaMTQyggMVy0ORztwfSuake4uHBlnmdhxlnyeO1AHozeF/DrfOMJ6Yk6iptL8M+HtRuHijgVAAPnYn5h7CuFh1C9igWNLq52cjbkgfma6rwfMZruQTySSNjqzk4/GkAzxL4GsYAzabcQB148t2Hf8ArXC3Fgllc+Rqts+wEn92oVgD3UnIP0Nel+MLW0tLB7xIV3L1YsQx/Grw8MafrHh2JrCXzYpIwwEjbtrY6A9V57U0B4PfQC3nZFYSRkBlYYAI9/f1FU3IHZBkdzXa6toE+i3TLqFms9sflYDnj2PY1yV/CIJysbZjzlWKgEj3HrRYdysjLnqnpwuaKXIXGX5+tFAyc7jgfvD+OK1/DGg3mv6rbWFlGjTy55dvlVQMliewAqpYWNxqFzBb2sfmTSsqIgBOSa9TNnb/AA00yeXULZZdfuYPJgid8gq332ZR/CMAAH71SiBniuPQ9D0JdA07VbSO2hKz3bKu+a9k6gKAOAM5GTis/wAY/E+41bw3YaBoyS2enRQLFOFQKZCO3sP51yvh7w9q/irVHh023e5nHzyHeAEXpk9gPavbfDvws0nSkhl1O1+2SqoWZHBdc85YD06c09x7nl/wu8FxeLdRk+3XLxWkBHmIrASPnOMD045NfSei2Fj4f0SO0s/3NtENisq4ySeSfc+vrXlXg62g8I/FK+0+98pI7lg0CogWPB5A9scjg17JJFI8rEFdpU8gk46ZyO/pTQ0kXFlG5ABImDyN3UelOmVcM5UJuyBk8fl71XVRIUY58xMgybCcBvr26VKUJXALbsHGSOAOlAyOGZ9oMrDkHBA4Az/ngVYt2/dk7Wwv3SQeR9TVWOSRUMYYL6mTBJ74yOMdfel3749xeNpA5Efynbg9gTyfc0ASyLGZWV1IVRx82M5HU0kthZ6hYC1vLO2urQvuMciZ6Hg4Pp61Xt5pp3ljRWiaN9rZAyBjv7+30qQ3psrOechisKlizEAYHYe3HNAjxv8AaY10iXSNGtvI8mImeRQ2CrD5QCOwwTWR8LpTqDGCxdfMCgyKo3lU74PGCT27Y6mvOPHes3Wv+KdQ1C7kEkkkpAMK/IFBwNue2Ks/Di31K88Tpa6TdXVrLJDKXkicKwQISf1ApXAf8WXgPiuSOBgxjTEjJEBlzya4k5JHEp69WAqe7d/tMgmIMgYhtz5Oe9RAE8gL+CE0hk+kXa2OoQ3LwpIEJIV3yCccZHpWrqXiFb22eI2Fkm9cbwhLrg8bT2rB2EcncB7KBQGA65xk9XApgS2d7cWd1HcWk08U8bbkeP5SpHcGvVm+IieMfDWoWXiSOGPWIYlksZwRGkjLywf3I7dD0ryHcSRwnP1NLgnHBz7JQBtarYSWNtbalYSgWd6jIWVuVb+OMgdsEEZ7H2r1n9lC3aH4jXjbleOXSHZSqkf8tYwRz3BGK4Xwotvq3hu40l4ZnuFcybVcZ5HEijttxhvUGvRP2UZXh8dapYXES+ZHYu6sW+ZP3kYYfQ/KfwoYjmf2m8f8Ld1DkZ+zQf8AoFeXJ8qgkckd+K9S/aYBb4v6goJ/49oD/wCOV5jBDLc3CxQISzHaoA7UhMm0+0mvrhbe3TLucAdQPcmvWvAWkWUU7rlHS3AMsjD77+g9hXICSDwvpYwyy6hcKc45IHt6Cs3Rr/VZbjd586WxPzKvAb2x3poR6T428U+Unk2ru391RxuPuP6Vyfh/SNR1i7muZZxCrDa/OWIJ6VYtrO+GuWk17GFimyijgkcd/Q131ukUSKEiCqP7oxT3Dcj0/TIbCMpbIuByxBzk+5rSCheGO4nnrio0YhwQAQOGHp71aQeY4yfkPG4rgUyyZIDKn7gZlbISPsSBnJPYDqSeBVm2mW2nMljNLNEYwrmaPYC/favXA45J5qG3lcWTWkaRqoJknkXO6cA5CtnsPQcHvRG5lJIICjl2PagB16TLcFxknG44HtUuj3BguGYgDI5OOvtVa8mRziMnGemOox1qKXeI42jAIj5OBkL/AProGdVqFvDqNhLG6LIpGdh+bvnp+FY2u2Mdzo0yLGgLIcDAHarNhdlkAU7EccYPIpxGzT7pOu1WwSOvFMR8xw3R0++dlzhWIxwK6zU7R9W0tJ7fiUgMcfyFcPckfa5iFGNx68d66W28Rpp9snlhnOMcEmoMjkb61ntJWWZHBBxzn+lej/CzxoYZE0XW5C9rIdtvM55jb+6c/wAJ/SuYvvGU90dk9tAIDwyEA5FYWowwxyRS2qsscqlgP7pz6mjYadj134i+DxcQSXtpDh0OGKrkD2P1rx2aMxMVfIIOMZx/Ku50H4l6hbaDc6JqTLcW8wASduZE9AT3X9ay/FdiNkeoQJtVwBLyBhvXPvQxs+tPgFj/AIU/4dx08qT/ANGvXxZPG0moTIoILSsOQB/Ea+0/gHn/AIU94ezyfJk/9GvXxr5TLNdSHdl3dUOO2ef8KQMdJtG1F4Rc7QT+v410HhfQxeI1/fEixhPOM5kPoKq+HdEl1W6Qsjraofnf+grY1jxWsNxFYaPawyCPCqvVQwPbHWmJHrekQQaLoyTsiLI6BioIG0dh7AV514u8S3eqzmzspHYE4LLx+A9BUF9q2sX1oIXSSWQLl/KQsErs/hzounyaLDfSwRPdsSCzA8MD6Uyt9EQeD/BD7UudYRVkUDbGoGCPevQreBI0VIlCp2UKABT0fkFRkdKkBxg8gj2plJWFUKFxkDHTLE0eXjryfQLn8aRgAmUbOTwc4p6N03EFiPUmgY/LMhGznHJwBVS6tIbq3MVzHHJEw5RyCKsrgoS4O08Djqaaz7ACchfoBmkITTbGwt7dUt7a3hXuI1x/Ss240Swg1J50tIA0qgEiLOCD1/Wo4r64ack7VjZvk+fBAq48xeVG+8B6nIFAjzf4raVFHZJcIiqFbHyjaTn6Vx3hXUEtrhQI8OxCjaDx+Zr0H4zS7NDtVGNskoJzkDpXl+hFRexH5fvjHUgc0CNv4kLqLR+Wm5oNob5en51xPh7xHqPh6/We0mO0H5oZHJRx6EV7PquraZHYqb0xsoH3QuWb2A7V5dq50XVriQ2sRsJgcJ/dbP8Ae9KAPYNMudL8Z+HftUEStExKyRvjdG/cH1ryXxR4ej0i8kt7lS1pNwkgUZhbsc9/T6e9ZfhXxNfeENVl8ry5ImOyeBmJVwD29D6GvUtf8Q6F4xsLWPTVIXZ5U5mjwyN1UnHH0IoGeDXELwTPG4wykg5YUVv6tpTxfaY5Fb7Vat8xxjfH6j1x/I+1FAHp/wCz1oAvfEb6pKm+HTowQWPAdhx+PWuW8eal/wAJZ8RNRulVriEy+TAq8llX5VA+p5/GvVYpE8AfBn7TDGsWp60qmOMHIQsmM8+i8n3NZ3wf8A3EH2XXdQBUSIZIojhsrjg89CT/AJ5peRNuh2nwu8Jf8Ivo++68kahOA8rKAqp6KMdcV1ksDS7iId/IbDMdoIzg/T2FK7ttX7ivIxKoSOR9Pb0qSGG4mYb2TAPKg/d9T9PbtVFbHK+LPC+m67ZxPrEUUdyhDK8LbCrZ7N1wSOnWtDSZzplnNFqUzyxW48yCeTJzHgdvUEHjvkVvSQqIlKhFjQbyzpnAz+Wayri1m2JL5Zlzw0OQOp5Ppn29KBkceq2NxYq1pcLdwE78gtknP3QOvXsfQ1Yt7m4umQ24/wBIHO502hVPXjPDe3PFYGsWt5dsRY/6O0eQbhSpES8cBejYPPPvirmh3kEVkttdyoLnzBFIzTEhj2ZeeM/3aQG75awxBGzMSR1HT1JwORn2p0rGQjY5JT5tucA+y/T+tSYYI284jkPzlAcMPbvj3qOeUxlgUcYYAFQAenUE/lgUAIw2gAgjackKSVP+971m+KrXXL7w7dWuiyWNvLMphH2tT9wghsH15HY1olpREylWDE72G4E4x3xzToITOrySuuSOFB6egI/rQB8vN8KdTnuXt7XUNGmuE4MQuSSD6ZIwT9KxNX8JeIfCmpQxyQmK7lBCm2wxUHggkV7lqnhjV08Uy6jYCaQoc2jLzAuR8xfHPBAGCOT7VQ8ZeLpdPfQZhHM88k8kN0gIRy/AG3tg56ng0hHzpcRTx3EkUmVdW+cZAwe/SoWII5fPP94mu9+Jegpo/iISrbXNrbXKB23RDcrHqCBwD04rhCzcgK/5haAIVVey56/wk1MV+UBEKH+IkDn6enFPhuZrd2aFlQuChLNng9ajMaAsCyHB4KqSD+dAxg7bn/DdSYQ475z3Jp6EgcBuD2UDvTXdvcder0COp+GF9DpnjvRbm4RPs4uBHJvQkbW+U/zr6c8HeFoPD3xluLmxjWOzvtKlZUX+F1mj3D6cjFfHSkgg/LuHI5Jr6y/Z48bT+Li1trBD6ppluVWYfL5sbFRkj1G0DNAHk37S4K/FrUGUncbe3HHYbK5zwnYLYabd6vexEpEvGR69Bn1Ndj8frb7V8Z7uIruDQW4Iz/sVb+LCp4e8D6T4dhVRc3bJLJjq2B8zfTJUD/dNCJPO9ItDrNzLqWrpJIrEJbxdA7f3R/sivT/DenadBFJ/ascqyOqrFdWwyLZhnIMf8SnIz34rF8KafDFaR+eAFgTZEcZBbqT9TXRxGQMFVgcjIwaY0h+oadLAYrh40ntd2IbqJt0TtzwD2OAeDgipEeKYhtjoFHORg5/wqYeatsbWWR40kdZZIg+EcjGCR0yMDkVq6pbRukU9v5KKPvsTt49h3oKKEUIkXdbgNx0JxitK205mhjuJyqqTyDxjHt68VPbWENjpS3EkLXUhy3J6d8Cql7qMuqRp+5ECRnAjc8j3NMZcvJrDziB5rFxtypwMelUXkt/JEcETJGeWAbr7GoHs5haC735QDJbpgd6fb6dfNGki2F2YpATFKsLFW6fj+OMUAQ4iff5eQq4wMdabMsgs5tjOEwM/nVu4sLyF1NxZ3EUTkIC0TKM46ZP0NOSWKK1ki2hiflIJByf8aBGGviOLTY1jmRghYDeOg9Oadq3imf8Asy8jsrUtPsKHc/C8dR61XaGyuWkjKsgYHHf+dc9qclvaq2y5A3LsYA857H3pCbZ5PIHNywIXeT06k+taX9mCbT5HkuY45VOPLeQDH1FAsZXl85rl0jDEuQvIHfpViGGO6vZBZ6ZFLJ94JHuY47sM9aRmcyYXDOCpUqcEKOn41rQ2Rn8PSz4JaBxgsc8HrTtUl8qRoC7PChGNwCspIzzj8q3fDRjbQb2BXUBlPIXr+dIZxHQkZJ+nAruPAgn12O40YRecwiZ41Bydo6gfTrXEuFDHOD9Tmuv+FeuReHvGljeXR2W7boHkxjyw4xux7cGgZ9c/BG3a1+FWhwSZ3RxyKc/9dXr5C+yvf6t5MSFQ0hQc52rk9a+4/DSQJoNuLQo0BDMpTlTliTj8Sa+YvhHo4n1m7vZYg0UW+RgRwTuwoz6Z5P0pg0YPinzNHFt4f0qIpeTqFbHVQx/mf5VveD/CMNsWjtGVp0+We7ZQRn+7H/jWbp7SeI/HOtaragtvlMNs3XaCMbv++R+teraZZrYWccEC4VAB0600NK5JaWkNvA0UEEcakYKgdTWf4egj0mSewUFELtJHx94Ht9a24wN4O0k4OfyprQrIoOxWycc9qZY9AFbPJbvz2qTAVirAe2T+tMtLS8knjiGxV7uwO7b61avprKxf7O/my3LfcBXjpQFxEVUV1LKvQjjP6UhOVUYkIOMcYqC1AT724ljyxPOafPktyRgADGetIBr4L5c5ZfujdwKjmKtuDYx25zUhVRnbg4/2KifduIc7F7sRjFAjm9RlNleyXDK7dNuOcfh2oTxhZW8ayXIuUU9xCcA+laWoyKSgQSFMYLsRk/hVUwWtzANpjYnqM8igRwPxJ1w6xFaCBJFtkBYBhyx9favPUlkWY+WWLdBtxxXb+PHea4+zWawhrdcvlsDB7gD865u0n8i2nigaNbgctLImAx5+7x9KBGDrV/LJL5S7lRRhsscsfeqWkoXud4C7F5JIz3revD57C6vPLi8xPMWRI+XIwCpz19KqRt59xlUaL5+UUBQPw7UDQnjTTjYawWQEJPGJB8oHUc1l6TqNxpl6lzCxJX7yseGHcH2rt/idEHsdLmG3ATaMtyRivOMDp8pP0JoGeq6uINT0231zTxvaNcSoM8xkYZT9ASKK3PgfDbax4L1zSXVTcLIZVIHzqCnB9xkEfjRQSdN45sr7xF4t8LaEMy2kNsty4GAGUdTjoOFxz617BHH5cEccKiJAMKg5Cisvw9pSWVw13dyLNqdyiiRl/hjHKgDsP61suv7zJaUr1I4A/HNMZVmjEaKEwjFgN7EYH+fSkyrGQYJY5xkYJ/yfWpMCTcX5HzDpx+XWnoiRxsm6QjggHt9KBkCJNN+8k37sg7Sd2D6jHGKWVyWY5XAyG8sfwjqD69e1WFMO/HmAOMkLu6+prB1bVrWzf5nKkkKqgbQzegPvkdemaAOA+I+sXWl+JrKxsYRdPO5le1clEUcbW3DHUqTg1PqOoNMsWpRR4jhcPmQbH2HrjbxwQfy5roPsltd3wu7qKO6uHH7qYgPsbpkn+6P8cVmeIPC914khltbgzWMLSA74c7mAGDlj2PpjPFICDTPFM8OmardXHnXFjCxe2WFCpaAnO4c7j1PXGK29L8XeHNUMX2K9iJIEnlFcMmTg5U8Zzzgcgc0W3gnSE0eXSoFaO2aMLI5kKyyhefmPpnseKwNc+Fmg6mYpbWRrOVlyGgGNwAxgA/ePTnvQB0Ota+um4eC4gNqComlLgqi9iSOQ5xwDx615hf8Axle11GQaZCXgDZUsx+c5ydwx/wDqrz/x3pmseG9Yk0nULp5Ix++jIPysG79evGD9K5cbto3SkNnpkCkK57/qPxSmu4YbPT2Q3cifvLi3BKZJ5QBiDn3rS1b4YQ6vp994h8QajeSagts0ixROqJHtXKg4HbHNeT+AopLAxXc119mjvJDGkowzqF5JHHTOBxzzX07qWkjxZ4NSyN48EV3HH50sQyXUY3Lz0zigDzP4g6euufDiz1O68gXU9vEWAcFPMA4+cZ9+M896+eNQjw6StcI00gzKixkNG2cYbPfvX11eeCtJ0PRrq20pJobaZkLwGUugx1Kqf4j+tfNvxOtYrPxJJFbiKKF0Vj5cm7J6ZJIzn1HrQBxRByc+aeh6YpvIXpjnnc9SzLCWyhcjA4Yk/rTNmN+I8DP92gZGJCAwzH9OTTc56E9ey09gfXHPPIFNdck/OeoP3qBDgTkffOfU4r3v9kXefFWsqcBUs93XJyXUf0rwIIu0fKSfoTX09+yNpVvHp+s6qAwuJJBb46AIoDfzNNgYfxdtRcfGvU2YkBLSAgj12Vy0EOpat4quL3W90piQQRGQZGwYwV9OP5123xShkPxi1WZMhRbW6k5x/BUVmgwzY5XjOOtJCtcjjhKR4CoABgKO4+tAiddzI+0A465FTMSrADlCBweMU1F5OFx9OmKYxY3BJJwp6kHuK0LVXfY4i+THy7s4AqC3tR522RxGD3IyPrWzY3EcMQjlZVJ+8GOePamMj0vWnsbuK3ufmiZxuAPC54zXcXOnWk0EkkiRoxjKmRQOBXJaNpVlqGqtdXaZgRsLuPDN7itDxnrGNNksdMZPPkXyweojToTx39KAIpxbiFoLe73BPl27cEjHQ1m28ECwMyuSBkBSThSSM4HQZxWPi9EMQluUaRFwzmPG76/402C7urd2WRFkibAPODx7UDN1IvNQBg208gljgnHpn9ayJmUK5lO08n2UVjan47ghBjjtbiWYExqCDnd6e5rhtS1bXZLyS8EMywHG5WXOB7+g4pXJckdZrs0sJQ2sgzMuwbXBJz7V5/rtpfQOZJ0ZT7CvQPDEA8Q38NzcwxQT/eRApG0dvzHOa9Du9Asrmzmt5olxIMb8cqe9FhWvqfNk032fS7ZWQEzu7uxzwvQD+dGl/aYtRWVp/LjgGd6HnHXAHpXXeMPCs2nzJp48vaoaSJ3OEZeSVJPAPpXEwaWxZ/NuEBHCx+YCWP4dqRBs29zaahot6kkUS3s7hi+AuAOnT361l6TL9gvGikIkAyrEAlar6SjQ3aoyKmxzvJHK8VV84vcGTuxzyaQFW6Hl3Ei8ABiOD/hTFPBwCT154qzqpP2phkAbQRtGBVdBuOAMk9OM0ij7q+CjmT4UeHmJyTbHJznPzNXhl1fXOgeDr3T9NBa71JhBlByCxOf0JFe9/CPTLjR/hnoFjeDFxFbZcehYlsfhmvJdItd9wjMuCrHHPTn8qpFWLfgvw5BomlxRBFEm3LEHqe5zW/tw5ODnpyCRVojCYHGOlRSfMcn9DVFIRioXILcnoe1JgHqGwPfmkA6EnHYk96lij25zwc9MUAxsc8tjcfaExheOWJ49PpW7YPY67btLsV5EO1hj5l4rnbklhKGwQVwBkZyfStfwxoq6PC05mZppVzICfkUe/qaCWNvdO+yMhWRdhOBuYA1TnTCn5kUDqd2f8mqGtXd5qOukQQqdOjTZ5j9WbOcj0pnnX0QffbrtHZGGf1FIY+adgpLOR/dA60vmGeJmbkYAGV7Vn3V7FboJ7wywmT5QDnJ/LpXOaz4pAhlg0pJ5nAxJIEO1T6e1AM6C+W6Cr9jePfg/LIAOnoa891/Vb6WR4rGMOyjDSQAnB78+tXrLxZqahYr2xDkjajuhH/AsY5ABzxXT+FbCMae8zxojF+F2gD/9dAjxBpLm3uGaYSb2PzCY43fUHrTtWto21JLeNHkkZFkDluVBGTjHH4V7dr+g2GuRzpLEgnHG/gFT7V5Vrdg4umhlkWO8twIlUkKZlAwGU44/PrQIm0GOO4Wz06a3hLqpbJJ/dtgnqexrDn0tLbN1AdyMAWVBxuzyeayZjctKYoUljZnyS7EYHqePTOavaV/yDpllZj5asgYE7WHUfWgZt+JrqLUfB6MVJeB1II7Z45rzZgM9Rn6k12WlEyaZfQN9zymYgLzxzXHknIyTznvigDo/hvqd1pni2ya0mki84mGQJkblbjB9qKzPDCyP4k0xIVLym5QALkk8iilYD7ZstPS38T3F282Xu7SHZHjGwRjB59TmtKTCDDZJIyf73/6qqT3Kf2/bWrfeFiJuTjjdjj/PpVtpm35XaH54J4Ge5pgUzHlEG5tgxtVPlJznqfwqNoDNKZS7Q4XaV3DjvVyQ5LmWRAMdAcqO2fc1IvlgFfmyBkcDcT64/wAaYzDfSri6jaK4CJbvuA2y7iw5wc4zk1JaaVD5IjkUMseDFuG788/StaEpB8xHylskq2Onr60IoLM8qKm48Eknce30oC5TgsorcMkSJEXOT5UQG7nuPap5C0YMRlKyLn5m5znvinSEhSGlPGdwIznPY/rVC8M/k5jVyR0JXJJ7Z5xj2/WkAw4SYIkiNs5YshB57Z96dakNlpVY3JzvGFUsOxA54A4yK5i5upGkL3VyeASm/wD1eWPfjIYDPBrQ0zVbS50N9Qu3UWse/MrqVA2nnrzjjpQM8Q/aBnt5vFVtEhR5LW38mQKN5U7iwHtwRXmC53cJJjOThQK7yfQNU8ZXWs+I4kFvbSSySx7w7lwM8Lj0wBRpXw01a+s1neWOItjC+WXwMc5OeCPTqaViS7pOoxTW0U8UwtSqiGJ7tgwyBknAGD3wD3xX094WwfDmmkFjm3QktwTx1NfGurabe+Gb1Ql9DOepa1IYIQcYb0Nei+EvGFxfXSXlxdTRSeQbe5mLH92gx8zKODnoG4weuaEB7h4svLO5jmsBqCwXQTJUckjrx+VfPHxdsVa2sdRSaJ5HDKyKQpPowGOmMAkGu+s/DXn2iXD3bQMz74CoZ8gnIzk8E8D+lcf8UrIpFFBZ2E0juAhdYyxhXHCAdcnGSehoA8ebcRycY9ZP8KYACDu2nPsT2rptO8Ha5fykJYXUca8vJKnlhfz6/QV3ej/C20tZ421ee5vCuGaG2j+UKOTuOc+2MUAeXpoGpnTft4sZxaHkSeWBkeoB5xz1rMYOvZhx3YCvqLxLJYWWgyyxRpDBDEVUfNGduPlXjnj0NfMtyQ0rlMhT0ASgCrjghtvX+8TX0V+yPrey/wBY0Jgzbo/tkZH3VwVVh9Tlfyr54PGc+Yfq2K9w/ZM2f8J5qfAD/wBntjkk48yOmB3finQpdY+LmvbJUjRLSAndyCdgx/Ouct22z3ERjYyxyEMN3QjrXQeINZt9M+Pt9Bey+Xb3lpDCSeisVBUn8Rj8ax9W2HXNRlt/mjeZnAHHWhAh8UPnOZrkGONRnCY4H09at2rWTFi6y7VAwuMDH4VQRDlQ2NvHLf4VJBOkUpMaKSONx7fSmM3rCTSGhljlgRZOoeUFsAdh/hWHqttAs7NHKZg3zHIxj6D/ABpsoJk8xid3Xr0FP3R7VG0jPTqcdgTjpyQBmgBLaXyQro+WGMkdqLiTzJjKrfM53fKvWggqCGOAuccZzVzSreO61G0hncJA0g8wjrj29OaBiW0kkoZJVaSMcuyj7g+v9KoTxt9pO1t23kFcHj/GvY7XSbOzt2t4IVWBjkp1ryLWbiy0+S7ljV1gikcqFOe/AH40Cvc891dVGtS3dpJMZI2PzRjAhcDGST61nWFxeahfBbmVVt2cGSDjaT0wR3zW7FopuooDfGV5ncyFC5Cxg84/D1q5feFoSRdWrG3lQcuqFkOPXHf3pWIs2dp4XsTHGJmkyQNq8DgfXrWtcyNOYjDEAPNDGTeB8vTI+tcj4B19hNdafqbRqYwGSUkeWVPHDf411C39lJLhJYlJXEeTxn0plrUreKdLh1jSLq3mVWYruHHIr5mv7d7LUJ4Y2IaKTAKjtX0RrniW0s7aU3bY2jAUHk14JqDSarq80kMblpXJCgFj+QpMmRSe4Yx7SiI7j527tUmm6Rf6rIyafazXDIMny14H412Phz4aa3qhjeeI2duSCWk4Yj6da910nSItF02G1tEWKGMBSFGC3ufU0rCSPlXWbN4Yi0qGO5hby3Qgk4rKtmIkVnB+Ug/Mcd69F+KksMmr6gqkBjNtwOASK4G3i3Sqq5JZgOnrUtAfoH4NvYtQ8J6ZdwH93NAGHNeWnS5NNvLeSQ74pjkZ6KfT9a774UJ5fw40ZB2hYf8Aj7Vy+o3EV54f0u7idWDyowGc4wNrfqKtFIHP3uMnPHFIwQMMSYyueQQM03fvGT6dDxQ43H5sAdPXNUUPUxFQGbK9CR2+lN1GAKzrZ3A2EBssM4/CnDp8o6EHp2pZChOVUhSOBnvQIx0tWkuhJI8jeh9MenpWqGaSHy5JJGHoxxikPykfdOCenYU3KlsEjg5570gBcr8pGV4+Vjmnyxrg7VjHHI5OPcZpLeNbhnDZJXAAHU/WrF/DHawROpCuzbSAfvdePrQBzfie3huNDuEllEe4DY542sDx+tedXV1c6VphtbWaT7NcSEymVeDJ03rnqDiu68ZXMo/s+2tFieeWfcVmG5Qi9WI9Af1rEXSYLu2uk1CWa9nmIG+Q42kdCMdBz06UhMseCbO6vbL7XczRy3WQBIMbwn90e3Tiu3NvFDZIrPHk4IAAHT1xXnmj3N14Wby7r95pzEDzlPK8/wAQ/rXWanqUAjVoplO7gLv5GOfwzSAmjVmeWWVsyMQp2DkAe1eYfGO2i860ulIWQja2F5PPevRnkuR5LeSRGR82VyQT64ryn4iXk2q6slna20hVScDB+ZvagDkINUvIyo86R1xggqM49yafJcXV5KsUMTAMSFiiAHPsBXTaJ8PNb1Nd8sSWcYz8055x9K9V8G+CrPw8POVhNesuDMwxj1CjtTA8f0jR76wkdNRs5bUXEbojSg85Bwa88njMUrK20FSQcLmvqTx/HEdMhaQ4KTrg59/evmbWGWTULl88NKWHzZ70bgdn8BXt0+JenfaiekgiLAYEmw4J/Wiue8CRu/ii1MRCtHukyB0wpooEz6e8PeJl8SXug6pb28kK+XLZYlwSw2Kxb6DbXdcMiq5OWH3lGNvevHbzUbHTNIsb7QVV7TSr6GS5ZcAtHMhPbsN2Oa9a+0pPD5kDbo8fKwf5Tn0xTGTy7UjILnIU5BfaE9zSW/lKvzgGTGdx7++awDqIkumhZY3ReeCSQCOM8dOO9b1oyuivjJP4D1/GgbJUjBIldVBU/KoHH6da4eTxhe6D47m0vxfZR2ml6i4TSNRjbdCXwAYpScbWJ5GfXGT1ruA2SS+4ZBwQNuPwrJ17TbbWrG4068hSaG4jaNlkAfGRw3PHHXJ9KBGnksx3MEC9ckfLVDUXWCFmiDj5ThCm45+ueO/51i+AfDtz4Z0M6b/bE2rWqztJb3U8eZFVuShOSHAOTu96t+M7eWbw5qLW3nu/kuVWJQSTjt0z9KQHiWt+P7SO+vfL06UiVjh3fYztnsF4wOMd+5JpsWjeKfFECy6m/wDZGhLH8wnfbujHfaSMn3OBzXJeCr3zfiBpM1+nn7rpVbfHncScck++Pyru/i5q93qOr6f4a0qJbiUurTxRMd0jk/LG5PJ/+vSEPuviRoek2q6fpVnNeRxAReYqBIii9MKe/XnH512EWtHWtI024hRrSKaNZGSQA7xyPmYY444A7msDTvgVNfvLd67fRWUsnzLaWaFkjP8AdJOOB04/OrUsF58PNKjstdkkuNESVzaXNnD5iJu/gkVuRg8g896LMdzM1PStF1SDVYdfVdLumRvs17nYN6gko4AAIPBAOT6GvPbXwfdJodxqUVypgkh3xrbZl8zHJDgHjvxzVnx14ttNRtRY6P57WvcyQ42gdlBPAzzXP6Hq2tx2l1pmji5ZLsbpI4kBZgBzjuOM9KAPZfg7q7ar4eSCSeRpLEiMxcgqvO1h6ivQI4oiiGAQxDafnaLLYzyMnkcetfNHgHxNP4S15Xmd4rWQhLleGYD1APcV9MWGpw3kCTwuCsyhuWG5uOCvqKAG3FqFgJkYeWAP9Uv3QPSqbsFtUkdPNtiud0bKyZz1IPfpnjArTziCOSERmQ/xt/CfXH9KztXX7Zo10jNC1x5LMpiBVd4XOc9V6f0oA82+MGrvb6UtrC5UXLfPHlSDgA7kI7Z4Oa8MlOW+Ynnrlq0dZvp726Mtwysx9CT+lZfAHAH4JTAaTGOu09PU17t+ylG9t8QNThnieKZtMLFWQqQPMj65+tc/8FPBtnqRuvEniMEaJpoLbXGFldeTkd1H6nArt/gLq51740+IdVZBH9qspWVAfuqJIgox9AKAML45lv8Ahc96EHz/AGaArxxkJmtfT5jeEyqmwyAFl67T3xWF8erk23xquJMbtsNvxjr8lS+GtRMtpFIQ6MuVbPVfwpIXU6SOMEybmAkxwTSCHbHvRYzjk7uop8TDazDG5wQPc1YLvJarH9n254BzVFFZUZ8nB65Oeg47/wCFauiNPHcMIEWSORDHNE4yk6f3W7g+hHQ1UUx2mWB86Q9FxlVPrnvV3S7uZ9QgZ2AUHAT1HrQBE1rHDDFKnnS2dwzrbyMBwVPzI4/vDpnocZFRkqh5cjPy7QDmtS1tYr6WWUxbAr7yFY4LYIyR0zjPX1qpqVkqRyGGZ96KcKw4+uaBk9/8R57CwjtWsi95MfJgcsTv7Fio7DqTXAX04tBHcapctKcFUt41zubPbnn+lZdneTz+PriOU5jt7fYoOSqjAP61ueEtEtvFN/d65qayPpdk4htolbb5z9z7CkQc7B4iu21+2hKRCzedI5iFOYgWAOSelfU1vawRWywwxosSrgKFGMV5W9lZG1liGj6b9iZtsiJHtbHsw5Jqv4t8U+JPBFjANPkg1DTZl/cSXC5kiHocdcU9gatuZ3xb0i1k8VRw2SxwzfZhNIiDAPJHQe2PyqP4SwxGz1PT7j99dwT53S8/KQMY/WvPrTXtSvr/AFHWrpJr+9dApXt1wMd8D0FN+HXiyWx8di4v38uC9/czcYCn+E/gaVxJnvF9oen3WDdWsBG3aSyjB/OoNN0K0t/MaztIIAfuvGgBP5CtBoTOX85xhfmAzw1aNuQ0CNhFwOgpljYLUIysT2ztAxVbV7iGxsZ55flSJS7H6VeaQYLZOB6nFeT/ABk8Tpbaa1jbSrvm+/zzihiueLeKLwXV48jDEjO0jH6mq3h2MS6rCxGY4zvY8nGOn61Ba2lzqupw2tnG81zcSCNFVeSTXsPiDw5png3w5b6VGUuNV4ur+cjngYVF9Bkk474zUkHv/wAIpRN8ONIcZwUkHPtIwrxPwlqMjCS2O7ZHIZEzyCScnFew/A07vhRoJ55jkPIx/wAtXrwnwpqEBMULN++LyIOeThiQKEUuh6s4JwoY4NHlYXbu4PoetQ2NwtzaK/Q9MDqKikvfJuRGVYgjBJP8qosvIg24LAewGalyNoVRjGeR3qOF/MUsq4z1z2qQbRjgsSetMQza4C5wAxzyajYAjII9xU7sGgQMCGVjyO4qswU8K2xeQMnrSAje5NhIJ/KMqn5SgHLHtgmsjxB4o+0XsVpptt5ktuS0qbgdjEcZPr1o8Uag2m6e9y8YdYo2fIzgnHBrjtC1NLXwi2oStGsjyOxJGS7knAz1NJiZo3F81vM090wmv3Xd5UbZKp2GT2q/4CuovEEl5I0DRCBhuVmzuJ+ntVXR/B0k2m+d4iuZIpLoiVYYE/eYPQMx6fSui0rSF0y883QFOIofLltZFCvKoOdwYdTzQBpXvh3SboEXEHlnaSskeRtPuO4rypdJa4VbkTMyqN6fOfnA6K2PTpXTeKfiJDHbXNpaWlxDeDMbNKMCMnv71wOkeIbyHRJLa1tHuZY5mi8wMWUZ5zxzmgR7dpl3HfWdvcRMFjkUHB9cdKkSBWkXbt3g9SOleffCnWHtlm0fVlkhmMhkh8wEbgeoya9JQhHDAquTSGCwZk3YPTHIqXGzOcA896fnkjqDntWH4o1iHRLZbifhWJVcdzigDifjDriW0EdqBllBbnBAJGBXz9MfmznH410njLX5td1Oa4kbgsQMjOADWTo2kXmu6nBYabC81zK2FUAAAd2J7ADkmmB0Pw2iEdxf377dkEW3k9zyf0FFdH4q0i18I6bNpNvdfaJ44/38q8BpmxuA74AxRQIZ4Ajy+7UedI1WM6dO/mElG42OfTDbOtel/DrXLrR7pvCPiQNHqVs+y23A4lTBxg9MccH0rxzw9qkvh+8uNO1W3LWjttuLaTgBgpAOB354PbrXtcGmWvi+1062utQkg8Q2UPmaZqKnY9xGB/EDydpxnv3HU0ISPQDaweeJDGolyrkLzk4xg9sYq9+8c7d4245Cpj8M9hXI+D/EN7NdT6R4itPsWtW+PlzxcL2eM9x6n3rrTKGWRywUA7flOB2JANMoVMK+QMIuDlhznHWqeo6hDaxCRmYAsEXJ4OfU9h65qcvEUCqrs2AT5Z6CvLfjh4kl0nRVtIDAtxOu0tIRuCnrtGM8+/pQB6rY3KTQHyWieVRyq8n278Vj+I/EVh4c0eW91i5hiyrKI2+8xx0Ud/8A69fINrr2p2cjS2l9cRSdCyM2Tz6n603WNZ1LWLkT6re3F1KPlDSEcD0HpU3Fc6j4dXemp4ou73VGt1EUM00KspI34JAHv6V6f+zlZDVNT13xHqIMt3uEaPIOVLfMx/IAV4IsEy2qXLsRFI5jQmTliAM8DtyK+0Ph94ctvC/hSxsLRRuZBLNJ13yMASc+lCBG9cz+TbvLHC85xlUjxuc9gM8VixXEPiO21XStQ0u5tFCCOSO5RSGVwcMpBIP9CKTxR4o0fRQLPVLswTzxllCxlyq8jcQO2ePerPhvXtN1q2ZNLlL/AGXbHKjqVdDjjIPtTGfHHi7w9feHNWmtL2J0QSOkUjRMBKqnG4Z7Vl6PqN1o+oQ3thPNDcR52ug2nB4Ir6y+MvhW18S+GLmT7O0mqWUTS2zRnDHH3l9wRXyBPtWQgqO/Uk0mCJby5lu7h7i4LPNJ8zMzAEn1roPC3jXU/DsgFtJFJbht5hlJYZ9j1X8K5ZckfKv5R/407cRjJYZHsO1AHu+mfF3TWt0N6k8c+35lRM4JPqevHY1zvjj4mNeQm10JTbxOpV5lXY7Ke3t9R615QzKc7myeOrk/ypMpt4VTx/dJoAfNNkZOOCOr+9RxfvpkjVkVmbGTk496sWNndX90trZQSTzyHCRxoCTX2lH8Fvh/GrhPD4G8bSTdzk49jv4/CgD5+8T+JbO68KxeGPC86xaRpkAknkcbGvZB94rnqASTjv8AhW3+yhFJL481S5AbyV09kJYj7xkQgfkDXtD/AAa8BPapbvoOYUYsoN5PkE9ed+a1/CngDwz4RuvP8O6Z9jldWRiJ5ZMg4J4diOqr/nNFwPmj9pMgfFW9ZM7lggDD6pwao6RfeXDHdQ73tmQecB/yzb1A796t/tHSeV8YL8ldyNbQK6+o2Vxui6m2kXK5xLaSjqO4/wAR6UIlnq2lXTSwDzI3g3EY3fxL2KnuD1rXMxYRq0meO3Oal8E+JdE1PR00rWCj2qjbBPjaYv8AZOOVx607VNJk0S4O9jcWL/PDdjlWHoSO9UUiuwwoDZVc5yOtSxS+TIkijJQgkkcVCJImjYRuu08jB61BcXUVrbedcGOJFBxuP+eaBm7pGp28UlyJZdkcjl1JP6VmeJdf07RdKmae+illm+aNFPzjPt6V474k8RS3eoStZzMIc/LjjiubdpZ5cMXeVzj5jkk0rkuR1HhrWo421bzVzc3al1P5/L+te5eE9EutD8E2OnzRE3q/vZF/h+Y5I9yBXlHg7w19m8R6FaQDz9UmnSWUBcrDGp3N+gr3268SINkDQG6ljufIcRjO5upVfcAjPvQgRzWqLdNqdjawrIkM8bB/KbBHH3se3H51e1TQ5NV0H+x5w3mgHY5GTnHUntWD4j0nX08RzRebcNJcybrQRkqhUcjAHTH6V29zdalZOsN1Awdbbb9p4+eQKCx9hnimVc+bnS/8HW+s208LR3iyrEhY/dBGc1wjzyyT+ZK2XY5JznNe0/EDwzfa1p9tf6PL599HHsurRzh2QElXwepwSPfjFeLTZjYxzI8bgkEYx+hqWQ1Y9b+H3xTl0+1Sx8Qb7i2TCJP1dPY+or13SvEWjanBm01CF1btuwfyr5PtlsyuXuWB9BGTUv21YE/0OSUN3YnAouFz6e8aeLdH0XRrhnvonuShEUcbZct0H0r5g1bVLnUrxprqV5Xx1PpTLey1HUWZ4be4nJPLKhI/Fulex/An4cabqniGYeKrZLwJatLFB5jAIwdBuJUjJ5PHTmi9wvc574ZD/hHIpdZksvP1eVClp5v3YF7vjux6Cs/xvqss7i3ZjJdzvuklLctn19819YP8OPCrli2lk56/6TMP/Z6zP+FN+A/tBnOhEzHnc15cE/rJRcdif4I7B8K9BER3IsTrn1IkbJ/PNfMvhmbNxewpt89JDLFnudxBFfYeg6PY6Bo8Gl6RB9nsbYFYo97PtBJJ5Yknknqa+I5bvbqMmo2YKvHM3noOiNuPP+61CEz1nTNft0ltVdyhnYx4ZeQ4GSp9D6etddCgdjgZUc59K8+8Mavpd7ceddWq3dpKAt3CeGXHIce47Ec16NPYfYYVvrK4N5o8i7wwO5ovc+q+/UVSKTLKg4A5AHqaViCqYIGOOTUaOGVWQhlwMHrn8aRiOw4z3pjHSTDyGAxuVsjFRSbpcGPDbj8wbgY71heMdUTTNNZ/NVZsZQE15BeeLtWmLiK7lijJPzA0ribsdz8WtYjisV023lBlkOGC87V9D6VU063t9Q1Hwpp9oBJaKRcSqvTA6k/jmvPbCyu9avTHAGkkIyzs3AHqTXs/wSsrK1i1Saf/AEgRyCzFw33QiqWYj2z/AEpCvc7S7IfUJgzFiBnKKcEdvyrP07UpprkTxKu2NzHKRlWUjBHHuK1/EN3DYaVdXdjC000JACdMBuNx74FYHgnWDJezW13aQJb+U0zzJn5MdSc56/8A6qBnD/GbS2t5/wC2LdEFscK4Iyc8kZrzz4d6qLPWbnz3ZUkQvgcAsMcfzr6M1+W0u9Ih0+OBJIL9njkDgZIPBI/2hkH1r5X1jT77w/rUtrco0N1buV5z27+4oYjpde8TXF9eAxjykQ5TBwR711vhf4pNDClvrimZQABKn3vxHevK49Rifabq0LMO8fy1oQ6/p1nHm20pWlH8U0mf0oGfQKeN/D7Q+c16UQ9N6MK8q+Knj2012KOy0pWaCNtzTMNpY9MAeleeavrd1qkjGZwkY+7FHwq+2KoJDJNKI4kd5HOAqgkk0gGuwbdgDr3Ne1fDX7F4O0O4uZEjm8S342Rx4yLaPH8RPc9cD0Fdb8B/hXoWoeGJb/xVpKT6ol6wjJnkXy0CRkKVVguc7j0PWvWh8O/CwcuNL+Y8k/aJf/iqLgz5I8UsL7U4rK3ldndjJOzjkHGWLHuepNFfUzfCLwQ0k0h0Vi8ylHb7ZcZIPX+OincR8dJdNqphjvJ4luI4xHHNKfvAdFY/yJ9MV0nh/wAVSadcW9n4gW4kit8rBNF8s9of70bdx7Hj0rh+nqeverDTXEkSxS5dUOELNkoPQe3tUk3Poa98QWPijwoia1cfJHj7HrsS4NtL288LzGTgZP3TnsRXI/8ACy/GPhhmt9cghu12lbed8bHxwHDrw4x7/WvNra91jwxdkwTG2lmhG5QQyyxsOjDkEEdjXQeFdch8yO1iRYZ5pNrW8iebZzg/wshyUPbIpjub2r/GjW720W3sre2s8Y3shZyTngj0/WvOdc1zUNZumuNSupriY92HT6V7Lpng3wn4k1Ga0g+2eHtehbEkFuxkiBB52k5/mPpVbWfgZ4inuFa31XT7xAuN0waM+wwAc/WnYNTxBicuCshz6sBTVUYPEYPu2e9egap8JvEmlhJtSjs7e3eURB/ND4J6cDmux8B+D/Ar2K3uqXN9dyqxQxSoUUMuMjCDnk+vSkCRyvwn+H2oeL9Qt7mVNmiW7gTS4xuxyUTPU+vpmvp7R9VnvfE2qWMUQh07TI44PnHzPKw3ZH+wFwM9zn0rnPCuoXk1optltbGygV4obGCPCbgeGLdfwpdem1aO7S7srKAWmqJFY3tz5uJYRuIDKvQ8MR+XHFPYqxt+LtCmv4n1HSFj/tdIfKTefklTOdhPIHfn3qt4ft7HwXo8tzrl5ZWl3eOJbiQvtjBxgIueSFHGfqe9QeCfBieE9RlNlqupT2ciFfstxIGRT13DjrWF4t0KDxl46eLVpyum6N5Srbxr/rXkUuS59MDGBQI7fXNatdHtl1O8vlWzYBURV3+cx5UJjkk+1eTeM/Bfhrxcsd/bXX/CN6tKuXtbpfKVm9wcc89VP4Vuan4OvL3xTDBFfyweGrCSOeCzDblWZecKD91Me/euu1nT4bi3MVxGbgk5jWXaVB7f/roGfIeseFdW02eYS2jTRRvsM0UgeM/RgcGs9tF1CK4jhksJ0ncZWMwsWYeoGMmvYvHXw9t7ZEmtX8iSa4WBY0Pykk8Hn6n0p1n4JuDqAluL6ezuonUCa3uGYk49T0/CkwR55ovw+8Vatg2ejXYQqfnkiES8dstiu7034KrZqJfFuuxWicn7PbHc7AdQCfb0Brtdb8Taho1kL7xLq91bxyEfZrC1Ub3AyMvKB364zXjHi3x1farmGAJbW+7dnBaUn1Lnnv0zTDUs+KdX0TSXa28IWq29vgq0krFppMjq5PIHHCjjuea+3K/PODTLi4097+SVY7ZSVDtyXYZ4AGTnr1wK/QykwPnrx18WNQ0j4vx/ZtSMfhXSby203ULfyCyTNKr+bMZNvy+UWiG3IJP419Bv95Pr/Q1nSeHtFksLyxk0jTmsr2Vp7q3a2QxzyEgl3XGGYkAknJyBV8IsYiSNQqLwFUYAGDwKQHxz+0uf+Ltah14trf8A9Arza3ujENjKJIWOWQ/zHoa9K/aXIHxbv+Af9HgH/jleWsvBDUEs27GR4Fe70yd8R8vGxw6D19x711GheK5Bbm2F1LaEnlQx8lvqvb6iuDs55YJVlgO0jv8A0NaMctpdn5x9mnJ+8oJjJ+nUfhTDY75LOwvpAzs0EsgJZRIcMPVSKpyeE7i8mMNgNUnYclIV84D6nIrnUn1PRdqSbDbtztJDKR9O1dV4Q+IU2hzSG1jaESYD7TuU/gaAOen8HX9vLLHcQ30Bj5bzrUpn2BJwTV/R/DOoRuXtoEtpF6z3J3Mv0UcZ+tehXPja/wDEkYt7mWB7UDd+6jKZPuDVSREYO7AiMnJ5NOw7Evghx4Rt76W1UXOqXQwbybO9B3AFaNp4jn0vR10/TJIv7XS4klilli3KkZ75/ibJNZ4iCplS3pyc/SkfYh3SfM0ecHuKB2Ox8M+NtRTwjq9xr7I2oWEZaKYKP3m4ELwPfA/GuK0DxXr1pp93das8+qCQFvstzJ0PbaR0+grP1WSXUbOWKxkMcDxh3J4Ei5yBj6iq0GuWUUaxEs0ny5O04JxzQItWLXU0smozq0V1cNwS20xx44QY7AdqNQ0+G7iO+3guJMcNMg/mKV9YtI/vNkYBOFP+FUrrxPp8OVffuPACpzQGhX0/wppsskUl1YwMp++qMw3fTniu70y28A6UqtD4c8yTHzG4xIFP1Y/0rzm78Yu67NNslJxgNKe30FYGrXWq3DINQuFhjfOFHQY9hSFdHp3jD4iWktq1ra+RFbA5W2t0GD7kjirn7N+sXerfEbUHlBW3GmSbQBwD5sX69a8SmOnWuceZeSDjn5EB/mf0r1r9lm8mu/iRqBlICLpUm1EGFUebD0FDYXuz6A+KepXej/DfxLqOmzmC9tbCWWGUAEo4UkHB4rzv4CeLde1XxBquleJdRurpzp1nqNqlx5EjKrr+8bzIgAAWIwjDcBj3z7Pe2ltf2c1pfW8NzazKUlhmQOjqeoZTwR7GqWh+HtF0BJU0LSNO0xJSDItnbJCHI6E7QM0ijSPRq/Ps3slpqk8kIDZkcOjH5XXJyDX6CHo1fnjfAm8uMZP71v8A0I0EyNizmDyrLpEpjlH/AC7u3z/RT/EP1rv/AAf8Rbm0ZoLiYQbjtZXj3RtxjDL2+oryAFh8x4Ocg55FdDHeWuphPtn+jXv3fORSySccbh1B9x+VNCTPSbjUNQ8zdo92ljv5ETNvgl/3W52n2NQahrHiOKFHuNQFkwJG2eEFGP8A10Axj64ri47m/wBDlMMoUxt96NiGRx6/5wa6nSPFNpJEiSeZGgUKYZF8xGH160xp3Ob1htT1Kffd3lrct6rcKQPwzVJdMKsqTz20IPYHeT9Aua9ptdR8I3Fsv9o+FLUgfeliRSufxw386rTWVjHcvc6TZw28GfkQDhR60BY4jTLDUPspstEtLiCGUgT3tyoRivcKvXFepWy6bpejaboej+dLaLcI15IBteUlhnk9s4z7DFZm2SRuChAHA9qVl8wFXUbX4bBoKSOguvFekeGtUubP7JcXgnmK3NwBlFz/AAjPUY6il8Qavp/gmK2g0OxhvJtSfzP303yheMDPpzwK5uC1jhsxDyyAkLnk49DWOLxr7XjHPGmyGIRxA84A7j0oA6bxP4hsDpKLDsGoykutkeTG5P3t3cA8g1zet241+0ii1qOO6lj4+0Y8t/zFadzb28l1HM6q0qLtVgOgPUUjxjqaAPNtS8D2EUirDdXCFjj5ojIo/GpdH+F7apctCmsW1tzgNNERu+nrXdzIkjoTlUQ5/wA/nWRqHiLTLJmiJklk9FUjH4mgRPa/CLwvp8Rl1zxK85XO5LXaufTHU1n3i+HNBuXl0m2FtGB8rSuXlb6k8jPoK5zUPFN3fObbToVt03YwuNx9yT3rKurBbQmbWpZNxGUhQ7nf056AfnQB9P8A7POqf2t4Nv7jZtA1F0A9R5UR/rWd4x1q91D4tS+Gr3xVP4V0i10pb6GSB4onvJWcgnzJVI2qB90defwP2Xplm8A6iY4Y4VGqSAKhJ/5ZRdSepr07W/D2i68IRrmkadqQhJMf2y2SbYfVdwOPwqWMn0d9+kWL/bBf7oEP2tQAJ/lH7wAcfN1445oq1FGkUSRxIqRoAqqowFA6ADsKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT images of a 74-year-old man with cirrhosis and a history of alcohol exposure. Panel A: Unenhanced scan of liver shows exophytic mass (arrow) in segment VII; panel B: Contrast-enhanced scan of the liver during late arterial phase shows the lesion more clearly and multiple additional enhancing masses suspicious for multifocal disease (arrows); panel C: contrast-enhanced scan during venous delayed phase of enhancement shows decrease in the contrast between lesion and adjacent liver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carinoma. Am J Roentgenol 2003; 180:441. Reprinted with permission from the American Journal of Roentgenology.&nbsp;Copyright &copy; 2003 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29936=[""].join("\n");
var outline_f29_15_29936=null;
var title_f29_15_29937="Femoral anteversion and in-toeing";
var content_f29_15_29937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65723&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Excessive femoral anteversion and in-toeing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In normal gait, the greater trochanter is positioned to allow the hip abductor muscles (the gluteus medius and minimus) to function most efficiently. In a child with normal femoral anteversion, where the greater trochanter is relatively laterally placed, this results in a normal, straight-ahead foot progression angle. In a child with increased femoral anteversion (left panel), the greater trochanter has to rotate to the more lateral position, resulting in an in-toed gait. When reminded by parents, a child with excessive femoral anteversion can walk with her feet straight ahead, but less efficiently because of the posterior position of the greater trochanter (right panel). As the child tires, she will tend to select a more efficient gait and rotate the greater trochanter more laterally, resulting in an increasingly in-toed gait.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29937=[""].join("\n");
var outline_f29_15_29937=null;
var title_f29_15_29938="Fluocinolone (otic): Pediatric drug information";
var content_f29_15_29938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluocinolone (otic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=see_link\">",
"    see \"Fluocinolone (otic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=see_link\">",
"    see \"Fluocinolone (otic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DermOtic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10501528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=see_link\">",
"      see \"Fluocinolone (otic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years and Adults: 5 drops into the affected ear twice daily for 1-2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8104372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oil, otic, as acetonide [drops]: 0.01% (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermOtic&reg;: 0.01% (20 mL) [contains peanut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10501525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of chronic eczematous external otitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fluocinolone may be confused with fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8106909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Acneiform eruptions, allergic contact dermatitis, burning, dryness, erythema, folliculitis, irritation, itching,  hypopigmentation, keratosis pilaris, miliaria, skin atrophy, striae",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Otic: Ear infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluocinolone or any component;",
"     <b>",
"      Note:",
"     </b>",
"     Contains peanut oil.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10503144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants and small children may be more susceptible to adrenal axis suppression from topical corticosteroid therapy; systemic effects may occur when used on large areas of the body, denuded areas, for prolonged periods of time, or with an occlusive dressing. Hypothalamic pituitary adrenal (HPA) axis suppression may occur; acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal or discontinuation should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Contains refined peanut oil; use with caution in patients with peanut hypersensitivity.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8104336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8104307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8104308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10501527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not well-defined topically; possesses anti-inflammatory, antiproliferative, and immunosuppressive properties",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10501529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     DermOtic&reg; is made with 48% refined peanut oil, NF (peanut protein is below 0.5 ppm)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15986 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29938=[""].join("\n");
var outline_f29_15_29938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097417\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501524\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501528\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104372\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097449\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501525\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097413\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106909\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501526\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503144\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299348\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104336\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104307\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104308\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501527\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501529\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/18/29987?source=related_link\">",
"      Fluocinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/32/3587?source=related_link\">",
"      Fluocinolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/9/23699?source=related_link\">",
"      Fluocinolone (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1220?source=related_link\">",
"      Fluocinolone (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/28/25029?source=related_link\">",
"      Fluocinolone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/16/5380?source=related_link\">",
"      Fluocinolone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/49/12052?source=related_link\">",
"      Fluocinolone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29939="Lactic acid with ammonium hydroxide: Pediatric drug information";
var content_f29_15_29939=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"64\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lactic acid with ammonium hydroxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19059?source=see_link\">",
"    see \"Lactic acid with ammonium hydroxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39875?source=see_link\">",
"    see \"Lactic acid with ammonium hydroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F186442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AmLactin&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-Hydrolac&trade; [OTC];",
"     </li>",
"     <li>",
"      Geri-Hydrolac&trade;-12 [OTC];",
"     </li>",
"     <li>",
"      Lac-Hydrin&reg;;",
"     </li>",
"     <li>",
"      Lac-Hydrin&reg; Five [OTC];",
"     </li>",
"     <li>",
"      LAClotion&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19059?source=see_link\">",
"      see \"Lactic acid with ammonium hydroxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adults: Topical: Apply twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F186430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: Lactic acid 12% with ammonium hydroxide (140 g, 280 g, 385 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AmLactin&reg;: Lactic acid 12% with ammonium hydroxide (140 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lac-Hydrin&reg;: Lactic acid 12% with ammonium hydroxide (280 g, 385 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: Lactic acid 12% with ammonium hydroxide (225 g, 400 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AmLactin&reg;, Lac-Hydrin&reg;, LAClotion&trade;: Lactic acid 12% with ammonium hydroxide (225 g, 400 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Hydrolac&trade;, Lac-Hydrin&reg; Five: Lactic acid 5% with ammonium hydroxide (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Hydrolac&trade;-12: Lactic acid 12% with ammonium hydroxide (120 mL, 240 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F186418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply a small amount to the affected area(s) and rub in thoroughly; avoid contact with eyes, lips, or mucous membranes; shake lotion well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical humectant used in the treatment of ichthyosis vulgaris, ichthyosis xerosis, and dry skin conditions",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F186455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dermatologic: Burning/stinging, dry skin, itching, rash (including erythema and irritation)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ammonium lactate, parabens, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution on face due to potential irritation, particularly in fair-skinned individuals",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F186427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F186437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lactic acid is a normal component in blood and tissues. Topical application in animals has not shown fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Physical examination of skin condition",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ammonium lactate is a formulation of lactic acid neutralized with ammonium hydroxide. Lactic acid is an alpha-hydroxy acid which increases hydration of the skin, decreases corneocyte adhesion, reduces excessive epidermal keratinization in hyperkeratotic conditions, and induces synthesis of mucopolysaccharides and collagen in photodamaged skin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Ichthyosis xerosis: 3-7 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability: 6%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39875?source=see_link\">",
"      see \"Lactic acid with ammonium hydroxide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact with eyes, lips, or mucous membranes; may cause stinging or burning when applied to skin with fissures, erosions, or abrasions. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. Do not use cosmetics or other skin care products on the treated skin area.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13280 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29939=[""].join("\n");
var outline_f29_15_29939=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059598\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059591\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186430\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186418\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059601\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059594\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059600\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186455\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059605\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059590\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059589\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299567\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221210\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186427\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F186437\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059597\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059588\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059603\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059604\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059596\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13280\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13280|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19059?source=related_link\">",
"      Lactic acid with ammonium hydroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39875?source=related_link\">",
"      Lactic acid with ammonium hydroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29940="Anagrelide: Patient drug information";
var content_f29_15_29940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Anagrelide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=see_link\">",
"     see \"Anagrelide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Agrylin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Agrylin&reg;;",
"     </li>",
"     <li>",
"      Dom-Anagrelide;",
"     </li>",
"     <li>",
"      Mylan-Anagrelide;",
"     </li>",
"     <li>",
"      PMS-Anagrelide;",
"     </li>",
"     <li>",
"      Sandoz-Anagrelide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691409",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower platelet count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to anagrelide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698359",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sunburn.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10932 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29940=[""].join("\n");
var outline_f29_15_29940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135406\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135407\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014557\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014556\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014561\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014562\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014564\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014559\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014560\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014565\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014566\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/19/6454?source=related_link\">",
"      Anagrelide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29941="Clofarabine: Pediatric drug information";
var content_f29_15_29941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clofarabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"    see \"Clofarabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/44/44740?source=see_link\">",
"    see \"Clofarabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Clolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16057714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clolar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antimetabolite (Purine Antagonist)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"      see \"Clofarabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider prophylactic corticosteroids (hydrocortisone 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1-3 to prevent signs/symptoms of capillary leak syndrome or SIRS); provide I.V. hydration, allopurinol, and alkalinize urine (to reduce the risk of tumor lysis syndrome/hyperuricemia); consider prophylactic antiemetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-21 years of age: 52 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily for 5 days of a 28 day cycle; repeat cycle every 2-6 weeks following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle (subsequent cycles may be administered when ANC &ge;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults: Refractory and/or relapsed hematologic malignancy (ALL, AML, MDS) in combination therapy: 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 5 days every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic toxicity: ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     lasting &ge;4 weeks: Reduce clofarabine dose by 25% for next cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nonhematologic toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clinically significant infection: Withhold treatment until infection is under control, then restart clofarabine at full dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 3 toxicity, excluding infection, nausea, and vomiting, and transient elevations in transaminases and bilirubin: Withhold treatment; may reinitiate clofarabine with a 25% dose reduction with resolution or return to baseline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade &ge;3 increase in creatinine or bilirubin: Discontinue clofarabine; may reinitiate with 25% dosage reduction when creatinine or bilirubin return to baseline and patient is stable; administer allopurinol for hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 4 toxicity (noninfectious): Discontinue clofarabine treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capillary leak or systemic inflammatory response syndrome (SIRS) signs/symptoms (eg, hypotension, tachycardia, tachypnea, pulmonary edema): Discontinue clofarabine; institute supportive measures",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clolar&reg;: 1 mg/mL (20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V. infusion: Filter clofarabine through a 0.2 &mu;m syringe filter and then further dilute dose with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS to a final concentration of 0.15-0.4 mg/mL; administer by I.V. infusion over 2 hours. Use appropriate precautions for handling and disposal of hazardous drugs.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3051225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Do not administer other medications through the same intravenous line.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store undiluted drug at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); diluted solution is stable for 24 hours at room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). To prevent drug incompatibilities, do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior treatment regimens (FDA approved in ages 1-21 years). Has been used for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Clofarabine may be confused with cladribine, clevidipine, cytarabine, nelarabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F153018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing, hyper-/hypotension, pericardial effusion, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, chills, fatigue, fever, headache, irritability, lethargy, mental status change, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Cellulitis, erythema, palmar-plantar erythrodysesthesia syndrome, pruritic rash, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, cecitis, clostridium colitis, diarrhea, gingival bleeding, mouth hemorrhage, mucosal inflammation, nausea, oral candidiasis, oral mucosal petechiae, pancreatitis, proctalgia, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, febrile neutropenia, leukopenia, lymphopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, bilirubin increased, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, limb pain, myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, pleural effusion, pneumonia, pulmonary edema, respiratory distress, respiratory tract infection, tachypnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Bacteremia, candidiasis, capillary leak syndrome, catheter-related infection, herpes simplex, herpes zoster, hypersensitivity, infection (including bacterial, fungal, viral), sepsis, septic shock, staphylococcus bacteremia, tumor lysis syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Bone marrow failure, dermatitis, gastrointestinal hemorrhage, hallucination, hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease),   hepatomegaly, hypokalemia, hypophosphatemia, left ventricular systolic function decreased, right ventricular pressure increased, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clofarabine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established with renal or hepatic impairment; use with caution. Avoid concomitant use of nephrotoxic or hepatotoxic drugs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May cause fetal harm when administered to a pregnant woman (women of childbearing potential should be advised to avoid becoming pregnant while on clofarabine). Bone marrow suppression (appears to be dose dependent and reversible) increases the risk of infection. Tumor lysis syndrome/hyperuricemia may occur as a result of leukemia treatment with clofarabine, usually occurring in the first treatment cycle; may lead to life-threatening acute renal failure; adequate hydration and prophylactic allopurinol throughout the 5 days of clofarabine treatment will reduce the risk/effects of tumor lysis syndrome; monitor closely. Cytokine release may develop into systemic inflammatory response syndrome (SIRS)/capillary leak syndrome and organ dysfunction. Prophylactic corticosteroids may prevent the signs/symptoms of cytokine release. Discontinue clofarabine (and consider use of diuretics, corticosteroids, and albumin) if SIRS, capillary leak syndrome, or hypotension occurs. If hypotension resolves without pharmacological intervention, clofarabine can be restarted at a lower dose. Transaminases and bilirubin may be increased during treatment; may require dosage modification or discontinuation of clofarabine. The risk for hepatotoxicity, including hepatic sinusoidal obstruction syndrome [SOS; formerly called veno-occlusive disease (VOD)], is increased in patients who have previously undergone a hematopoietic stem cell transplant.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects and resorptions were observed in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Women of childbearing potential should be advised to use effective contraception and avoid becoming pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal and hepatic function tests, blood pressure, cardiac function, respiratory status, CBC with differential, platelet count, uric acid, urine output, signs and symptoms of infection",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clofarabine, a purine nucleoside analog is metabolized to clofarabine 5'-triphosphate which competes with deoxyadenosine triphosphate for binding to ribonucleotide reductase and DNA polymerase. Clofarabine inhibits DNA synthesis, terminates DNA chain elongation, and inhibits DNA repair resulting in decreased cell replication and repair. Clofarabine disrupts the mitochondrial membrane which results in the release of proteins, cytochrome C and apoptosis-inducing factor leading to cell death.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 172 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 47%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Intracellularly by deoxycytidine kinase and mono- and di-phosphokinases to active metabolite clofarabine 5'-triphosphate; limited hepatic metabolism (0.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Children: 5.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 49% to 60% excreted in urine as unchanged drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: 28.8 L/hour/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/44/44740?source=see_link\">",
"      see \"Clofarabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Female patients of childbearing potential should avoid pregnancy during clofarabine therapy by using effective forms of contraception; avoid breast-feeding during treatment. Notify physician of signs of weakness, fatigue, pallor, shortness of breath, easy bruising, petechiae, purpura, fever, tachycardia, tachypnea, dyspnea, or hypotension.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Faderl S, Ravandi F, Huang X, et al, \"A Randomized Study of Clofarabine Versus Clofarabine Plus Low-Dose Cytarabine as Front-Line Therapy for Patients Aged 60 Years and Older With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 112(5):1638-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/15/29941/abstract-text/18565853/pubmed\" id=\"18565853\" target=\"_blank\">",
"        18565853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Gandhi V, Chan KW, et al, &ldquo;Clofarabine, a Novel Nucleoside Analog, Is Active in Pediatric Patients With Advanced Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2004, 103(3):784-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/15/29941/abstract-text/14551141/pubmed\" id=\"14551141\" target=\"_blank\">",
"        14551141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeha S, Gaynon PS, Razzouk BI, et al, \"Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(12):1917-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/15/29941/abstract-text/16622268/pubmed\" id=\"16622268\" target=\"_blank\">",
"        16622268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Gandhi V, Cortes J, et al, \"Phase 2 Clinical and Pharmacologic Study of Clofarabine in Patients With Refractory or Relapsed Acute Leukemia,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2003, 102(7):2379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/15/29941/abstract-text/12791647/pubmed\" id=\"12791647\" target=\"_blank\">",
"        12791647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12924 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29941=[""].join("\n");
var outline_f29_15_29941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152997\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057714\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046474\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046467\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152978\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152966\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046477\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3051225\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046469\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046476\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401601\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F153018\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046480\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046466\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046465\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299065\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152972\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152986\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046473\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046464\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046479\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046471\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=related_link\">",
"      Clofarabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/44/44740?source=related_link\">",
"      Clofarabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29942="Lymphedema stageII AB";
var content_f29_15_29942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Lymphedema stage II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 408px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGYAgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uoor7a+LHj6fwRHpqWGnjUbu5MkskW4jZbxLukfjpjIxnjrSbE2fEtFforFf2cmlLqbXMceneR9pNw5wixbd28n0xzXyd8avjJceNIptD0SH7L4bWUOWcfvbsqeGb0XPIX2BJ7BJ3FzdDxuipQQegwfanB8jDcHsaZRBRVsE5OaJAOvVaLgVKKlZSMnHFMpgNoqeFS7bR17V7F4ABGi26tjeFw351hWreyV7XOijQ9r1seLUV9NpBmbO08r1pwhCRsHQHac5xXP9e/u/ibPBW+1+B8xUV9MXUPBKjgiqTWyqg469aX17+7+JSwF/tfh/wT50or3LxXexabpU08hIAGFA/iJ6CvHGv5ZJnknxIXPOe3pXRRruqm7GFahGk0ub8ChRXWaZ4m1KyjaGCfYjgEAnjH61bgmfVRJNfz+RpsR3TSrkKPZf7zHsP6U3VlHdfiQqafU4iiun1jxNJdXCx2EfkWMPywRnrj1b1NYk88s7F5nLscgZOfrVwlJr3lYzkktmU6KsKCg5ZcenevcvgF8UNWt9dt/DmqXEl/Y3AIt2mOXjYAkKGPJBAIAPQ4xROfIua2grHgtFfo8pDxpIudrqGGfQ0hpqdyOY/OKiv0abpXzj+1918J/9vf8A7Rqk7gnc+c6K734Gf8lT0T/tv/6Ikr6B+IPi+58MXGjQ2y6cpv3kRpr6Vo4otig5JUHrnHT0rKdVxlypG0YXV7nyDRX2l8PfEc3inw6NSnto7dvOeL91JvSQKcblJAOD710ynJIGMeprJ4mzs0WqN1dM+B6K++MHBA6etHrxS+t+Q/q/mfA9FffJHUjp715V8Vx/xU9gv/Tp/wCzmh4u3QuGF5na58t0V9MaX8iDgeldPaLyO/rSWLv9k1+o/wB78D5Aor7Vg+baMjOavoAe/aq+teRP1L+9+B8N0V90iIKMDPrxTWSVSnlqhXPzFj0Ht70/rPkH1L+9+B8MUV9ySIFwR3/Wm+VvXI4xyD3Bo+s+QfUv7x8O0V+g3h/W/MkW21Jikx4jkHR/r6GuplK78OA3qa6IyUldHHODg7SPzQor9MEwCCoII96g1O2NwFkiIWVR+BqiLn5rUV+iiyqs4VwUl7gjqKnfHUNj61TiSpn5yUV+jqdBzUwcthN2EHXHc+lKwcx+blFfpSucYVdvvWhZJGi+awXavUt8xP09KGrAp3PzGor9OpX89gIY22r0IFVJ5Y4IWlnkWOJOWZjgCgfMfmhRX6A6rq8moy+XblorIdSeGkPv6D2qOFAFAwAB6VyTxSTslc7YYSUo3k7HwFRX6DYGQKzdSJ8tgOc8GhYm/Qf1TzPguivv74j60/hrwsb2IATzW620Sr3lP3fyyT+FYPhXShofh6zsn5nVd8zf3pG5b/D8KqtiPZS5bXMaVH2kea58P0V933Ddcda+EKdGt7W+mwqtL2dtQr7n8SfDbSPFHiaTVtfe5uk+yCzitkleFYlySxyjAknccg8V8MV+kKqWOB1NbMwkeHfGcDwL8CrLwtDqMl1dXkyWUJfCyyQIxdsAdh+7T6EDvXhukeALu7jWXULgWoYZEUa7mH19K9U+JupQeJvizdzRky2Hh+1js4cnKPM2WZx+ZHvtBosF3EE85rx8djpU3y0n8z1svwcZx56iueY6z8Nrq1s5LnT7n7R5a7jE67WI9jXAHJFfVNrGCQCMjoR2r518faU2jeL9StTHsj80yRehRuRj86rLcZOs3Co7sMfhoU0pwVjDV9o5AOCCM9+a9i/aI8DWfhfWNO1XQrVbbRdViB8qP7kUwAJC+gYEED2NeNYJU/nX2PqmmxfE79nmy+ygS3q2Mc0BHUXMK7WX8SrL/wACr1rHJRjzxlE+PH47ZHeonG046jqKnzvQ5+8OoNR7cqV9OVoOcfYSLFewO/3A43fTNeteGGawvfKfiNjkV46a9n0EjUtEsbgEF2iXJ9GHB/lXHjFomd2BerR6LGqsiuhGMflTd4w2evtVPQ7jzLBQx+YcfQ1CJmkc46hiOuK8u9j0eW5ZkbdCRkhfpWZK4S3dicYrQjz5bKwBJPFZXiCRbHTXmkIUAHGeAOKN3YpKyPIfHutPqWoG2jz9mtjg+798/Tp+dcttJFbfhzX5tM1OOaQJNasHW5t5F3Jco2dwYepBwD2OCMYrFPCAZ5r3acOSPKjwak+eTkx8Ejow2k8HoKs397PdhIpJP3MfKrnjPr9ahijIQHHJrtvgz4Xi8VfEPTbG7j8yxgzd3KHoyJ0U+xYqD7Gq0vcIJyaiupx91ZXNo0UdzbTQCaNZ4/NQoXjP3XGeoPY96qOdz8HgcV6R+0PO8vxh8RmRs+W0MKDsoEKDA9qf4A+GUurQRajrxkt7BsNHAvEkw9T/AHV/U+3Wsq1aFCPNNmkaEqk3CHQ81T7wC5J/2Rk1dthdrKstv9rSWM7leMMGUjuCOhr6a0/QNN0qARadZQW6AY+ROT9SeT+NMubcKSCMn2FeTPOF0h+J6EcsVtZfgee+AvjZ4m8NzQWut3D6vpa4VoboYnjX1Rzyfo2fwr6i8Oa7p/iPSodQ0mdZYJVDD1H1H6V4NqemWd1GY7u2jmjPZ1zVfwVqN18PfEVqltIZPDd9OImSQ5NpK3AOf7jHAOfr9dKGYRqO1rPt/l5nNicudKPNF3PpMivm/wDa/AB8J/8Ab3/7Rr6MtJ0u7WOePIV+x6g9xXzr+2F18Jf9vf8A7Rr1otPVHmrc8s+Boz8UtF/7b/8AoiSvo/xb4UbxFeaXdwahJY3Gnu7xOkSScsoByrgjoPTvXzj8C/8AkqeiY/6b/wDoiSvrSM4GcYwa5MS2pprsdtFXi7mN4K8NQ+GbK7iiuJbia6uWuriaVVUySNgEhVACjgcCt9TxjoaYjhm5yD15p0nDe9czbbuzdRtoTH7vJppIOPyNIBkdKc3B4zQFhuPl57V5b8V1/wCKo03PezH/AKGa9UI4IxxXl3xYUjxFpbdmtWH5Mf8AGplsa0fiRnaXgsueVrqbIYRnIPHIrmtJT5FTHua6ezQMoz93NOJ0s07VQQCB+FX4cqTheKrRgIAzkAHpV9SGHIPHpVEjxyMc5pzR8+xFPRdw9xU+DsycZ6VQmUZI1LDrj0FKsYDgAED3q0VDDPpSKoHXkUxFCeBXBVl4rW0XXDbOtpqLlo+iTk9PZv8AGojFuHX6VDLbhh8ygj3qoTcHdEVKcaqtI7qBu4YEHmrYRWViP5V53ZazcaSQkiG4tB2/iQe3qPau70fVrLUbJZrKZZO2MYZT6EdjXbCpGex5dSjKm9dijqdmLiP5htcHKkdQa546nPbahFZTW0jvJny5UxtbHUH0OK7m8gPlDI56EVyuuIINs2B8h3ZPatYvoznknuiZ71wqQW8JNy/DFuAi9ySP0rUjACjkcdh0FZcFyPJTZHhXGR5eOfc0l5qdvZIrXkyWwJwDKcA/Sn8O4rOVrG2pXGe3qakjeCJC9ywWMDLM52qo9a56HX9NL7W1G1YAZ3KSf6Vzut6lJrFxgbksEP7uIjBf/bYevoO31rCpXjBXTudFHDTnK1rHT6t4utv9TpKPclRjeSVjH9TXNXUtzfyiS/mMhB+VQMKn0H9arQREYP8AD2FX44ycZGExXn1K0577Hq06EKeqWoJHtPIBB7VaRSFwR8tNjj+YFsmpuQnPNZotjVJI5OcVQvGHmRqejOoOPrWgVGDg445qrYxiXW7FNgcGYEqe4HNa01eSRlUdotk3x003zvh/dzQgGWweG7iPoFYA/oazorgXlrb3SEbJ41k4/wBoZrvPFVl/anhzV9Oxu+0WksafUqcfrivJvh1cvd+CtLZzmSOMwt9UJH8sVrjY2mn3RzYR3g12f5m7KQFz36V8H193SKQxwPfNfCNVg/tE4roFffHxH8Qp4c8MzTF2WacMqlPvKgGXI9+ij3YV8D19i/EKKXxN8QrPRojm3s13sp/jKFTt+hd1z/1zrTFzcYWW70/r5GNCCnUV9lqeUaRFcxLfPfgC7ub2SSRV6LwoCj2A4rqdPQ7QcZFZV6S+qXG7kCR8Y7jccfpit3Slyg4r5vEvmkfQ4fSBs2cXAOPwrkvjB4U/tzw7/aVpHnUdOUthRzJF1YfUdR+NdtZr61qxp6YI9PWooTlRmpx6DqxVSLi+p8XqeRivbPgT8YbTwVYSaBr9pcSaXLOZku4G3NbbgAQU7rxng568HNcf8YPCH/CM+IPtFlGV0q+JkhwOI2/ij/qPb6VxFlC1ze28MZUPLIIwWOACTjk19ZSqKpFTj1PnpKVCbXVH2H45+Hfhzx1okt9p0VmL24j32mqWowH7qWxwwP3TkZHPevkbV9Mu9I1C4sNSha2vrdykkb9VI/mD1B717F8EfFWpfD7xuPC3iiOW10zUHEflz/dglPCyKehVjwSOOQe1eh/tN+E7K78HTa0lug1CxZCJQMMYy2GQnuOcjPTHHWtV7ys90b1Eq0PaLc+S3AI3Dr3FeofDq0uZ/DIuLaYgRzshQjjsf615lgDDgZQ8GvZvgykieEpzLt8uS6Zox3xtAJ/MVxY3+Hp3HgHar8jf0d5Y/NWQFeNwFW4nSG7kEgO1iGU/X/Iq4YFMb4HPPPpULW5kgHHzDjPqK8aUnHc9myZckCLNCY+d/XivM/jjqhiFjpMLYLKZpQPToB+PP5V1niLUbjStDnu4mi82FflaYEovI5IHJrw7xJr1z4i1H7dqAUzlQnyDChR0AH412YGk6kvaPZHDjaqpx9mt2ZkaZB9as6Tp82qatZ6fa7ftF1OlvHuOBvdgoz7ZNReYEHEfbqTXafBGwGofFfwvBIMgXf2g/wDbNTIP/Qa9g8iCvJI950f9nDw1apGNZ1fVb+cAbxAVgjJ9hgnH413Wi+HPCPw/Ly2cFlo+nxJuuLq4l+aQ54DSOcnvhfyFducbtxr5O/at1d7zxpZ6PHIWisbTzmjU9JXOeR6hAp+hpnpT5aUOaK1Mjwvpg+IPxA1rxZqkROmNePKkT/8ALRicoh9lXGfwr2f8Mf0rC8GaUuh+GtO09Vw0cQaXHeRuWP5mtZpMjbkCvm8XVdabfToduHp+zj5vccxJzjvVeaLIOanUenNOdcKciuBxOlXMC7jIrFv7eK8s7myuB+5uEMbZ7Z6H6g4P4V014nXbgn3rAvhjI6fSs4twldFSjzRsz1f4UahPeeHYo7s5uFiRn/3x8jn8SufxryX9sL/mUv8At7/9o13/AMK9RHnwRsR8263Y+/3l/wAK4H9sPr4S/wC3v/2jX1WCnz00fLV4clVo8t+BX/JVdD7/AOv/APRElfW4Xk4xg+tfJHwJGfirof8A23/9ESV9dqMfhRiF7xvQ+EYUyckn6Uo+6N3OO9OySTjBwacUz19OlczR0ApGADkE9qeFBYd6iZMMc9PWli+YHr06+tSBJ9BXmfxeTGoaLIRx5cq5/EH+temj7yjjJrz34xofI0ST/prKn5hT/SlLYul8aOb0picYzj1711VhLyAoyCec1yelt8yEniunsiFwxBzQjqZvWy5UEgkD1rQgOFI7VnWZyByfWtSAZ960RLJox04x7VYwMCoQnzg5JFTqvJ4yfWqEIIwFOMCmkHONtTFPlO7rnio3BCgdqBDVYdGGPagkfd7elIxKsOOajzkg4x7Uhkciq42kDNYV/Hd6bcLeaVK8FwnOU6N7EdxW1ISCT296ikG9eR1pXaegWTVmavh/4jQT232bxDbSWl0nSeNS0cpP6qfrx70vxD1yXQfDd1qtzYGSKJ1jMSSDflmC59O+a4nWIlUuDjp2roPG7nXPhDLPP8zvFayt7srqp/8AQa6adZyTv0OGth4xlG2zdjJtPHFxNYRrp1gluAAPMuPnYfRRx+pqjJHNdXDXF1I8s7/xuckD29Ko6XEEijyMqK24lLuAB25rklVnU1kzupUIUl7qJbK3CkMMcjpWnFFuHTp0pkMaxkHaAxGPwq9EMrg4wDUmjYQx/IKuxLhOetQxA8seOelWUPHeghisuTg9PanEjAHWjOeKNwAySDQSRSfzqLSEMviOxwOEZ3P4Kf8AGnSk7cepq74RjWXxJlmx5Nu7Y7ckD/Gt6C99HPiP4bOxi4kQ4714j4HhNlc+JdJHH2HVZQq/7LdP5V7YAQSD2ryGWP7B8XfFNqPlS8t4b1R6nAB/UmunHRvGL8zjwT1lH+v61NN+GyRz3r4Nr70dcudxxx1r4LrPB9TTFdAr7Cs7sS6t4hv8hbmKIujhuoZpW/PLr+Qr49r6hsB8uqKp2ttiBx3zGlZZhNw5X6lYOPNzfI564x/aL89MD9K6HSjuOOK5q4ONRm5J+bFdJo+A/wBa8Kqj2qfwnUWq7AM4FaSL8vHX1NUrUAqB+laUAGzjgepqUgZz/jHQbfxJoNzpl7hRJ80cn/POQfdYf19ia+T9Rs7rSNTntLpDFdW0hVgexB6ivs64TKnjtmvFPjl4WF1ajXbNP9JgAW5A/ij7N9R/L6V6WX4n2c/Zy2f5nFjaHtI863X5He3+l6d468EWY1WPcXhWSKdf9ZAxUHKn0z1HQ1c1LW7nXPhfq2k6xiXXNLtmiusj5blBG3lzr6hgOfRgwrD+C18L/wADWcTH5o1aI/8AASQP0rWMYTxTYxSZ8m/D6bMOzLIDtz9GA/M+tfQ9UzyMNNxlydGeH6d4A1PxR4Oj8QeE7aO6W0jMGo2cb/vRImTvVf4gU2nA5znip/Avi5bSDTtLFgNyFlEscuSwLZO5cc4yTxXpH7JNzJpvifxRoFyR5yBXwORujco2P++hXI/tD+DpPBnjhdb0UNb2OoOZkaM48mfqyj0B+8B7kdBUVqUakLM6oOVNKrD5noud2DwVbjNSiMKnUDHf8q4jwJ41tddto7S5Kwaqp5ixhZPUp/8AE9u2R07yEEoCMfieOlfPVoOnLlkevSqRqx5os89+LbmDw9NFg4kKL6c7ga8YWIljkYA6kV618a5/ktrUEZZw5GeuAa8oTgyA8D+letgo8tFHj46XNWZEULMM9O1en/s6y2Vh8RZNZ1e5jtNO0mymnluJPupkBAPcneQAOSelY/w++Hmt+M7yB7Ozmj0fzlS41BxtjVc8hSfvN7DPPXFe3/HPwdb2fg3wz4S8G2FvZwXOomRwON2yI/vJX6tgN1OewHYV2qLtdmUIOK9p2Kniv9or7Rc/2d8P9FkubqVvLiu74feOcZSIHnjkFiPcVQ0vwksWi61qniG5/tPxLqMbNeXb/N5eeqJ/IkemBgVq+B/A+l+FrU+Qv2rUnXbNeyLyfVUH8K/qe5rZvbMJp9/GnCywOoX3welFrpmE60pNNszZLsLCGz1HXPalsGMx3HOD0rj9M1NdVtLB7diVnjViO4x1B/Hj8K73SLUmNcKcd6+XqRadmfRwkmrotRQkkcHjpUwhG3OavQWxxjPenzQkrxxxWfIXznN3sY6nrXM6mhAbI5rsr+FxyygVzGppjhhz71z1I2ZtCQzwTdtbahOF6psnX6qw/wAaoftiMH/4RF1+6wu2H4+RS+HW2eIUQdHR1P0xn+lUv2qZDLongGQnJaC5yfoIBXt5VLRxPBzKNqtzzn4Ef8lV0P8A7b/+iJK+u1+YYFfIfwL/AOSqaJyB/r+T/wBcJK+uBnOQeMc11Yl2miKC90n6cnA7U5eVwfwqPLA8emDTlJUgj0/Kuds3sNUZG35jt9etCqUY4JIJ4B7U7kNnp2zT1BzUjH4Aw3cjHFcL8YIi3huxkA5S9HP1RhXd47g1yfxTiD+CrhjjMc0Tj/vrH9aUth0/iR5xpe4j69K6/TFOzYw6VyWlHcFxnjGa7G1HmbO2MUQOyRtwKuVwORV+PIAyfes6EMrbelaUK4AGOT1NaIgtRgtzirCk7uuMdarxsM9amRgWIzk9elUIm5AxnP1pjNkY7jnPanEbeelNJO3kYNAiu5Dc55qFyRmpXxuPPGagcH5snjHApFETlmXg9qY7bV56CgnyjjPXnAqK6bEZ56ioYzn9dmCrKWPQZrfe7s7T4YR6ZeXEUd3c2UckUDthpN0meB3xmuP1sPdyR2kRPm3Mqwrjrljip/iZdRjxpHbRkFbC0jhGOxPzY/LFOEuWEp/IzqR55wh8/uJ7MhmCjpiti3QE7ueecVh6XmRBtOMjuOlbducLsPJHBJ71nHY6GatsNz7yBk8A1cUZJ2ngfrWdbMxGMkdhV+3AGFGT/WmZsuRj5fmqaMcjb0702LBJGMmpFyDxQQxQF78Go3ADccipd3HNM2+nJPNMRXmJVfWrvhFP9O1KbnhY4s4+p/wqlddTitHwbuS0uZsH9/cscHuFAX+hrpwqvO5yYx2p2Ottl3OuT14NeWeOovsvxo0eXGBd6VJDn1Klj/hXqUQAIdOQeSPSvOfjQBa6v4O1sAjyNQ+yvz/DKMf0NdOLjek/I5MLK1S3e42U4bGPxr4Ir76uhtdh6E18C1hg/tG2J6BX1HZAR+INctyo5SNl98KB/Q18uV9WX1sbb4gSQEf68yx5H+zI4H6MtZZjG6j933l4J6yRyDAteyHHVjn866LSVOVwea58oVvZFbgq7A/ga6HSyMYHavEr7ns0vgR1VmMgHrWtEVwOuKxrNvlH0rRiYmsVIuxamUbT/KsTVbZLiGSKRQ0bgqwI4IPUGtsHKdaqzoGDbgDQ2NHmHwtgbw9r2saE7HZDMJ4c94nHGPpjFdh4rjkgQ3cAJltHW7QDqxjYPgfXbj8ax/EkQ03WdO1pFx5cgtpz6xucc/Rsfma6/UY1ljidhlWGDX1WDr+3oqT3W581i6XsK2m26PHfgLrsEnx9uri3DLbas12sQcYIViZVz74Svefj54fuPEXw6v7bT7cXF8WjaBMgEsHXOCe+M/5NfJGmX9z4B+IwvbWKOSbSrtyschIEi8jHHqpr6s8IfFnwt480oWUdydL1twCtjdtt3sCDiOT7r89Bw3tXWpK2pvQqRa5JdT45vtH1fRpgdQ07ULCaM7gZoXiKkdwSBXaaV8UNZ0/TYYZ7WC6lKkJPMT8wHAyB1/OvtSCKYJtkkJjYYIPNfLfx88MXerfFTU4NLj8y4OnQX3lLgbwo8pse5wv1rPEUqco+8rmkaUqTvBnmXiTxUPFN7DLqlutm6jaXtslR/wABJz+tepfBP4StqEui+KvES6dd6BKSYbQSeY0zglR5gHAAIOVJzkYIrxKFFHmLJGUZeCMYI+te5/s1+Jvs2vnwv5rGwv8ANxDE/PlXEYydvsyA591FTScYNRS0IhTcpc83c+l79UEllaxKscMbDZFGoVVAHAAHAFcz8RwggsZ5M4gmdiQMtjYcgfXArqnQyaqmBkqua8y8W+PfDOq+J7Pwrp96L6/d3MktvhoYiEPy7/4m/wB3IGOfSunSxeIaVNo56fxFITi3g8r0ycmn2GozXMm25IOaoX0OyZ43UCRTiqtrP5d3tOQcHAqlZq54junY5n4PaTMlrdzTjdGLmSKEHoADz+ufyr2Szh2INxwM5xmsPwzp0Wn2MUES/KCXP+8SSf1NdPEvYrn3r5itJTqOR9TRg4wSZNCiHPAwT+tSSQDGSffg4z/hSLtGBjimTYKnDYWo0NOpnX1sX3Hrntn+tcrrMROfl9h/9auou2KE4Gemfb/OKwdR2SZBOcjr/wDXrCokzWN0cpoyFPEtr/wL/wBBNZ37T3PhzwBn/nld/wA4a3LCLb4jgPGArnjp901i/tQDHhz4f+8F0f8A0TXoZWvefoeRmLvNHnnwLJHxT0TH/Tf/ANESV9brk5BNfJPwJGfirof/AG3/APRElfXwVc47114r416GeH+EFz+PvTyhx9B+dLHkD0pzA4yAea5jYYikjP5CpgPakT3qY8CnYTGY9RgVynxQJ/4Qi/8Ad4h/4+K6rPTJ4ziuZ+JChvA+qcA48s/+RFpPYqHxI8y0b5gBx1zXZ6bjYOMnpmuK0UEsCBx0rtNPYYGP0pQO2RtwAKQOMDir6NzjpxVO1AYjJ681eWNW4HQdK0RLJoslgcfhVlcLyeBiq8WORn8qsIcrnrVEiO54wCV9famsSVLLzTskgdKjdiP4MUmMrszbxuBqIkg5JOO+ankbLHjmoJv7w6elIZHKwBzisfVZwsbc/StSZh5JHr0rkvEtwLe1lJbhV5rOTsioq7NDwBaf2n4ta+lG6201PM56GRgQv5DcfyrgL2/bU9d1K/fcWnupG+cYO0HCj8gK9d8EaadN8FxFyUub/wD0idiPuhhwPwXAx6k141NOkuu6p5fA+1SbR6AtxW1WHs6UYvfc56FRVK8mtlodnpE2BHxwBkit+BizAjqxyK5bRsIoYsSW5xXRWb+ZIOTx1rnidckbttnBfpxj2q7ahixJ/DNUYiCuOOnetC0ztBJGe5qjJl+MZwAce9TdFBqBTjpT1O5eDQRYGO1gVJ5B+lL34ODSbPmyRTjgcH8qYFW4baGLEAAVseGwF0LTztKu6eYwJ67ju/rXO665j026dT82wqv1PA/nXYQxLDFFEg+WNFQfgMV24Rbs8/GPZGxaIWxjAyO/Q1xnxw0yTUPhxqog4mtNl4mf9g5P6ZruLMLJZpjhwew6kVFqlvHqFlPbTKDHPG0Lg9CCMc/nXZKPPFx7nHCXJJS7Hl9ldx6jp9nfREmO5hSYE+65r4Pr7P8AhlI58Hx2VwD5+nXM1lIp6jaxIH5EV8YVw4PqdmKVrIK+w/FwXT/iDHPJzG9wHz6b44z/ADhf86+PK+z/AIsWuZ4LlThgkLE567ZSn8pqeOV6N+xnhZWqpd7nnviKH7L4jv4hwBMxGPQmtHSiMDmn/Ee3EHiISxrhJokYfioP9aqaTICAMjNeBio2kz3sM7wR1tkRtHOa1Ilyo44rJtiNoK//AK617bACjjJ7VyJm7LsK/Lz+lRTICMcipYwvA3UkmACW6etXcg5rxFZJeWFzbP8AdlQr9Ks6BcNf+H7aR+ZAuG/3hwf1BqfUIt6Nt69c15MvjebwJ45v9O1KGS40G6cXIVf9ZAX+8yeo3Zyv5Y7+vlFW05U311PKzSHNFTXQ5D436ebDxsLpUGy6hWTJHDMPlP6AVv658LW1EJfeEnRTNGsy2ckm3qAR5bnp16H861fjjBYa54T0zxBo1xFe2kM/l+dGeiuOjDqCCF4PPNdB8J9U/tLwdpk24+dZ/wChy/VPu/8AjpWvfgk9GeNKTSTR658KvE8mveErW31llg8TWKm2vrOVgsxZOBJtPJDDByOMk+lcD8QYlb42LG26I3vhO5jVkO1lkQyyBh7gop/CsX4u+FJvEC2F5pkiQarbPmKYuUyD23DkYOCD2/GvIrn4heL9K8TW0+r3q6hqGmRy2YF8gkwrK6MpYYZhhic59KiS05TvpYpNLmOQjkeW5uHd3kd2LF25ZyT1Pua6bwBq0Ph7x94d1W8mFva2lykk0mCdsecPgDk/KTwKxvENmdInjjQ7HlgilKnvlQcg0vhTQbjxP4lttKhmWG4nbAeYHCKFLEnHsOnfNZRi27op1VGNkerfFf4uah4/vP7B8GWt9baXMdjqP+Pi99mC/dT/AGc89T6Bngj4bS+H7iLWdXuMajbjzYbW3OVQ4/jb+I9sDj3Ndd4M8JWHhYSQ2Jae5fiW7kGHk9gP4V9vzzXRaoAiFT6c11xj1Z5tWs5FXxLD5jQ3cPSRQ3HcGvL/AAHe6p4r8cXV1cu8OmaeW226cKWOVVW/vHqT7ivU0mQ+FxNMcCzDBz6KoJ/kKw/hLpH2PwvbzOm24vXa7l+r8qPwXFcOMqOnBxXU68FTVSak+h3FhagBTgnitWKAYAwD2zTbaPCcDGfSryxnbwSM9a8Ro9rmKvlLg4Xn2NQTRgIdrkH0NaOzBAHGPeqtyPkPykc8+9S0NM52+kMancBz3FYd3LuG48ZJ963tQTcpHXtiubv12DABGD09KwmdKtYq6cA2qF8cxxPyTn0FYX7VcZi0XwDGeq29x/KCt/RFMtxcEcttEY+pP/1qy/2wkEcfg2MdES6X8hBXrZZHdnhY+V6tjy74Ef8AJVtD/wC2/wD6Ikr69Awe2T6V8g/Ar/kquif9t/8A0RJX19ESw4xwRW+K+NegsP8ACP8AXFPVizfzpgxk4x/hT0A3ZrmNyUHOfX3pc+uMCoiRnginD3phYU9cnp7VzXxIOPA2q9OkY/8AIi10xxxjFc18RFL+B9X/ANlEb8nWk9iofEjzPQsY55GBXY6VF8m7OB3FcRo3CIDwTXZaU+8FQTnGAamB2yN+EfN8uTnitKNSoHTNZkG9WHI54P1rViUFcjHTitiGWI16cc4p+GOAAMVFED1zxUkbbs4B4OKoQ9wBjg896ryHGep44qUOcZb16mon2cgckGpArSE7/wChpjsB1HX0qST9MVEx3ICCCCMg9c0DKdw+xDuAwa898ezrHZNkg72Awe/1ruNWl27iM5HavLvFjy6lqttp9uC0sjhFA/vMcCuetKyNI6K56xYS6t4o8EWc8MsOlXF0pDMql9qA4yo7Ege+P1rkvHvhSy8PaDpU2mg7kmaCaR/vSFhkMT9VI/GvU7K0j0/T7Wyi+5bRLCP+AjFYnxGtxceCNUGzeY1SZcdirA5/LNXKTm7yd2cdK0JWirK555pTERoF5O38q6Oz3Lt2cDua5fQjmFScnIBrpYmO1VXhuwH60kdzNu1JfjgLnnNadplVOTnJ71kWWfLBBHfitW3bAUsSM0zJmpATuyepqXI9cH09arI+HA4C1NnceKZAoc57n1pCNxx60HG7g9O1PU4PPFAmUNWjEi20RGfMuIhj1G8V16Dgbuua5Nysms6TGxwpugSew2qzc/kK7RIS6MwBA25z2Fehhl7h5eKd52J7R3UKNzBc9O2avAjhj071CiRm282NSFIGEJ7+tSKu+PrwRXXE45aM8L8PL9h8eePdMzwt8l4g/wCuikn+lfFtfbuuRjS/jfcMQRHrumblyOBLC2CP++R+tfEVcdGPLOa8ztry5oxfl/kFfbnxaAGlxt/F5Tge+JYT/SviOvtn4undY2cI+9JHLj/v5CP61WKV6Ml6fmZ0P40fn+Rx/wAQPnTS5JBh5LCBwfX5cVzukviUAmuq8eDNx4YibaVWws92ffn+VcrJD9j1B4lPAYEH2PIrwa0ebmXZntUJ8tvM7KwZSoBwT3zW3bIGXaflHt3rntLfdGpzya6S0+8c4Ga83qd6ZoQxhEwookiPI/pUtuRjGKsmPPIOKtK5m2c/dJtbOOv3vavC/j/pxS50vUVHDBoGI9vmX+bV9C3kWMnFebfGHSP7R8FX+1cyWwFymOfu9f8Ax0tXVg5+zrRl/WpzYiHPTlE+e9Jv7m10++tYJW+y3ieXPCTlXxypx6ggEGvSP2fNWK65qOiSvhLuLz4QTx5kfUD6rn/vmvJ4C0bBsZTvitLSdQuND1qz1SwfE9tKssfbOOx9iMg+xr6pOzufOyV1Y+utSi8yxXrnFeReL2huNT8L6bdWltcLPfCN2lQF1TzCu0Z5wTIM/wC6K9gtru21TRLbUrEg2t3Es8fPQMPu/UHg/SvCPizePpni3RrmHaJrNmu4ywyMhlIz+KmqqO2pFHWSQR6t4Z03VkvddC3FxHptmLQIomZXCkPkfdDcL97kdqb4D1iLxB8chqcMD28c4mZEfBbiE9cdzjNeVqzS3Ekr8liXYn611nwkkf8A4WXoXlkKZJmiJPoyMp/Q1EZPRM2lDRs+k9PUZmuXHAOF9zUF2rT7sdKs3Lqu2CH/AFacD3PrWfrOv6N4ZtvM12+jt2YZSEfNK49kHP49PetHKzOZR7nJ+LNTey0mXQIlY3OuTpaow6RoT+9b/vnj/gXtXouh24SBFQBUUAADsBXkej+IIvHfxBsZbOxkttP0uOSYGUgvIzgKCQOB7Dn617Zp0WANvSvKx9TmmketgIctNvuakKALx9eKskcURIdo9MVJt644NcDO1akEi4XjFUbokfw8DnrWlJk4wBmsu9VtucdTzWcjSJhaicAluwrl9SbKt3966XUnIBIxxwcCuP1yXZG2PSsZas3vZGt4EtvtOoWif89roE/Ref6Gud/bI5fwkfe8/wDaNd/8K7E/2nCxHFrAXY/7Tcf1NcB+2N/zKP8A2+f+0K9zL4ctNvufO4ifNVPKvgT/AMlV0P8A7b/+iJK+viDnjpnNfIXwI/5Ktofr+/8A/RElfXwBOGzxjtRivjXodGH+EkAJU9eKXHcdaUcEDn5uOKNp74we9cxshRwMfzpBjPGT9KcRzxSoQRg/X6UDHBMgcc+tZHjCES+EtaVuM2jn8hn+la7MBgA8Gs/xEnmeHNWQt1s5f/QDQwW54rojZQBuh/nXbacAIgy4zjpXDaANyIehOMGuyti3lkdSamDPQaOlspGdMSKBWjapIm5n2kNjYAMY+p71hWTOoVMkD27GtmJ8qBu9q1M7F5enTHanLlXOen86jhGQM5/pUwHDcfSqEM25HzdKrttDdOtTyFwAOPyqu4LHA3FTSGMcDBIPPt3qNzuGentSyDBwg5qJiw4Pc0gMXXGCIxGcYrivhxa/2t8S0mcBo7NXuDn/AGRtX9SK6bxbeLBZSsDjAJqL4E2JMOs6q4/1jJbRk+3zN/Na556zSCbtA9SIySTjNVtQj+0abe27ruWWCRNuOuVIxVzHNIuBIufXFaHGmeEeHpi1pDyQ20DFdXaliVY9hXLWNt9k1K/t2b5be5kiB9QGIrrdN2smTwD0B7Ukj0G+pq2YBPPVucegrTh/gHp39KoWo2yZPStOEKQMjiqM2WUGRxVgEYGe/wClRRDJ9VHT2qYqAM8/U0iRyqSeO3qaf/DyMZPSmbiMnPFKrEqRjmqRLMbUNb0zRNZs5tXu47aAxzbdysxd8KFACgknmu58Kat/aNjcyCC5tmRyqC4QKzDqGxk4B5HPPFeFePFGqfEXw9pnVA0bMPq+T+i16/pt0LbUPMc/I/yt9K0o4lqfI9jkr0E1zrc62OZSxUjiQ8KP4W60+yLSblPG0ZUe9cxqHia2tJXt7G0vdQulIIWFNiKeo3SNgflk+1c/qA1nXUmXWb77HYycfYNOYruU9RJL95vcDaPau6piqcFZas4IYepUd3ojndbux4r+L8s0Lq+k+G42WCaD7stzIAJFZu+ORgelfEtffNraW1hbJa2MEcFtGMLHGMAV8DVjhpucpSZ0YhKKjFdAr7Q+LkrC+06KM4dYCce7TIw/SFq+L6+zPHN4sXjNroIJhZmKCSLqQPIlYnHp+9/lV4lrks+pnQX7xPsYHxAIHjqOxYsI7NIIfTGyKuX1uWODXYgqO/2obTJ2BRRhQB9cn6imNqV7q/iua+uUY+bK8mSPQY/rTry4jTUL2yS4Mc+rtut5AuBCVAUDPYvgqSOgxXiXvUlLueq4uKjF9jotClJTDEZU4rqrOQ4Hb3riNLMkM6pOoWQAB1ByAw4Irr7KTcpAGF9K86suWbR6NJ80UzetX5AJ47VpRHI9OO1Y1oen6VpxseOtKDFNDrmPKNnkVzuq26zRSW8w/dyKVIPcEYIrqNm5OelZGqwAxkjqO9aWMbnxpdWrWGp3di+d9vM8Jz/skipYZYRbTW1zB5kcuGWRT88LDPI7EEHkH2wRW78VbNrbx/qTRjaJSk2PcqM/qDXNy4KKec5r6yjPnpxn3R87VjyzcT6K+DWrWEngkaRZ3T3EtmzsN4wSrHJAHUYYnr6g9+PPfjnPNa+JtNFsqmSSwaM7kDcOzA4z0OO/auA0rVNQ0q5+1aXez2ku4NuibBLDOM+vBP51N4z8V33ii+s7nUFiS5trcQF4htEh3Md2Ox+boPStW7qxlFWlcxXHlJ5ZILnk89K7H4LWz3PxJ0gopZYPMnYjsFjbB/PFcMWLMSeSa1tC1W70yC/SxcQtexfZ5JVHziPILKp7ZwM+w+tJI0lK6PXfHnxMFnNLp/hiRZLoErLfEBljPpH2J9+npnrXjd3dS3N1JNNLJc3chy80rFmJ9ST1pmQDjGAOmKTCort3IzQRGyPb/wBn3SyNKvdQkGWuJtgP+yn/ANcmvebCIKoAXkCuB+Fmmf2d4T0yDaAwhV2/3m5P869Ft1wAcjpXjVZc03I9mC5YqJdjX8qeUAycURjPQgipAARgVk0UmVZVxnjGaxb0Bd2cnHpW3cLjOAcetYmood5z0A6Cspm0DmtSYhW2j3NchfZuL6GH+EHc30HNdTqR+/niuTgcy6zNFGMuUGPxbFYrcqtLlgz2L4b2Rg0SS6cYe6fI/wB1eB+ua8Z/bH/5lH/t8/8AaFfRVjbrZWVvbIMLDGqfkK+dP2xf+ZR/7fP/AGhX01KHs4KPY+b5uaVzyz4E/wDJVtDx1/f/APoiSvr+Nudp69zXyD8B/wDkq2h/9t//AERJX1yhxy2OtceL+Neh34f4S0G+Xn+VSA5BAH58VCmex5zzin5AJJz0rnRuONOjAUkg4zSK3IyOKdtIJxgDqKAEIA4OcioL5A+m38ZGVa3kU59CpqySWPb8BVe/wdPvB/0wk5z0+U0AeD6EdsERHoCa7awjbYGOAeua4vQBmGMnPKiu2smZgoBzx3qYI9B7m3aKM4wST6VdiA6ryR7darWyBADjJA9atxpu+Y8rnoK1Qi7bswI3jB68VbDBl9KpKrIAQOPSpE+dcA4pkNE0h2rk9ahBAGR1p3OefzqNsqOMYpCIpOhOMk1SncBTk4z0q4X3rg8Vnah8qMw6L60xnm/xGvNkXlq2Nx5r1b4dacNM8EaTDjEksX2iTj+J/m/kQK8W8Xq+o67a2UZy0jrGv1YgV9GRxJAqQoMRxqEA9ABgVzQ1m2RiHZJBTCfnB7Zp56004yBWjOZHh0wceJNYibPy3sxP/fZrqtPH7jaMjjqOSK5y9BPivXGXGDeyY/76roLJ9ygcjBzQjv6I27UERx4OQB8xx1960bYleeNpHp0rMgfgAHr6itCMjeoGeBzg5pkM1E+6CoBx709nO/HJ9KoRkLI7lmyeoz6egp6XKgt5mfrQTYtK+QW6Y4pVf5eOetVY5twO1Dgngnp9afcOqgYPBHP9TVITPNtOAvfjYGB3rbK5z/uxkfzavVF6dDXmHwqX+0PE/iLWG558pCf9tif5KK9OQ8+1c0Xe77sia1sOZu3amMxC81IcAEDrULKcHNXchEDNk4FfANffrADr1r4CruwX2jkxXQK9h1N7/WNRvNYvbiRbmaRriV95ATP8PsAABj2rx6vXfEuqIli+nQIIljkDsokDByD3PfB5pY7mfKkaYGycnYXwhHLN4xtQsryGNZJX3sSTlSMfXpxXRSkpe6lBA8T6hK8k+mI5y8aABXIP95sHaD3UmsT4TI0mpaldzkBFjCSMT0DHJ+v3avRLJHaz6nPbK+t2ckj26Z5W2Z/lmZR12ktt9jmuGcdbHTKV5aE/hTVLm9+2pfqUvrO5MUiEbSFwNpI9eDXf6fKXC49K8l0me5tviTqKahbvanVIFuEjb1wGH/s1en6RJuxg81w5hT5ZKS6pHVgql4tPozrLPkDJNbVvHuPr7ViWLBUVsnOe3JrYhuMLkbiPciuOmdNXYvNgZz0qjfAGM7gMHvUwugSA/BPakfEyleo6V1xV9jk2Pmn49WJtfFdjdj7l1alPqyNz+jCvNiAQa9z/AGjbEHw1Y3aj95b3ewE/3XU5/VVrwaC4DjbIcN2Ne/gJc1BLtoePjI2qt9yQAjdnkVa02/0m3ikh1XRDfKcsJYrloJVY474ZSBg4G3qcnPSqrkqMbc+9NwGO5lB9a607HMjTisNHvra/k02PVTNFAZEhk8tgp3Y5YYLALk5AHOOMVjRKyrtJBxyAPStzw3cfZNctJGG2EuIpCTgbW45x6cH8Kn8X6K2h+Ib3TwqMsTB0KnPysMgZ/HFTz+9Ypq6uc+7q/AVjUtjbme/tbYKR50qR8n1IFKEKZHatLwjF5/i7RY9pJN0n6HNOTsmwgrySPrbRUEFsiDgKMCtu3bJ4/GsjTIyVHvW7Cqxx9vevFeuh7BcgPTjNWVGfQVlC4ZpQinA64FXIicZ3fXNQwsSXCsFOBmsHUs7CemfzraklZQflyPY1kak6upBGG7ZrOTNIbnF6wQCTn25rlPAGL74nNankL5ef+Ancf510+vOoVyhGUJBrgPC2rSeGPHy648CyWzMUmB6+W3G4fSlRcVO8ttPzHiE5U2o72PqUnkmvm79sT/mUf+3v/wBoV9GW1xDd20VzayLLbzKHRweCDXzl+2H18Jf9vf8A7Rr6VO+qPnI7nl3wI/5KtoeP+m//AKIkr67Ud8c+lfInwHGfivoQ/wCu/wD6Ikr69RMcE9+a4MV8a9D0cP8ACSow3E4PPGRSmMMu4fnSgDbyvHXrS5wOeBXMbggxyxyfapGIwOMDpkimxcs2cZxj6U5gV5IB9hxSGKnsAR61T1l/L0jUXP8ADbSn/wAcNWlfkDHI61W8TsI/C+sv6Wcv/oJoYdTxjw/b/wCiwZ9Bmuws1CY3DgjpXP8Ah2ELbRM2eR2rfZlVFzxjjmqgjv6m7bKAgzkCr0e0nC4z6ZrAtZpCuWOD35q/DKznIzx3xWqQWN5cCIYIJ6BTVIls5xgZqu10wIC5JHXFEOpB8gcHod1JoixbyQuc9fWkJ5A//VimxMXJBIGPSpmUcdMUhMryZUk9qy9WcLCwzn2rRmkBG0cAHv2rC1eUJbSs2OB1oewkcN4SgGrfFOwQjMcMpmI/3AW/nivfTyOvPWvGfgpbG48RavqRGVhh8sH/AGnbP8lr2JTXNS2v3Mq+shzUi8unfJpGOKROJUPvVmSPFY236rqjn+K7mYf99mt+2dVZCFHHcVhWy41C/iI+UXEuTj/bNb+nqvljcRzkD2Aq0tDtNW1kGR6itCEnBIbn6ViQlllCJghufWtqNSiZL7QcE+tIVi4km9ACDwcdKmSBtuDjPoOaZFd2+QAfxNBuQAShB/XNA0ixHCArBlPTtmsvxXP9j8OX8rNgpbuVPoccf0q8l8BGCzqGzyK5D4oakqeDbkq6nz3WEAc98n+VOXuxbIe4/wCDlqIPBfnFSGubl2z3IUBR/I13CjOCKyPB9gdO8K6RakYdLdWf/eb5j+prbgXjHYdKwitEjGT1uBOBnFMfpVgrjrTJOBnvirSIuZdwSFZhngH+VfA1ffl7j7Ncn0jY/jg18B124L7XyOXFdArrGkMqu5yS2AD/ADrk667T7R71HZQyW0Q+Z+3HUA9zzWuIsrNjwnVHefD+2ZfC2ozvGp+0O20Zwz7QFCg9eSxFXLXZZWlp4vnSZbueFYnticIpwV3sTzsKIMKe9aeo20Vl4XS5jj2xQJDIEjO0ybcED6ZHJ7AGvP8A4jahdw24nt76RrXxBGtzJETghVP3GHoGBC47CvOgnVnZdTecuROTMTXdfjk8cHWrCa4ktvOVkecfOV6MOO3UCvctAvIpgkkT7o3AdWz1B5FfM5bACkcYr0r4Wa4wQ2Er7mhOUyf4Cf6H+dbY/Dc1FcvQjA1uWo0+p7zFcmNMrgDFSJqcqMSW69sVm2LedGD1/rWlHa7wSBmvlpNxeh7ySkicanHKNsqBT2I6Gr+hTGZpEY5ZP5Vg3FjwQuQ2eoqPRbxrHVViuOFk6GumhW11MKtLqYX7REAbwHduF5inib/x7H9a+YZEOTnrX1r8ZrX+0fh/riE8xxeeMf7DBv6V8kea+Bkg+xr6XLmuSS8/0R4mNT5k/IfHcSwjb1X0NWormBj8wKmqauWz8oNNYc9MV3tHEarTRcAvhscEV0/je/j1EaHekLG8+nKHP95lYgkmuD34A6ED1re8TyWX2DRILWe4lmhtiJw8e1VJORsOfmHJ54qWtUFtDOlnXA2tu4roPhfib4gaKpGcSMce+xq5LlsbR0rtfg3GW+IFgxH+rSR/p8pH9amrpB+hpSXvo+tNMjG0f1qxez+TCMDdIx2ooP3jUVgyrbhmwAByahMu+5a5cZ2DbEvoe5rxW7Hr9CzbhoJNjENKwyxPTPpV5XbADdfQVmWqF3LtnnmtDYABwRmsZS7DSY95ODkHH1rJvQXUnOR2Her7qRxnNULs8dDn1qL33NFGxx3iCPCM3bqa8i8MaumpafcJdYWOKXajkZ2biTs91OCQO1eu+OJfs2galcNgLFbu2f8AgJxXzNpUpj0y62kgh0mUg91OD+jGtqVD2kJfIUp8skfR/wAMfFEvhyT+y9QlluNIlYGH/R3DQE9eSMFa539sBldfCDowZGF2ysOhB8jmuZ8KeM2jCW18zSQngHPKfT1HtWb8cb9r208PKtwZraP7QYuchc+Xn+QrvwVWUX7GZ5uLoWl7SJkfAX/krGh/9t//AERJX17klwG5+lfIXwFz/wALY0LBwf3/AP6Ikr6/2HaMdCO1Vi/jXoLD/CWEwUx+VRshx+maaWcJnjJPIxTgRswM5PNcx0JDR8oyc/gKnZt7D5sDrio1wGB5/PrT+N2cfnQUSiMBgQee9Zvi9CfCOtBeT9jk/lWqgCjqOKqa7EZtE1KBQCZLWVf/ABw03sSnqeXaAFaFBjIUA1p3EKORksjZ4NY/hhybOInnIH1rp1tnkjY5BVhxxWkNUd/UrWzNH8kiK3oy9DWjAvzMS2CRxiqzwT2+GSNZomO3g96nimwDvtpgR6DIH5VpYeg6R5UkAVt+eNrf41DJtaXZJnDDIJGGX1we/wBKto6Shh5bKwGcYxUdzGGEboAV4Jz1FS9RWI4ria1dVlYGM/dkHT8a00vBIBwD7iqfkh42jO5B79jUNrBLD8vBHQHPSkiGXZCX3E9xiuU8dzeRoU7Lwx+UV1YDEDOOPSvPfijdiOzhtVzvkfcR7D/69RVdoNiW51fwYsltvBrXOMPd3LsT7L8o/ka7wHmsrwrpx0rwzpdiQQ8MC7x/tH5m/UmtUD1rKKskjCTu2OPI6Uwn51+oqQD1qI4J447ihko8jOIta1GJ1YM95OOBwBuJ/CtewdV/dOAB0U1W8SI1n4xv4mGI7krcJ7hhz/48DVtQJCOm0DPHHNarY61qSZ+zBXAPB/EipreWW9ZZZMqmMBQeWx61RBd5CzAeUDzk9f8A61asChlCwkbDzkc0ii1ZREzAYIBHTgg/jV9IwpLNhEPHU1SijlLYihBxwW3dPatKGCfcTIo2hQTtOTn8apIG7Ed3BHJHGditGmfvc5PrzXBeNon1bXfDmg97mQTSAdFTOP5BjXpQT9w3B2heOBxn2rhdGUX/AMZ7yQtlLC0Oz2O1V/m5qa/w27mN9Wz0SXAY4GB2HoKlhGBUOMnrxU4PAB/Cs0Ysfknr0qKXoakqGU5zz0piM7Ujt028b0hc/wDjpr4Er7219mj0HUmUZP2d8e/FfBNdmC3l8v1OXFdAr6F1PSoR4N0CK2hWKNIpbdwBxuPDE++4E5r56r6jhtSdL1XSpVzLZXXmq2ezZ3f+Ph6eOb5LL+rWDCO0jLtvOv8AwvZMEYTWGRKoOdzR9Ux33Lke+a8k+IYa4v7TUEdXs7uIm3AGPLCnmLb225x79a9hwtj5ly7MtvKqx3JVseU3RJvoM7T7YPY15z8ZdKOn3+nOHAjmR/LhAx5WCM4xwQcg5964sFNOomuptio2i0zzgMDyavaHczWmr2k1nzN5gUD+9njGO9UCMnK/e7iug+H1p9s8WWI25WEtM3/ARkfrivWqNRg2zhppuaSPozRMhQM8Ad/SuxsU3RgnByetchoS7oUPHQdq7KwUYGTge1fFyV5M+oi9CW4tML05Fc1rdiXi3R8SKdyE9jXbhQ0Xr34rH1OEc8D8RUuNndDUr6M5y7uF1fwtewyjiW2lhdfQ7CCK+R0SMRoeWZhn2FfV0OLbV7i1biK6jZlHbcBz+Yr5OjdsKNqsB0HSvosok5KXy/U8XMo2cfmTeVLIvyBce/FRtayKMsMn2p4uHGdymrEV5F/Fn8q9g8vYoeU3OQRgZ5FatvZzXuk3AClvsQEoJOMITgj8+afEY25GOneui8FRfatTktGkRVuLKdOvBwpYA/lUy2KT1OJ8pkJ+Vhjnn0rv/gpHu8Zs+BlLVjn6sorkGAypJJ+Tv613HwSAPjSYetqSP++hUV/4bLoazR9IxMTEqnO0Cpoxub2HNUoG8xyq9BxWzYwhgCefavFkevEngizGMZFWxEdo64qSOLgH0qbZkY71k0aIzJwQM/hWXck7sVt3S4B4yfasm5TIbn3qLFpnLeI7JdQ0u8sZeY7mJ4vpkcH86+VNMdozNDIpBQlX46Doa+tdSO0nI6EV5T8DdPiX4xa4biCOa08ya0kjkUMjiRmG0g8EEA8V24OStKL8vzsc2Jk4WmulzycMbaQI590bsf8A69V/ENzJPHapIxYJux+OP8K95+LPwak0qO41XwlbyXujcvcady0tr/tJ3ZB/30Pccj5+1iFIjCYpN8TAlc9R0616EYctRc25zTqqdFuD0Ov+An/JWdC/7b/+iJK+wFxyMHFfHvwGOPivoZ/67/8AoiSvsBCcZHFY4r416GeH+EnQhs5OQOlKVKnsfSkiUkknv3qwVypGMn261zG97FdVxUoG4jnH9akEYCDI6UBQB0zQO9yIEqcZGfrUrrvhkRujIwx9QaYUDYAJz1NI8iwwzOzfKkbMT6YBNFxs8c8Hv/o8KntXfW5UpggfN+leceHN0NtESTggMK7mxmDRqB949Aa2pbHa3dmgq5h2qoyvc+tLuAILpyemKdsKncn8fUVIFwqdDzyDWzQKQ+KM5zjgfmaZJAnzBlwp9KsedGONxGB1pSAYyQ/OOvepsHMVQoMf7zG4cUrQjIbjHtU/k723dMj8c0jLtzkjFS0S2ULhzGh+YKB6VwPh+y/4TD4hiSQFtPsP3jZ6EKeB+LfoK2PiHqp03SWjiOJ7jKLjsO5rpvhtoX9geGIfOTF7eYnmJ6jP3V/Afqa5qr5pKHRasiUuVXOrPUk9TUXt3p5fjpzUf8XuaDnRInIIqB+CfapUPNRyn97j2pPYa3OP+I1kXsrTVYx81m/lyn/pk5H8mx+ZrJtZfMjjYKGUryO49xXoFzbxXltNa3A3QzoYnHsRivMNPSW2nks52IntpGhJ9cHGfx61cH0Oim9LG5AQG2bMxkcHv/n2rV0xIkC5Iz244qlAvVicg9wMc1egcJHwSuzoCOlaNFpm3DGueOB1PFQynyJAq8bvvLjrUcM4eL947YOB0x/KlWC0Z1Zo/Mcnjc1CVmFywblXhMScuxG4joPauJ+HgDfEHxg7/fU7QfQGQ/4Cu6jjPnRlQNq846AY9q4bwav2T4o+K7Rv+W0fnL9NwP8A7NUV9ovzMXrc9C2559KUdKQdO9OX2rJaGY7HHFMk6etPNRuciqJMPxOSmgX/AD/yzx+ZFfB1fdXjU7PDV5jjJjH5utfCtdmD3l8v1OXFdAr628QosHxB1pI1wrgg/Und/NjXyTX1R4kuPP8AGerSxEsfM+Y4xg72wPyUVOYS5Yx9R4ON5v0KlxbTQyOYyGIG0xsMgg9QR3FeY/FC3lOj6eUkLWtnK0caPy0QcA7Q3dRt4B6V6+oie7ieZyqN984yV/DvXjvxq1e2utatdP0/b5VkjGRlI+eRj39wAOO2TXn4CElVXK9Dsxck6bujzg5DZIOa9B+DcQk1bUpiPmS2Cj8WH+Fc1pVhZahZRxxXN3NrtxP5NvYQW4KtnAUs5I6k9AD/AIdz8NdJ1HQfFWuaVrNq9pfwQossL4JU5BHTg8EHI9a9XGy/cSRw4RfvY/10PZvD8REK549q6uxTsF57j0Fc3oKAwpv7etddbqFGQcc/rXyqV2fQXsXY1/dgY7elUNRT5Sevsa1YlGOvPp61RvgPm68dRTlEmL1POfG3m2unzX1um6e1RpUUd8KePxr5Xg8kxqGba/PWvsPXoBJCynJUg18f3kSWd7d2sgY+VMycexI/pXsZNL44+h52aK/K/UmSD5fkcc0NZb/vJtJ7iqqtGOY5GQ+mKlW8ljJ+YMPUV7p49hPKe3kBzlfeuj8HTiLW7KRVxgPwOh+Q1zpvA6kSRhh7VoeHplinmuY1YLbW8jn0yRgfzqZbMaWpXd22RnIxsrsvg1OIfGUz+lm+P++lrhGlAwv91MH6103wvnA8ZWsan/XRtH/X+lRW/hs0o/Gj6p0GIm3DN1PJNdPaRYH+FZGjRARKCOgrordQME49DXiNHroljQde3TpSvtUHAwB1zxUijAPFMdPMj2sAwPXPNRYtFCVRkkZ561nXUYzkYDEdcVq3CkZ7is+529hipaKOV1f/AFLbuorjfhPZfZvEhuXXEl9q0k2f9gEhf6n8a7HxKdlrKyg52nFYvgFd/ibR1/utu/JTV0W/aJea/M5sY/3f9dj2oMyPuUkMDwRXyx+1d4e0nStY0XUtLtEtbnUvtBuli4jdk8vDhegY7znHXA75z9Ruefxr5u/a+OT4T/7e/wD2jX0TPDg3c8y+A/8AyVbQ/wDtv/6Ikr7BibocV8ffAf8A5Ktof/bf/wBESV9gIccY59a87F/GvQ9LD/CTpIM4wc9anVgR14quo+QngGpFB2gY61zXNrE4YHAJOaRjsYdz/KmDOeOM04kcb8ntSuOwrtwexrnvHd99h8LXpz+9uQLWP3L8H/x3ca30GRkjPYCvPviLcfatfsdNQ/Jax+c4/wBt+B+Sj/x6ky4K7sZGnWuYo4zkADGQK3rWGRI8K3A6ZPINN02HMYxxgVqImAcDg10wdjo3H27fINxzgdamIOz5Sx/CmxFeAV+YcVbgAZ+mB05rZMLpEGyRowM8AU6JJdpGMgetaAiRhtAwO+KcYeTjp6VLkkFyrtkIBI57VHIGwTj6+1aHy4x+lULlxsdVGOetTuS2eWa5E2vfEvTtKOWhjkRXH+z95/0Fe1ytuzjgE8D2rx74aK178UdVupDzDHMy+2WCj9Ca9f3heG7cc1xQ1bl3ZFTdIickHjpTTID16jpU0hyBtqvKN3HamyVqOif1zSSk5Ug8dOagUHd8tT7Sw7UlqN6ai8kV574gkii8b3sa5+eKKRxn+Irjj8AK9BBNeV+I38z4gaow6KY4vyQVcdy6e519koYKBn5h93qKvR2oIIIOc+uKy9EmzbqpO1vet6Mg45LZrZlkcUQU7Afp7VYtikYO4DOeM1IgUkgDH1qWGLHB+YD1qoibJoDuf61wVyhsfjTYSchL61aMn1O1hj81Fd9bjEmBxjrXB/Etv7O17wzq+MC3uwjn2JB/kGqa6vTb7NGSfvWPQMHr0pvT6VM4AkYDoDTMAVgQIOmD1pkg4P8AWnnjOBUYUrAgLM5AwWbqaaEc543GfD0qj+KWP/0LP9K+Fq+6vGZH9lQr13XC8fgxr4Vrswe8vl+py4noFfTk8qI2q3l3LHDGJctJKwVRwOpP1r5jrqvFGu3Wv6lPcXbstsZWkits/JGD04HU4wM+1PF4V4hxSdkr/oLD11Ru2rs7Pxb8Q4fIntfD/nGbds+2sAEA7lfU9s1xfhXwpqXiaW5mtjFBp1uC95ql6dlvbj1Z+7HPCjLHsOtYZbD7kzn0NPuNTv5rGOzmvbh7JGLpbmU+WjHqQucA+9a0cPChHlpkVK0qrvM7+Lxxpfg6wmsfh5Yk6gx2y+I72NTcSDuIYjkQKfqWI684xZ+El1bXmoahLcTXc+tXDF5JJn3jyhjkseSxY/pXlZru/g1KE8VSxnGZLZgD9GU/0qMZD9xP0Lwr/fRPo7RI8KMfdxxXUW+GjXad2PXtXOaMRtUHPTIro7b7uU2+gHrXy8T35GpBjBGOnOc1UvV4/A1ZjOM89uT2zUF4VYdRx61bWhmnqc3qi/KV59ea+SvGFiqeNtbgyQBcO449Tn+tfXGpEfMDn6Gvlb4g4T4j6yBxlh/6AtehlN1VkvL9UcmY/wAJPz/Q5lrEgHa4465phtG67lNXVALDuTTxkRuuEIbBzjkYz0PavfPFM17dlPPGe9alpFdDQ9SjhkYRq0byhRw4zwD+IzUMgyp3cqRXQ+GFSfTfEUZUbjp3mLkgDKsCfxoewLc46SJlkcFicHn3rovhpmPx5ojNwDPj8wRWLMS0hOAAcGtPwfL9n8X6NMTwLuMfmQP61NRXiy6btJH2npIHlLxzW7FwMnjPSsLRuYUx06mt2HoMkA14rPYiWBz93mkIAwMYz7YpyDJHFBHJH41FirlOUED8KzLleDuHFa0yEj09xWXeAGMgDmpY0ziPFzmPT5znBwRiqnw2Tf4ss/8ApnG7/wDjuP60z4iTeVo1y+cNxj8SBVz4Wru8Tzv2jtW/UgVeGV60fU5cc7QPU3NfN/7XnXwp/wBvf/tGvo1uua+cv2u+vhT/ALe//aNfQs8WHxHm/wAAlL/FrQlHfz//AERJX2KIgPT618cfAVxH8WNDYg8ef0/64SV9hrcjGCfm9K83F/GvQ9PD35SysWBkGlKvgnrz0qPzwyjbkt9KnR2ZV2ByD1IWuU3syNc4yBihhznP61Z8qTH3W9elJ9mdgQyMR9MUWDmRBGcyqCMA15PFcnVfEOo6ifmSedth9UB2r+gFeneIn/s7QNSu1Yo0NtIyg/3tvH615j4VgKWcKE8hQc00tTWlZ3Z1Wl24VQvbrk1pxqA2D0qtaAhcEYrQT7hIArW5rYZ5SqobA2j0qxCikcHp+dQ45AI7ZFWLYHaSx4I4NVe4tSaHYq0kzYwf0oIxknHNQtvY8gYB45osFxvmqBwME9qpXz4RiTVpwwAwv4Via5ciDT7md/lEUbP+QqlpqS+xxvwa3SeJ/EFwOgi2kn/akz/SvWWJOOhry/4HQMukatdt/wAtp0jB9doJP/oVenwHJI4rgh8IVPiHIDux2xmgjj0Jp68rkj5j+gpsvCrxwe9XYzuMCDsOetP5AxSbsj0PfNQyy/wjg9zTTsh7kg5cDrzXlEzC58TavL1El1IFP0OB/KvVLTLTqM8da8k0Ry8RnA5MrSE+xJq6erNIK1zr9IbCjcvI4wO1dBa5Ax1z+lYenAKOcFiePcGt63HQDHArZjZaRsEAA8VYV8jtkVWiICnPX+dSxncMFSQOtCRDZag+8Wxz71w3xmg83wg8vGYp0cH06j+td3EehBrlfijGJfA+p5HIVWA+jCqmr0pLyM18aZv2Vx9p06zuBndNBHIT65UGrCAkcnNZHhJjL4S0OTAybOLn/gIH9K1gcccc9a41sD7CsD+tMYkA9af1JAqOXvziqQjmvGbf6LYKf4rjP5Ka+Ga+5PGPLaag/wCejt+QH+NfDddeD3l8jlxPQKv7DuJ43e1UK2HaOCIAjDE5I7k13nIVSVVQRn0z6U2RVAyT39PantLIRnoPQComVjzITnsPSkxoYwxxx+FdP8MZjD42sOR84dDx/sn/AArmwuBnGBW14LIi8VaWw7Skfoayr605LyZtRdqkX5o+qtHfcg6kDgY710lidw3Eg5HOa5Lw9MrKrAfgOldbaA7RgLg5/CvklofRM0IzgYwPpmo7qTKEEfN6Y4o3biTt3YIxjvUV6AYznqRwf/r1fQzW5i6iSyE9s8cV8pfETD/EXWME8yAA/wDAFr6muX+Vvm4AOfwr5M8eymTxzrMinn7Q4GPbivRyrWq/T9UcuYaU16lAS7GldiVRcBG29zjIP4ZNK95FvZQrsmeHxgn3xTL6a2ndTDFLu2gN5jjqAOenHOePpVYr02n8Ote+kePOy0RrRW8k+n3F/GB9kgkSKWRmA2s4baMZyc7W6DAxzXU/Cazsr3XtRj1K7jhtF02UM3nLHu3MkeMn/fz69+1efrEDKu7gHimyhecDjt9KLEFqZVRRuZGKgg7TnJ6UyG7NvdQzIuPKkWQeuQc1VOB0ppOaGNaH3b4ckE1hE/BDKGH5V0sBA9j6Vwnw0uftng/RrjqZbSMkn12iu3i6jHOfSvDkrHsxLiNk4BAAPTpSu+M5GM0xc45wG7Y5zSsSR0z7gVFy7EMgZlypB9sVk3vyK2eT2rTmyFZscDn3rIvj8mT19Qe9SxnlXxW1GPTtCa6u0d4Umj3KhGWG8dM10XwXkhvmvtRtn328tvGY2IwcFj19+K8w/aEvsaPaWqMCZrjJHqFB/qRR+zp4s/si7fSrknyjyc/882Iyf+Asc/RjXXhKailWff8ADb8zz8c23yLsfThr5y/a66+FP+3v/wBo19GP145HYivnL9rj73hX/t7/APaNey9jyofEjxv4e3l1p/jDT7mwlMVynmbHABIzGwPB46E17V/wl/iaXk6vcBenCop/MLXh3gkbvE9kOn3/AP0Bq9aCnHYDsK8bHyaqJJ9P8z3cDFOm7rqbH/CUeISOdavxj/ptTJNb1q4GX1nUTnk/6Qw/TNZe9Y1Jcqvrnmqs2oxIRsDvnv0FcHNJ9TuUV2Nv+09QBY/2hfZ7n7Q/P61nal4qvbVdp1S83nj/AI+H4/Wub1TXGVdqtwRkhe341z8Pm395H5xYR7se5renSk/ek9BSteyPonTdem1f4KXcl1eie9hlWFwz7pBG0qhd3fkZAJ9Kk0BB5CAegrzXwLP5fh7xNbKT++mtB9Qsjn+lel6MdsMf06VstzJR5brzOmtyQMk8dAKtK3zHHHHFU4H+6QP/ANVWVCkkjr0wasCdCJCNp4zVpQyj2rPjGJFIyV7irCTjeynPSgTLIIDE9vWkztx3Gc81XLEE7W3EjGKVtzDJ6VQgmJBJUj2FcR8R7ow+F70lsGUCMfif/wBdddO+SR+NebfFi4/4l1rbJk75ScfQf/XpVHy02xR1kjrvhbafZvAunnbgzM8x/FiB+gFdfH8q9SMmquj2g0/RrCy6fZ7eOMj3CjP61cC9K5kraEyldkqNxnvSkBsD0oA49DSkbck/gKuxncjkQKDjHWqk6k8j0q0zEjnjNRyKAB3B5qS0QW5KyrnOc44ry7w1tEbJ6Oyj6ZNerRr+9XA7jFeUeHV/eSrjJSVwR/wM1pS0ZrHW52NoPkUDAb1ratZAFAHLYx1rKtz+76bgOPer1s6lyozW7EzUjIwufxqZDhiVGd3FVo2RyMqMip1IPPP0BpJiaLIb5s5xn1rlviU+PBuqkf8APMD/AMeFdKCQfmHHauR+J0gXwdqJz1CD/wAfFVPSnL0Zkl7yNvwXkeD9DBHP2OP8OK1io6flWX4VIj8K6ID2sof/AEAVomQEjkn2xzXGtkGtyU9OntVaUgE81IGYpzkH3qvJjk9aoRzvihs6lpq9tkh/Va+Ha+2PE7/8VDpynp9ncge+7/61fE9deC3l8jkxPQK0ZRFHtYct2z3rOq6u6Vgz9zjA7V3M5iSMF+c/MR2qU2xzkg8+pp8QwOAvTpVohYxx8zn8qkZnvEc4xj3rQ8NKI/Emk4GM3KLn6moHlAA4XcOuBUmiyH/hINLdeouov/QhUT+Foum/eR9LeE2BiUMx3K2MfpXeQhlIwcbjnjtXAeGz5Go3cOfuvuH+Feg2fzqeBg9BXyjXvH0V9C3EpA3YBYcDB4qC6LcAk9DgZ6VfjjAB4wPXNUr9R5mDnp2NVYlPU5jUG2SZyAD3Hc18j+L+fF2s/wDX3L/6Ea+tNV4lOepOR/8Arr5K8VfL4s1fsRdy/wDoZr0cp/iS9DkzH+GvUz1QdTgjFTeWB0SPNQHaMFcAHnr0pwfHQDP1r3jxhZGOVKqBjnionODSO7ZIzjtxTec4HJNACe1AGenNOxwcHgdTSk54HT0oA+u/gbP9p+HejNnOyMx/TaxFenw4yOPbpXj/AOzrJn4c2gb/AJZzyr9Pnz/WvXodxbjv29a8WrpNo9elrFMuxL8pIJBPXIqRgSep45NKig4H6U9wF5BIGMY61lY0uUbg4Ukcj1IrD1X/AFbY/Stu8O0Fh2/Wuc1eQiM4OAamTKR8yfHu73+JrC2zkRRmQ4/2m/8Asa4fQtb/ALK12zvQGMUT4kA6sh4YflWx8U7r+0vHOovGcrBthBHbA/xzXJuPMj4X5gefevXw0F7FRfVfmeViZXqtn258N9ci1fw5FGs/nSwDKtn78R5Rvy4/CvH/ANrY5bwr/wBvf/tGsb9n3xFPaX8Nq7EpDcJFj1jlOCPwYZ/Gtn9rbiTwuPT7V/7RrejJ8rg91occo2qJrqeKeDpDF4js3XAI39f9xq9QMkjJvd22jsoxXlvhF9niK0bJGN/I/wBxq9FmYSgMXeRewPT8q8rMFeqvT/M9/LUvZP1/yEumhX5iSW92JrKupnfGDgjgZq7KMI3AxnFUJ2VSSO1YU4nbJFCaHkYOSe5p9oxidJFOCjZz/n60y4JyTz1qOGQbmGM4HFddm0YOyZ2/heXZPeQAcO6HPrhj/jXq2ithVz1HavHvDL7tdutuT8qsfQZIr1/RwSituPTNZRQpnR2xGPvcmrpbaozyM1StiDGueo61YEm7AGfQ5rQknUKBwSSD1py7CWbBz3qvEq7sq2R2wOlWI/mztwD1piYAMOOg604jPIJyeuDSqzFm6E9Ka4Yj72KtIixDOwAx2FeYeKF/tbx/oum4ynmoGHsWyf0Fel3eBHjPIFeQ6Fr9ufjFcyyQyPFY+ZkgqOQuzqSB1NZ11eNkOO5728m52I9elPVgwx39q5GTxtp8Y4tbjPoZoj/JqIPHmnZLG1kyR93zkH9a5+ddyHTl2OxBweTTgxJI6+lca3xB08Z/0Vt3p9pTNQyfEqyX7tkCfQ3S5/lT549yfZVH9k7KZG2kgdetNRixwcnFcYfiTaOpH2BcdP8Aj6H/AMTVRviPaJ832OPr3vP8EqXOF9GWqVS2sTvwuHGM9a8ss4fsuv6tbgYEV1IMd8FiR+hrTPxShRG8vToAx7/aycf+OVztvrCar4jvLyFBD5+1iivvwQuM5wOuKunOLlZM0jTnG7kjuLJiqDnK+9aEDFWwOc9aybUg7GPA6n3rTjbavqK6hF04LKwYgY6VYRjuA7HnIqrbsGXoM9KnTCnO7qeRQkJlgMTxnJri/ixNjwpLEBzLIifjnP8ASuzi4+YduteV/HfV5tOh0C3tVjZ7m8JIcEghcdv+BU6ivTaXYzXxI9as7Q2dhZwAY8mCOM8dMKBTxnA7kV5U/wAWdYLndptlliRjyX7f8CpknxX1Ptp9gfrA/wD8XXD7Wn0Zaw9Xt+J6z5ZPUHFRSKAnT3ryWX4s65tylnp/XAHlNk/hvqlP8WNfzgWun59PJP8A8VTVWHRi+rVTsvFUm3XLWQ9Eg5OOnzGviyvqm18R3XiK2+16kkEc4kWBRCNo25yOMnnk18rV24FpuTXl+pwYpOLSYVpW3+rYYB569zWbWpbhsZOMsOB7V3s5idCfuqcYPccCpJV2KF55qFOWOMlfX0pTy2SSfTNQABMJ0xVrR1C61pgHX7VEPf74qLA8rIHNafhe2+0eKtEjJyWvYeP+BCpm7RZpBe8j6NgtvK8R5UAK6ZI/Gu6sQmwYOcc1zl7DjVrdgOfLPt3rqLGNQgY9uoIr5bqe/wBC/EoKk9fb3qreRMFcnOCeCTV+EBsccHtTLkZQjnA74rRrQyT1OC1rKphVAOcjmvkbxKd/ibV29bqTH/fZr648T/un5IwTXyFrbiTW9TkXJV7mQj/vo13ZT8cvQwzF+5FeZRJ+Ug0gJAP0pW78U3rxXuo8die5/CnqML9evsKaMF/YU8cr7mgBvXAHSngbOf4v5UKccjg9qGGeM9KQz6U/Zln3+Dr2PvFesPwKqa9ytOSMA5PvXzv+zHKY7LXrdzgrLE4U+4I/pX0VpSmQeYASnRcd/U15OIVqjPTou9NGpGoIyPxOKGBEYyAR7GpQAFGCQDxzSsozn1rFmlzJuwNpwOOuBXHeKLlYLKWVsBY1Lk+gHNdpqK7FZcHb71418YNYWw8MaoA+JJYjEgB/ib5R/Os7OT5UWnbVnzXeTG8urq8b71zM8vP+0SazHysmOgarpUoihRkAcioFtpb27gt7ZS800ixoPVm4Ar3VaPoeO22z0X4LrImryTIkYxdWwDt0zu/lyPzFdh+1vnz/AAzn1uv/AGjWvpfgqPw74bjsI4o5r5AWuJpCVVmIB4ORwDwM+lec/HLUb+6g8P2moyxzfZROY5A25treXwT3xjrXHhsZGpUlHvt8iquHlG0ux594W/5Dtr77h/46a9MGAwWMKuemB3rzXwmQviC1LDIG8/8Ajhrv4pCcqwwrc59Pescer1F6Hr5Z/Cfr+iFuGKKegbd0x0zWXMw3nIzn+VX58lmPPYYrOuMeYcVhSR2zM+c/L9OKplyr8HBOasznkjBznNUzy2Dzzniu6C0OWbOv8OuV8TKEJCtCrMB/FwuP1r23RzuhTb19M14X4byNYhkO0ZtlBBGe+OPyr27RWKwwntxXPs7DkdFHIQm1Rk55xVhWI5BJz69qpo2WAyfepmZUXduG0DmrRJZizgc7R6etSlvlHI/Cq6OHwQ3HUY71YTAXoMGmImQsVGfSnHAyd3HrUQLKc5zjrTmbjk/lVIlmXrF2traXFzNxHEjSE9gAM/0r5z8CTW9zNq2p394YZp5QAoXJbJLN7dxXqvxp1j+zvBt2iPtlu2Fuvrg8t+gNcP4Vgk0/QLO3R9rOPNZdn8Tev6VjiaihT1W5VGLlLQ01/soSfvdYmZeuUQ5B7VG0mj5BOpXWNvzDYT+g/nVgyyk4Yk7eoBxikjmcEH94GAOTuzn2rzPaw/lOvlk+r/r5FdG0A/8ALW4kxkZERDE9sjPSrMcuiqo2u4PfMWSfpSvLOzfMZVTHTOalsXtkNwb17vcImEHkkAmTsST/AA+uKPaxb2Dla6jSdD5CNIwJ6GDAp5l0tfuifHTb5PFVmlcgq5k345A/rUiTBni86RzCzAMdpGB0z71HtE+hXJbqMZtLJP7ibOOT5JB/SnaRLbQ6khtVlVT94OhUGmxvIfZf97IprO6bdsYLAg8Hk+9VTrJTTCUNGem2EgMa4GQe/YVrQSOMFB8voetcxolyJ7ZCmCMA9a6SKTMWAcjpXtLY4jQiLFQdvXkVPtkKBiQG7n0qpbSD+EnBPANXSCUY55prcTJl3YPzg5HavFPjdP5/jzwrYiNpPJje4KKfVv8A7CvaIm4JAxgdq8C8d3Qu/jHdksQtlZohx2JUH/2alXfLSk/Iimr1EgmuW3kmyuMDuWH+NQu4O7bZybc9Sw4/WleccYkYHHr0FRNcx7SC249DXgJvsepZEMsgIBFnIuD1Lr/jVSSZ+WFsxwf74NSySxEEAFcehNVnaMIAEz6Eg8e+a3iu6JbsdR4X/e6XFKY9jC4yBnOcZr52r6K8NBv7AgZdwJlfaAeucj+tfOtevl/2l/XU8DG/H94VrwlWJkZtqj1H5CsitHbvQux2wp/nj1NeizjLMDBFYsBj6+9SKC6kqV+g/wAalNnv0FtQ28JcrD9AVJ/HnFQmJvM3wsBuUNtzwalO5TTW45QQB256VseFZ1tfFGiXEgISO9iLE9MbgKz7fcgBUjDZB3DOKll3rbh13YVsg8cAGlKN00OMrNM+tLlDcaxarH02kEjtzXZRWIht85B9q5zQFRkgn+9vjXk/QV0wckBdzZ68V83GK3Z7kpO1kOEO1cK2AfaoLvIwp5z7VOpctlpPkqpeuNyjNOdrCjucX8QNsOjT3J48lGkyPYZNfGchLgyP95yWP4mvs/4iQtN4V1NIh85tpNoHfKmvjHbmFD2213ZWkud+n6nLmDdor1K5PSkHQmkzSg9q9k8sBwKeFy6gUzpj86fGcEsewoAmGCcnv0qzFCsaiWQd/lFR26AAO4yo6D1NW1JJMsgGOwx0pDPR/wBn+9eLxJqtop/eXUEZXnqVfHH4Ma+sdMlAt0jTaqKNqgegr5B+CdnLJ49t54lOLe3d3b/e4H9fyr6s019sYBY815OMklVsephYXp3OkjYMMHBA9aeWwMsM9sCqELKE+8Qae0isvPX61gpGkokGoSIYiXYLnsa+T/jbfzS6zZWe4tGQ91t7Y3FE/QMfxr6Z1t38l8OuMEYr5k+PECxeMbNASoXTIR6Y+Z+9a4VKVVXMq/u0mecMXKNgIWHYcVd8FxtP4s0oRkq3mk47ggdPrWZKxQEucqDwqir3h7U003Xba9uIjtjByqfex6ivRrxcqclHdpnBTaUk2fWV3D5kjglwBIec+3f1P6V4J+0BCsU+itHCkKuJjhVKnP7vOe35V6h4Z+IeheIv3cE0kN2qszROuDn2HPHuK86/aOTEvh9w5ZGSfHIK/wDLPpXj4ROOJUWrP/gM66zvSbR5X4a/5DVv9HH/AI6a9EtBmAkj73A+led+GQTrdsAM/e4/4Ca9EUlILcD+KuvH/Gl/XU68s/hv1/yIJWyHOee1Z90MqTzV7bmNmJ9apyjKEH0/OsYaHbIzZELMCOoqmwPmkDuOKuyNtLDkAVu+GfCtzq8sVxcZiseehw74+vQHpmuuLtuck2lqR+HnCX8AUM262wxxwpD9M9q9m0JiYIB0OKwYdEsLa1ZbeFo3WJiNq8njgE963PD7DyIWxn5R35rD7VwjPnTOojJeMEYyBjFSxkgkFarR/NHwwY+tPiJCDDbjjnJzVoZbRlIyOlSxMSBg457iqSs4UBV3ZPJ9Kn8wYzgj1FMC3uXacjkHmoHmymVPFNyW4BIqnf3aW9u7uQkUaksfYVaIkeQfF5bjXvFmlaPbYMMHzzZP8Tdv++R+tXVsL11X5FjGdq7mI+lJ4bVru/1DW7hgJLmT5FOchexz27CupZJGX9+NwOP4gTiuKratbm6CVR021E5f7BfKzYjjznB+bPbt61JNp2pqzRoiMQeSGHTs3/1q6EgiRSsRZ+5GCR9KuWwcgAqFxyNo7D0NY+wpvoW8TUORbT9QAygikx0wCMn8qU6ZfZKFY0OR95sbgep/D0rrWWRZkaONCjZZzyxY+uPSkkfzMfdlXcf3hPHsOetH1en2F9ZqHJR6TqRB2JEACckscAdjkCozpOq7CzCAptJxkk5HbGK7GFfKSTZ6YPP+NTqd0QmjztA5Qpz9R+VNUIdgeJn3OEGkaq1usqPFIJACmCwz9Mj3p8+i6jEWLzWpBxjZJuJ9eB6YruPnYKI0bHfLZDZ46VRmgVZSYimGJ3qAMAjrmm6MOwfWancp+FpmiVoZP9Yh6V2tmy7PlyQenHauGgkWLVmG3CyIMgev+cV2ViVCAjIHTjv712U37o731NqyPbaAOw9KvoflO4GsuxIVuMjnv3rUSTcowNzZ4rWO5MiYKSBgcAYNfOVxYS6j4+8VXwkRg9y0Sgg8AHAz7cV9GEiJDknjnNeI+FIUmsru6ckNc3UjnORnmoxD93l7mabT5iH+ww8TSNOFkBC8IcE8ZI9cZpqaE3l5+0Ku1sHKjB9cHPFdVGpRjvJAGcBuR0oaNdrFFV2ZQxcduOh9a4/ZQ7FfWJ9zjp/D87FglwGIXdt2Zzz061XudEnhKqspZG6/ujkHv7fSuwZRtBUvuxjaRtODx/n6U+JzKkyiRAcfdB5Bzjn34pqEewnXqdzD8MHyLKwiJyyuTz3yetfOFfQc80kHiKyjeLZE0yhSOgJPI/nXz5XbgFZz+X6nBiZXabCtO5U+cEIIiXA+vGf8azK2J03L8rAPnIB4BHpmvROVnYW5h/4VvdrIjMS0TLs7OWyD/OuaVQIwuFyB9cH3qdZJl01IDcOtvKFITO0blAJUr1OOMHgZzUSx/KQoGOuBWNKDhzX6u5vWkpNW6KxLAcKx4xn5iRzmn3TAWs3HG3g0/TbO81i+jsdItJby8fkQxDnjuewA9TXsdp8CngMF1rfiCNoEZfNtra2OXOeU3lunviqnVjT+Jkxg5bI9W8MOG0TTGJwTBH+e0V0dk7NI7jGM7RXO6Zn7Kkkabd2digZxk8AD2FdBEqwRqnPycdepr51b3PZexcUkyZ3YHcE/yqrqSbnTjOecmrUIZ1HAX6VWvsrsUnI5HSlLVFLc5rXfntJ0YkkqVxj2r4xvrRrS4uYCMm3meEj6Ma+29UiEkXIPPy5r5R+KOmPpHjS5LIfJuh5oB4G4fK39D+NdWWTtUcH1X5HPjo3pqXY88PBIHSm1c+xyXFy6WqF2ALED9as6z4e1XRkik1CzkjhlRXSUDKEEZHI789K9vmSfLfU8nldrmZkZz7VJEpchQOpqGrVmcE5OBiqEXQp/1a49fwp+4KjAkEg/ez0pqSALiLrjlhz+FWtHsH1LUYbKPO6ZwvAztXuaTdtWOK5nZHvHwJ0QWXh8X0ik3F83mFiOdg4Uflz+Ne36dFhVJPPpXKeEdOFlp8ESjCxoFHGMYrs7JACM9fSvnJTdSo5vqe6o8kFFdC43GMKPxoZF2nOAT0GKf1YjHT0qC4byjllOCeBWhBjarGGg2nPXJ46V4D+0RYBLvQdQYj95HJaN68EMp/Vq+iLrljkZDDr6V5p8Y9Ei1bwPq5ZMz2EIvoG7hoz82PqhYVeHlyVUzKsuaDR8sSL90Y6cn8KhmbbKHPAGUx6jHFWl+eTqeVyKr3kbsyBEL5YHgV7djymFhfy6dqtpex8NA6v9RnkfiMivQvjlOtxaeHyhJRDcKmePlxERx+NeayxbQTKdpwQsZ5JP9BXbfE+4+1eH/Cs27d5kLsTjHPlwg/yrjxEf9qpS/wAS/A2pv91JehynhD/kYrT/AIH/AOgNXfzsokiToSBj9a8+8KnGv2p/3v8A0E1380RM6PjbggLk1jjYt1V6f5npZfNRpO76/oiKV/kCjgY6UlnYXV+D9kgeVR95z8qL9WPFa8QtbYoRD5sytnM3KD/gPf8AE1ZvL65mtneR2MaL8saDaq+wUcYrnSsdE61/hK/hnwvBPq+66mjuERgPkJCl+u0E9a9Ejgw4VXZIuWUAbiB1A6DPQ1U8I2T2ukwtJb75nAdtmByf72fb0Nb4tXhEjypuUjLeZwR2x/8AXFb7nBOTbM2VMxPDGg3yYXYflYeufemeFiRaRA4yvynPtWpDDE/MjgyZG8FRxgY+tYujMsd3dwqQyrMwB9s5BqHvc2oO90dSsR2L5JKKrZIHOR6U9+ACvBam2jFVOfmBqwqK0mQfUjFWbj4CD1PPTrQcKSB90ntUfl7c8/L1zmng7vYY596pCJmYLkbs964n4h3btYx6fbkm4vHCYHUID8x/lXXuCGLbjgjGM8VyERN/4lvLolhBaKIYyCPmY9SD25qaj0t3M5O2pNpenQ2kCwImFhAUE85OOeKmW3lMiuqbdp4BHU9ue341YuJJV2zRxySsSEYZAKE85OT0Hp706W2UBm3tHkAYVDkn14OBWXL2Ofm11KkSSpuLHK9QV4IPTkVPbQk8KwyOORkg+uP0qxBbERYVdygbd2OVPfH+e1IIYS0gidDC5x5uehB/yKOUdxFz5YG0ADl2VfmwfQ+nFR3gWZklZZPlOQzEcg/TirSWqCVpGcqqAbVZehPXv/nNJcW6Srbl0eNecKhyDTcWJMgto/NJGGbzFC/KAdvqccc1ECflBCIm8h/lBBI7Af0qSWIRFljkA8sDkAbhnvViII+QQxUrltmcYx6+tTYdyoYg0y/MiAZUeWvHPrn8KglzvBYb5BkHI5I9enWtFIoXTa0knkg8IxIxgd+OtZsybEdHddpYDLHfyfU9qTQ0zJ1SSNpbaaGMpg7c/UcD9K6XSrnKoQSRjpWFq6D+zU2CQorgjPOzHHX0+tT6ROyBVOefzrSm7HRDWJ2tlIrFjjOfU1qR7QAecDke9YenghVI+57CtlF2oqjjiuhCY3XLjydJvZxwUgdgfopryzwxAIdAsY3cB5E8wjfjqf0zXfeNpjD4S1MqSG+zsvHqeP61yVhEYrO1QRsq+QoIXHBwByayr7pGUtETRhY5PlwUAO3J3Y9QfpSK2cnpu5U44H4elShCISeTj5iRyN3+NK0KuWxuLFQ+cYxj1/z2rEzZGruxLNtDHqXXqO3FQXK7Zt+wBgu6I4wB9PWrrxHaVZAzDGW3Hpjj2pjp5krGQAKBjyyP1H+NOwrlLUIyljHIsHnYPmMq9c+59a+VK+tjCjSMocM4wQBxnnpkdec8+lfJNd2E6nNX6BXRvHYiV0d7gNGDtYbCGPG3OG9znk9veucr2740eENF0DQdMvtCjkR/ONvOzMSzhlJBcdFIK4GOuT7V0SqKMlF9TKK0bPMBAm1HlbftX5WEqsx+bAGM5xx07A56VseE9Ik8Ua1FptpcLAdm+SVhyqcZwO55rCPkqbc26bZMfvBJh09zjtk/pXpHwftEa/uNYI2yNmJABgDJyxA7DgAfSpr1fZU3JbmtGkqk0j2nwloel+HYPK0e1jgL4EkuMyS4H8Tdff0ro9Qme5lgskbjZvc9xngfpmq+jwpcKOmOpq1pCeZqN9IRnbJ5an2UY/nmvDcnLVnpuKjoi3bxLbyW6ovzE9PbvVu5XamG+8zdqh0w/aNQunbJSHEaAHjPU1KzrJIxXcypnrzmpexUVqX7dlMYDdqiu9piZiOAc59KbE+xgTtwRUqHdGwPTHbsactbgjKaMPGw7Z4Pr714/wDHvw4dQ8Pf2jbIzXdq+/Cjllxhv0/kK9sSI7DtAPbI71j69YJc25jb/lop7dD2NZQcqclNdBytNOD6nxx4CUSeJbcAMVZZR8oycbCa+oJ9NSXSrWGeNHVI0Tarb92FAxg/zryLwx4RXTvi5fwzsLTT4pFMZIOCJcHaoHUYDLx04r3W8U+VueAW5f8Aj7dfuY4HP+1zXXiKqqVuaPZf5/qcMYOEOV92eJ+L/hlpty7yafutLhs8xqTGW5yNnX8sYrx69sZ9NvJ7K5A+0wOUcKcjPsa+u9UjXzx5jPNsUlng6ov9044H15FfNfxY0mTSPGtzIx3W9/8A6VC3bDcEHtwQfwxXfhKzk+WRy1aaWqOUsiVDHndnivVfglobX2rXerOv7qAi3hJ6bzgn8hj868rRisYAJ3H5VUDkmvqD4R6Sml+GtOtpU2zIDPPnvI3PPrjj8qrGztT5V1NMJBOfN2PUdPtxHGg64HWtO1ODkdqpghYdx/iH5VNZzo8YKZbd6CvJSsz073Vy+JN3OSV/KqN825sZ6DP508s/IVGYqM7sgVWUmW4Xjkqcg9PrTbZOjI5pNlszkY45HtWRrtqtzo90pG6Oa3eMg91ZSpH61rMVKyxMD2znoaptxYTwk7ii8f7rDj8ulITPjbXNOk0u9iUxlUkjVoyOhGBn9ay5gFgWaVmSMEiNSh/eEdcHpxkfnXqvxEit30fToWjBndXAbONgVWZm/AL+teYaWDLDPaMS8UsSnDDaFc5Cn65OOoHPOelexhazq0lJo4a9FQqNLqZDMWlZk3GV+FAGSSe1eg/FjT59O8MeD4bpAsohlUgHI+VIB/MGo/gt4TfXvEyXV3FmwsWBYn+KTsB6kdfyrpv2mOZPD/CBR9oCqvYARcH3rGpVU8XCC+zf72v6+8zjG1Jy7nlfgwA+JLPccD5z/wCONXpyIGYsn3s4IPavNPA5x4oss/7Y/HY1euJGSmGypHXPBNTjH769DownwfMrKm1V746jvV7RbaS81WFSSLeFhJKyYJX0B9iartCxPDKq9Mk4A9zXaeE9JSzDSTMguW++Q4ZSOnBHbHNcsVdnTOVkajSychzInUb9oIJz06/09aSUR71aNHkVlHzLzz39sfhU8MR3bIzuYfwhjll6ZPFTxwTSMY44kLFdwZ+VA9K2sc1ypLO0KZCKQQPn7/ljp/hWDbYTWr5eM+cSea62O1kWPy5pUVcndGR+R9+a5a5j8nxHeI4QZKuCowCCo5H5VMlY3w7XM0b9pKOhfn3NWWnBcbSVIPUGsnhR8vWrMDoyDccsvSmmdVuppGQhBtPHv3p0RJA54qC2f5icAmrDnIz/AJFaIhmd4gvvsGnTzD7yqcfXoKoeHNPW1sURthcAvMFX+InPOe/b04pviFY7q806wdl/fy7mDDIKoMkH9K2fJ2x/uV2hDlmUfMg6fMO4+tQ9ZHNVl0K8qeZEGRGwWAJxg5+v6cVYiiEsmWXIxzjlgf50P5bOhjZtiYL7OcEDr+PpU0ShmRiuJVBZc9SP6fWnYxCMOM+WRluJA4C8dv0pYIoPs3mIMIFIMYIZTn/69JbNiNhHHscZLRswPT09asRwxq0hiYIRnaOFOTj+dOwECxSiKIB1zg/vA2ABngEf/WobzIkHlqduTvZXDZJOOB/nFSqdjyMUdHLHcQdxIIxkj6+n6VHsEg2bFeOTAJwAQR1NOwrlJhECiGMZYlGUsCcdjzRbwbt+R82cbc4wOenPNagRfNO1gkYzGysqsGwOp+oOKrC2EccCFSsbsSwKDgDuD+nep5QuQtb+aTsA3H931++M/hk+9V7iNBJJDsjOBjZGNpJ/xHWtCSKIMI0IOAArZ7ntjoeR2qEeWbhtsH3wFJUnaB0HHHfNDiNMw721MtpcIrlzsYANgHAzWPpVwPIim4IOA3sa69ImUDAXAJQKTgk9+DXnlg3lm7tGHCSMv5Gofu6nVh9bo9O0yZXRSpJUjpWuknIRP17VymjSlFjVTnI79BW/psu6SQYHHPtWsZGrRlfERt3h+S3U8zSRx9cdXFZqnhBHtaQcY3Zz6Vc8VKbqfTlfekPn7mZezYO3PtmhIEk3iRgAuSCCRg+o4qKqbnc5pvoVpgQzNsAYKeGzt9hx7VPAjbCyTLgLxIoyVGc4+nakNrJ5yMpKYypBHUEde4pscO2Q7TjHBk7de1RYzJ1iVijP90oxxnkHrjHf/CmFCzMVwNg+TeCSRxwfzpsyjy9srsFyDuZdxz7YpbYMpX9z5gJJJJ+8R7UxEQiQKY41C7sBh0z7e3FfIFfY+1MooYup4K+hB46civjiu3CdTmr9Ar7Q1rT7bU7Gayv7cS2tz+7kgkIO9c5U5HQ5wR3HXivi+vt6aMXcRSEDyXwG2Nhosc9fTissc7OPz/QdBXvc+R/EejLpnim/0u1d5hbXLQI7DDN2XP5/pXp/hC1bShDb5yo4XmovGOkRzfF9pIo3EcltFds5HDEDbkfUqPxBrfmg8kwOo+6wrDF1uaMY+VzrwdPlvI9d8Lqi2yHs3WrWjA/2bJMBh7iR3GOwLHFYGhXpNmNp6Jn9K6XSiGsLUAAlFXg9xiuRbHU/iJdNQQPdgDCeYAfwUf4060BFkm7JaR8KB+dTWcKE3W5s+Y3mc/TGPzFBjMQs8jneR6daHFgmmmTOd0cyMAAiE/XNLbts28/KcLk+tG9Rnf8AxqeTTogkkGN3zAgfrTSbCSsiO0OJ54WByrZOD09KbexDaM44H86ZMrw3pmXLCRNrc9wf/r1Q1i/8u1YqCX3qoA7lqSWnKTJa3PO/iDaEXkOowIQI0+Yp94bWGCPxb+VdLbXTahpEF3IVeCUAvsxt83uJMd+KZ8RLSey8MRsVG/yikmO24g/oQOaoeDJBJ4VtI8gmNpCqNwrPvPJPfr1rFx5KrSInrFMvz7w6fYCCiZfY4wnmf7GeT9K87+IXhmx8Q6DevPM0N7Zq89u+Ms0mMvHs4wDgc+tek3m6OUtbMrqi7myu5Y29VJ/nWLNBEokuRIqkciZjuaViOUK+mK6qU3F3RzSjdWPmv4faYl/4iglmG+3tAJmX1P8ACPzr6e0eJtPmtPMP+vTYB6kEkfo36V4x8PNGax1TVYVjZCL/AOzoj9dobA/Q19A+J7ZbfSbOWNB5lvOhVh/dII/mRXVXl7Sb7I1w8OWCfc3ZnDQ+Woyfu/U1bgG1/IDERxgfy6VQUhFVo8gNt2n1qzFuN1McggkZ9q4rO51NKxZdSIWIBB24UfjVdv3UsFwsh8v/AFcikdPepr8L5SHcduOcnkVHcITbxLnG4l2z2VR/+qm4i6IrpCyxyuSW+Y4BP6VWtEH2ld2SzpskB7/T+VX5HZYYY0XJY7wD3BPGf1qvcgW85uJpPur1xgDHtRy8upF73Pln4l3G28mjA3RW801qSOqqZD0PbOMZ9Ca87gupTe3bITk/ONq52lG3Aj+6OK9WbTIdej1M3e7ybyR3DL1XMhYEVjCGTSfAHiKSW33Rz6lHZLclVDSRphiN2M4Gz9a7MLXUIqmt72+8wxVNufNfQ7j4MXccKPaxosKvM+7qN29RJGwJAJOOM+1YH7SzZfw9t2lMXBBz82f3Wc+9Yvw1vxa6jbRyR7lkUwkAYZnibcO+SSkncDgY7VuftLxBG8OOshkV1uCrAYXb+7wB7jvWNODp45rvr96/zuZ1Hejc8w8A/wDI22H/AG0P/kNq9g2A55Yg8HPPNeOeB8nxRZAck+YP/IbV7FHuhU79ygD5jjiujG/GvQeE+B+pp+HbWOTUCjJJK2APLVAV2ng59Pau1ghtoEjQNuRFJMZi+7j2B9K5TwqP3eo6pKsimDakaqxXcDnOOMGu0feLUSOYnwMpGEOW9s/1rKmtCqjuyKNZIHV12lpCCCmMsvYjA/8Ar1OupSBxEsUgD5AyOFHq1MeWSFX2R4IYKjHoDxwCe/1p6wyRokoKM+D8rHOW9zWhmipmV0aIyuT8ygMSAzdfTI4rhbq/aXxNeSRRlIQVjUZyDtGCfzzXZatcPYWM1ybd4rkKdyEggE4A/WuAtEdXwjbj3Lc5rKfY6sNG7bZ11vcJIFyO3bitCJdy7mjO31Fc5bXM8SnMS8D7y8j8q0oL2UKrtGhX+8nQ0RO1w7G0qlcGPJHpU6y4XDdR096rW1xHJFhOGJ5FJcOAuep7AetbJGM9NzIkd7nxO7ZULbwhRuYr8zE/4CtZ5GMeREwjTbkoc9cfe57cVU0Z0jkvGkZWZpwMFsHO0H6+tbKxne0z7o0UbVIx+RrK2rOOTuyOAMkhyjxPEcjO3B+pHBpHxHA145ZpixOCMg54wcHH0qM4htELklR1I9zj8RU6rM7okZjkQSDeHUnjHGO2adyR6zAkbmKOwDgSkFc46AfhV0ujlXK4UL0YjH+B71UPmuhhdHMcRypZBnGewp4Zo0dSiyJv2hduAwP6dKd2K1yS5EXmkvMVAXO7GcZ5zkfypN7RiVmUuSMMY1+YDufapJrZWJ+VtrdHAClcdeR0qlCGX50EqowYbSdwfnk+2eKd9RWJVkgaSMuvm7eA6HoQOePXP86eLvzBJKiAy7idr5wMEcAe/wDSoYodixvIzFmypVFDEKRyQf0qIorMFL5c87du07cDuDijmHylxnRgVSROCSfl7+lNZwh2qoH8Yl7ZHbHfjtVOKONsTuUDAlkUgjHqBjr9aRXH2ZxLIR3XLHIz0Pr2p8wWRppHGbltoSRWK7ZGXPPcfl6+teSWGDqV552dxlcfjuOa9AuGIiAhlkWQKdyg8nPJyK82tGxdkMcb2ycdjWdR3sdOFjZs73SGLQpj7mOR0NbehXGZriNxjsGzXN6DIRuRjwDj/wCvWrp9x9mvZgT8p5z6VCdmjqaumjTvbcSoVkXfGRtbd7/WmaQWmsAzEgxu0chXDbiDwQB3/wAams3E4JAz6Mec062jjtr3lB5MrZORwGxjke/FdPxao4asbDnglQEqruBJgsFJxz1A+pxike3DAFo2DCPBJ9DzwfStZ487v9YAuWUcjcO34dah37ZGY7gJMREkcEfh6EUcqOe5n/ZGkUvtVyyFowGyw4yTnt0pkOkkzN5OSygM5YZxnufU/StqaEtI+N24sCo6YPtgdOtSxGRZQyRZRvvgHPPQYP4U+RCuc++l+ZFnLbWO045IOT+Ir4mr76jhEkqyP5ZBUKAq46dQfevgWuihG1zCq72Cvsi61BdG8u3tl3iFsSqpyWOOn+6K+N6+xbS5juoLW91O1ihvVLGDef8AW7V6t6gYrmx/2fn+hph+pzGtNaXHiN5rWLZsiWFieuQSSoPoCf51NNB5lseM1i6dM0pM0hLvIS7E9yTmuitSJIjkn6V5bd2eqo8qsXfD90YkAODt4x6iu58LZltFL8qPlAPpXnKqbaUsvKnrXpfht2ttOhJwoOO+D9a0SuhM1JF8q5lC8ElTg9OQR+tErMZbZWOCHBHv2qhFetP4iuoFGYo7eNt3bLM/H6frVzUvljtX6OkgwfUHine5NmiSY4jnfaPlOMDqKROASo6jhfepmAMUhOCp71n2c5nkdEGfKOGPp6UPcpvQmuvMeRUQ9R1rEtJUn8TQR7s7UE5U+xKA/wA66C8cgtL0IXA7D3rxvSvETf8AC2bqIyhbOONbAN/t5L/zJFVGylcqK59D13xzZjUtHu4zgs6/KPTFeX/Du6KWN5p9ywQQyi7wSWb5htPPXGR0/OvVr2XdZs2DIu3OB3+p7CvG9Fm/sz4iiDeEiuQ3zgk7dwBHPcFh0rCsn7RSIlH3GjuJt8ewOjfJiePDFc9sn1XjoaybqMRyzTZRpIv30qAYKA5OfTseK23h3S7SHOXw8vH7vHRiDwc9u2DXL+Nr2S28J3A80h5ytuqr33HGeecbVJx71tE47XaRznhRW1XxJBcOXJnnNz8xy21emfXHFeq+NLpINEKu6gAq5B74YVwXwyszJqZlKZEUIVRjuT1B/CtP4xXSLpIsITm6vJI7eP13Fhz/ADNbQT1bPQUU0kd/pZH2EEnIYAqPSo5Lia2vIBIAY5Qygj+915/CofC8xlsoS3zDaPxqTWm2yWhBB/f/APsprG9lcz62NduYgSFwOc56VWTddXLYIKxJsVT0JPOT9BirCLus8nmqOjuC90HxjzSOe+AKdyXdkiPu1WCLglYiT+Bx/U1i/EJ2tfDGrzRsSUt3YYPQ7a0wyprcjquX8gKuegyx5/Sue+Jgf/hC9Vy3lk275JHUHtU2uioxs0eY6ZaiHRYcDpEv8hWNrFhJqHw71wrJ5g0y9Nw8XGVjdVDkZB/hLc47V1N0Fi0+FBwRGvHpwKxtFctNr+mxKM6nYOrFsYA27MDPruH5VlTlySUu2oVE5RdjyHSbma0vI5gXW6hG8kA7t0Rwx7nmMtnOB+VdL8YLl7nQ/DAYSBYmuoiWPDMPKOR+BWuPjkEMscjqwXKStvzjaw2ScZy3OR1HQ+vF7xpfyXWi6Fb3DyGezE0Eit2KlFz+IUflXs1af7+nUS7r8HY83m/dyj/W5T+HyCTxfYIWKg+ZyOv+ravavKRkaIOoDEIC3AXPFeL/AA5GfGWn9f8AloeuP+WbV7npOLrVTHLAGhij5DHAV88Gs8WrzXoXh3aDOn062MOnx20GZFjAX95j5sDrz6HitGExKypEpeDB8xXbJU+oqNI2jMbqhKhioKN0b39R3qeJVeLz9u1/MBbAX5W/qOnT1rJFMryCYKqxtEeOXDdWH9famFvs4MxjjYADfhSQc9R9aLmGXyRJIqshB+dRtxkdCvaqmpXUEUDPd3L28JHLEZ46Z9/wpMa7HP8Ajm5RbWG3WSWPzn4x0CKe36VgabGkKblnY54weWFEsrajfy3MwLMxwm4dF7f41pWtsVPCj61le7PQpQ5I2L1mJwwaORZB24wR+FaNtH5jMzpJEx6mIZ/MVDaWeGBPGOhFbEFnKyh48hh/EpwfxraKuW52RLBEojxuVj2YcGob11jiaQkZUevf3qyQ6Y807m9ehzVeKBptTREwUj/ePlSQT/CP6/hWxzVJaXZe0y2+x2CbwTdgln2x9OpOfwOKvrFuiV4UmVwxIHUcZ4wf1qRYzModpApH8O3IY46A+lTQRyNuR2RMc4Dje5bt7Co5TkuR28auGk+VGdcFtnAOOB6ZHaqEVnPAULPGySYIyu0gZyeh+91/wrYWIQwRgSKGyFaRfu47Bh6cUXKIk7CQI5j+YMucnI5osK+oxlEhDxszR85XdjBB/lTFhEDlUUKUJxKx457Z70qpEZW8wPEAwKlzkZP9KsxBBLwvQYZlyqhT0wOxzSsBVWJzKWljUkMABG/UY+97/SoJgnKySBieqsSD1PfvwK2X2FISsX79CQGTlCMdD7UJHJE6lfLm+c5dhgnoe9PlDm7mKLYm3xCjAEjDHBz6mop7RDM7eSWmbGfkwNvQEDscVrtGjSSOAohY7UKZI28g5HY8D8qkkibd5gHzlCiqpPynPXpntS5Q5jCit22kL5vlxkKSUHHHGO/XrimLIT+5dFnCf3hyuCflz29a22tAZg6swU8E9TuPXFQPZYLm4fcpJ/dqpAzxjrzRy2HzI5+S1+0bjsZRtYhAQQPqT71xnibRPsbm6s42MIQGZO8Z/vAelejy2ciZeUSLBGcvvAJz/hxVf7MjzSR7hER/E2O/UDv07Umk9GXCbi7o8+0m6cRCReXU4J7OD/WtlbnzpFkjzg8H/A1NqWiSrJJcWK5hD/PAkZCnsGX0z6Gq9okM8jNbuEkQneDwQf7pFYyjY76dWMtTYtrtYWG9sKO2a2EuY54ihXIxjkVz4Ux7ZX2+YT39PUVtaNcM+ASp55y3JrSE7OzFUSkros2l69t+7njmltVX5Soww/E9cVoW89rczBoFwxAGAoyTxznvzUU4jfO4AN6kVm3EZtixjfGRgsnFa83Q4pUr6nQWywyQMwZSHPTnBIPfuOtS20MhjdFUgMQpXdkIQPU81iafqzLdI95GXjK4DxcsO2SK2rd0nnDKweLOd8Z5xjgsO5GMVUWmYThKO5cCKF2fL8vOAD+NfnxX386KkUewANJIAJN3zY6nPp34r4BrppPc56gV9H6hPH4jV77TLtCsUeJoJAVaEBfur2IJ7V84V9USaZoeoWDWs8L2boWaLYjRDf24Bxj3PNceYNLlv5/ob4W+rRzOmzDyFbpxxXS6Y+5Rnr+dcHp05+yhWOGXjI74rsdGkEkKc5Yc9a8ySsz1nsb3kiRSByOlemaXbs+mgHITGcZrzqx3SyRRqCSWAwPrXqNs5itRAFPTqOmcVrDYzadtDI01Yvt99IucbwhYnGSBk8/8CqXWpAxtkQ4Z51wPasvwnN/aWitcqrDzZbhRt7YmdcnnrgCrjWzjU7NcsyRrnBG1QwBBOPxFS1poN/Fr0NWZWjsM5OfX2rG8LSvLDesy8fanUdsgYH9K07q8WSJ415KAnbggnHpVLQnSDTQ5YL5kruPfLHFP7RK+Fk3ieRbbTpX2qpVCxwfavmTQ7tkhGqEb5GvTdNn+LDZx/OveviXqBh8L6lKCwaO3dhk8YxjivDdMtRF4ZsxjBZCcn3Jok92aU9EfSPhrULbWdKjlt2V1kXK89a84+LGjXGmzwa7ppCmCVQ7MMiMgggn+X41N4ZlvI9B0jUNNMYeS3USwlsJKV+Xcp7NxyD1rqIvF2l3lpJa6vGkUjqY5IbkY3D6d/wAK0ko1I2e4KXP8P3FOz1G01SwjvrRg0EqrtUtwjHqh9sjgH+VcN8Q7h5tW06wZlZIw1zkZ/i+UZ9+DR4Ptrqw8X6vFpkNwnhsh0jjnJ2ljjDLnkkcj6Vm6tJ9s8X377iywstupznhFAP65qFsc0IpT0PRNJ1LSfDuhRstxEzeVuZwR8znqfw6VyAM+va3FrN2rJbQA/ZIn4Zi3WQjtx0qeztYXwzQoWHIJUHmtLb2YVve6NnU05Yqx2PgmfbpcK7WLLkcD3NXtTkS4+z9AwuATxjsay/Cqt/ZcUajdHvYOvGSc+9aWrQ7TZDcflmAHGOSD1rJx90S3N6F4hZhQQT1HNY8JeGa88pDs3hg+AwJIHAFPWGTyxLJkMinqFJJ9quaEnm3FwWXa7hSQRg9P0qkrtE7alTTZJH11d5AVkYDAIyMjrWH8aGWLwfexqctM6R/m4zXSlAuuIinbtiJBHqSP8K434zIy+FpC7An7TAq+pJcf4UpaRZcVeSZw2rrgMAflTjH0rN8GiGXxTcTPbm6mtbN54rcNgSsGXAPqPb2qz4kuNgkGfmJrjtBvjH4hubyEXMk0AWOJIiEVjyTuY9B06A/hXNGPNcJ6ROcuvBHiC8kuryxME1u/mtcNGwhCfPyh3YB5xwCentWB4w099NTT7e5t5La8CH7RCwXAfCjcpUkEMoVvqT1r1fXotV1F47qRbiK0zKEtkXKhsqSUwcEnOcmuK+LZvJLPQZL+3ETBZYUfOWZVEeAxwMkZ7dM16mHxMpzUJWPOqwUYuS6nN/D6dbbxfYSuAQvmcH/rm1fSvh+zWK3LTl4pXbzJAAMMpxx79a+dvhPEs3xB0lHVWBMh2t0OInNfTUbmOKGP7OkewK4VQeGK1riF79/Imi/dsPt939lqXDLuOFO7GAM9verZMVxAcvGyFCMnBHPr9KhCCOTfHOlxsYgqcnr1/Ee9MkP2Qo7bktwpd2UYKIO5rA13Ibi/jhjaQTIPJ4kYr8m0f3eK4XWb9tev1kcFLSL5YYvQep96teLNSk1jUHhtty2qfMWIx5noSPTp1qtZW5iiG4fQ1lJ30O6hR5VzS3COFAdkYAPvW3ptuzufNUJtxyOQaoW0R3cL+J71u6a22JPMXI6Ag9qcUkbvbQsR2vl4Kk5A/OtS1Y7ehB6c96gV4wo3/d/I0ks8cTqqHc78Ii5P4n29TXUkkc85EGqXSRzRRH5pZG2xxr95z7CtbR9NNtH514mLi5ySivkKykDace1OtNEji8rUHMd3eMCfN252g/wKOoHv3rXu4o2klnC7IwQ2QMcjHUH2FJyOWUubQqiMRyyCNtykY/efw4OMD39+9STBQWZWAjdTngksMcjPrn9KtNH++xcRoJZiHyTuU9jjtnuKqJEizvF5wIjU7H3eo5zj3FSzMmFtLJ5sbfZ44ygYcZxweSR6d/wp0K7v9TbleMOg6kcZPWoJp42iT7NJuULsmLcHPHH0oeM+cEy/nJn5QPvJ1znqMenelcLD447eaO5SISrvIA38tj1B7CmJCSwZGaU9GJ5PHBOe5x+tTqIyZA8jQkOFUoPun+LAPX6c1XJkgvRmFmEhYgqxwV7nPvjpRcCW3EyPcM/7uEgMI8bvMHuc1agcyXK7dkYCZIYkFWHXPrkULHHEStuHZQAoVn+YZP5YoiVt8olkBdsqd45xnnmhCZEh32zNGrSE8ct98nt9cVOEm3K0J2kYk2Kw555DE9Mdc0gZJFASGQMjA7C2MnOMk9DxQrRvcvs2SRsShbPB46HPPrTArxIGnEskBYy8CZfTOctj6dan2SEJIg27W3sSSSPz61AVni2o6PBHtCBlO4AA4GR0A+lSuBGgMiF2Y5IU4yM8Hrj3oQiuxWWaLe4ZXI+YuOck5wPr2p09j5qoqmNducgjPHbj/wCvUjZ+xzQy4+0M/wAjsv3hnPb2p1u0i3zxNEeihjnjp/TnmgZlNaTxXOyNPKyTt2njAOSD/nvWNeaNbyefNb28cd2+P3gG1j744zXVEiOQtCJJGYkKsg6kHBBNJJCsj+YB5UkStjc27Oe200co1NrU89YSrE8V1/rF5XHRueSPyo0q5drgCPIAb5QK6jUdIa7hHmpyMHgAP74I/D61gaPZTWNyxvISsCsSkwORjOBuPY1g6bTuejRrQmmpbm/HIyoFaUYI+Utxg0lzNFHEDPLz74xVTUgxRpImBB6+9YF7cKGi8x2dVXayt0X3BodS24vZt6o2JZo2kBljKgA4mjP3fQ1P4euRBe/vwHycKy8hj71h20kTwObWXLk4KZ4IrR0u23pP9nkeG4CkmJurL3PPWnGbumVye64s7hYFmMErD95jdGnmZ2j6dCa+A6+8tJuft8MMctsIp4WVJS3yseOuPevg2vQo9Txa0XF2YV9FLcywsGCSx46+XO4/Q5FfOtfTFpPp95GG0+/srnPQCTa35GvIzu9oO11r+h3ZZ9r5fqcOxKPcFc7VlYYJyeTXR+HLs+WAetZniC1e11u6jlTb5qLKoyDkEY/mDUeiTmNlBPIOKyi+eCZ2tHrnhA+frFoi/MfmYZ9ga9NvZfIsDM4/1YLH6AV4z4c1A2N9b3sYL7Mhk9QRg12vjfxpFN4Qu7bR4mm1CWBoIVAICswxuYnsM5rely8rvuRZ3JvhAjzeAtHnkGWnje4P1d2f+ta186Saz5GwMyw+YB2++P8ACofClhLpvhnS7KMgC0to4gem7aoFMsSZ/Fl82CAtrCuPcs5qXbZDa1ci3eWrJbl4zIm8g538+/8AOquhQJ9jG4hQZWcEcfL2zWv4iZLTT5JAo3LHkU3TbZbXR4UY4ZUC4z3xVJe8Z3fLc82+OV8kPgy5jhVh58iQAscEknnH4A155cxfZtOghBJEcYXn1xzXTfGO7F/4q8PaFGxKRFrycdvRf0DfnXOazKCjAcAVFXU1hokdx8OYmuvCWmRXJmIWSYRxlSiGMSHLggEkjdx+FbaNcxs8VqZJbeP/AFTSw5kQHqQPxrjPhpfajP4cS3TxDplnDHcTCOKeNiwXdnDH69K6L7frHmh7bX9CYxt8yksuT3Jz2NRKajuckqbcnb9SxevHDC11DPIxBLpK2SJBjJ35AA78DNeX6A7zyyzS43zSNIxxjljn+tdZ4p1LXLfQ743FxpksDp5ZNvJkhWOMKPTnpXL+HhtCgY5wacZqSujWnTcU7nZ6eAAR3q4Rgdeap2ZVlyeCRx9auEjZkn8K1TE0bvgy52TXFux4JDjPT0P9K6nxGFGnCYYyjI+fowrhPD0wj1uDP3XDL9eK7LWYX/suceYTmM8Z9qbehcI3szdgjElgzDqKo6RPHbXl68mS25QAB14pLXURFp8aqNxdcnHOOKqaDJ5+sX20bhlPoPlp7tW3EoOzuWo3jm8QxsrYzDxj/ergfjTPG66RpkMm+We++0Oo7Rpkk/TJFJ8Vb2bT/EHhaaxnkthLcSwSlDjcCBwR36VyutykzzXDMZJ24aRjlsen09qipUtFxtqaJJWaOY8Q3BaQgt19KyvDuqzQaUhEdumbiRgz4UOucDdk89O1M1y4O92LcCofDmkxrplq8qgs67yD7nP9a552hTu/63LUeZ2NNvFOp3kswm1UGOQtIyKh2gsQBjAAHCDp61w3xJvpbz+zVluZZhEsiqrAhUHy/dGa79LS3U/IsZ9gM/yrg/ifjzNOCrtH7z+EjP3avA1VLERt5/kYYuCjRf8AXUr/AAgXf8RdIXDHJlHy9f8AVPX1DCVmH7nd568l25B7Hoa+YPg8VX4i6UXUsuJ8hTg/6mToa+pLYF3t57eFIgOSWXCnjuRxk162I+M82j8JFhMKu0kK4+YP97HJ9x3xXP69M9zbmKZiYoHyW/ilyfkT6Dqa3pF8pyYtoWViVbP3HGTjHvmsCWWxjvb2SZJSw4htiuGLnnn8f0Fcs3ZHbho3nfsYOp2k6zWv2QSPcTgyTsV3DHbjsPT6VVsLqZr14J4nLqM7Yx93nvXSraTadA97ezMJW/eMCcZ9APbtUnh6wlgtpL6YqJJGMjZA4zWS1O9uyM2+ngtLFZzMrIxwq9CzemKfpl5dTqhdYVlzzGTgAe1QRQrqGrT3EsGYBITFnp7n8cV1EOnQugYwDC8jIHNaR956FbR1I3chQjjlck1reG7Bo7sXVxG4lkTMSgA7VP3WB7Z5zVSxshqGorDMj+QUJdgcbuwUHvz1rqJXEbIBGSYlOAgwGBwCP64re6PPxE9eVFm2iU2odysbu2xgTgN7D0+lCIs7KwMgVkK7dwbce3NRROsUrvMJAivkNyxVQAD1/wD10izzfIhlVozjagTbs9/5VNzmG3Dg2E0ph2tBtOQ4DDBwSR0BxVaN4Lu3jmt5mliDHJjfCsO+R9SOtWSDOm7yQNjYLoPQ9cdx/I1DMkbxSSRqkNu6lfP7hs4GVzzRugLHnqs8OJI4xI21Xbu3uRx0xVe4CxIRPIput2NiclQew9uTU1sskUSeZtmMQ8yJEwc9Rz/nvUMibRcXCOUkO2T94OQO6nHbtRqGhK8UfktCYNqR/NuDZ3EHr+vSo402k7G2sEJVQ3+s5PJ64HNOsY/tIV2lcQPLhWf5VAJ/D0IxUtrKNjybmUGTKFjjcucYOaAJLVpHvMON8SDmQAYPTj8xUO9VMysxjlJyhVeTyccZ54qS5jIVmBG4N8sanhieDg+vQ0x/MilYysiMIlUELnoe57dxS1F5jtOuBcCTyzIqoRnd/Ew64/LmpIXPkvKytIBlhx8yc8H8jUMKOtyZN8gicsWGc8+n405Gf7ciOXiHl7yo+5zwMmheY3q9B7zDFwzq/XarA8M3TIA600zrHIzGRzJGMBQMgg9jxx3qlbidZpzdRiOOORVtmjJBPGW3dehq7KWjmluAXG1RghAcHGefzp6oW5HJErxgkMyO+7CHdtHXGO3epHR3tlSzmMDq24jYM7ScHI7Z9feoklRQFjykI2hh91t5znjrkUilJnEQEg5LZcEc5xj1xj8KYth9wpl3QiNzHneuxSHGO+RTILZYo/JjeSQOuMEltmSckE8/h7VJKEZUMwYyKPlaNyVAHT/64qv9qcbhbyRDA5ycDn0Hc8dKALUfyyr5js8COFJkX7vqQfTjqelSTwwTBpXTdA5OVOCCe5x70Qs7LuLBFbli/Az6dKVDJGVK7AoYhkfgk9mHb/8AXTvYW5kXugxsyR2Zki3EIoBGOuc49ccflWLf+Er2Qskmx0D4Lrz+Y9u9dzICUgkZJZlBJ2KQcNjj6dqWGCeNpysgUE4QNywHcVLhGW6N6eJqU9mcPbeF0t7aWLyYvt65CTKxKq3UHpx9K1rfTWkNvJGIIpgf9IIY5C4xwMd/WuhV51nHlSB02bECDkc8kHp7c1EZI97LdBFYBi28fN154Hof504wjHRDqYqpUd31I5bcCUynCgpjcpLcAfdA/CvgKvvlYA7+VbnCqBwGGdp/i59+K+Bq6aHU4avQK6BBj50H70HKM2AWHsc5/GufroiUlDo48xW5SYDO3oMDaOP5V0GLZqaLqsv20LcXb3HG0ZbcE79Tzzmuq0yRRceobpXBkv8AKpUIVBJjB3EHPB5OR2roNGvNx6gkdwcjNebi6Nveij1MHX51ySPUdKmKqo5PFbUTl3jXBJcgD8TXK6RcgqvODXR2VwySJMoBaNldQfY5rzlozsZ7XbWpis3LO5cAAbegrnNIeZdc1yUqC/nRQKPZUB/mxqJPHVpHpzh4pNzc7FGT9B2qx4Je61C0kvZrZY5ruRrh0Ug7F6KPfAArsajKyiEW7PmLWtzPcWsaHcd8iKVKlc/MKtOsqpkspDHpjH61X1VGuL6xghUgNLnJGOByat+JpI9K0me4mlIhtYDM7MAOmaSpuzbHzRjZHz74iuPtnxg1iTduSCIRKf7uEHH5k1R1uTEbZOPSq3hVpbx9S1m4/wBbezMwJ6kZz/h+VRa5LgszHAUGueWsrFLcteDr6UaA1lp95M17JfO5txllAzjkAfLwM5qa0vzqdwsdzLdNcQg+daEKI2bcQWDDll4xj1qv4At9PgtZJL62uBewjz5ity0LxxschtuCroQQex+tVrslLuPUrCORbe3vUVQxyfKkO1geOmSD+Fc1V+9JRf8AXRf16ijFbtCa7qVtqGlW93HZR2rGcopi+UOFJU5Xp/Dmtjw+4ZEJ5GM5FcW9q5sI5W5htwEjGOMu7MxH5qK6bw1M8SGNuij9K6IRSi0n1FLY7e2kKOFzwemavGXgDH6dKyLeVXjVlI4FWlkORk+1UtDJotLO0E0c6Z3RMGwO+DyPyr1/7KmqaAzRBWBiDR8nuM14qsmXP94VsaT4m1bSrZrWyuE8g9FkTdt+lawmo3TEr9GeheH9l1poZIwW2DjuT6CqOnahZWPiZ7O6lW2lmQTIknG7b8rY+nH51T+HmrW1rYR2N7d/vklZt8p2lwxznPTgkjFcZ8b/ACLvxP4XSwZJ7mG5eRzE27ZGQud2On3a0XKkpo05rtp7Fz4y3MOpal4fsrB1muILxrmQoOI4wvUn3PSuM125IR8Hjk1ozXATcUwvr2rkNeuTIWyevIFck5e0lcF2OT1+9SNHecuIuhK9efT9ajl8Y7lA06y2xKPle4bPA46Cuf8AFN0bi8S1jP3Tk/U9P0/nVSN4gqBVEcSgZLYHmEfWvRpYOnUipVFc4cRjJwk40zfl8Rak7HdfvDuPEUCAAfUjnFc/4gnuZ5Yvtcs0jLnBkcsOcdM8ircRZshAy8b2JYlU9hng/nWbqmzMexdvXOCCp6ciuuFGnD4YpHFKtUn8Umzp/guVHxL0cvt24nzuOB/qJK+o7FZIba3hRC+nchzGc5J5HuK+W/g1EJviTo6F3QHzuU68QueOD9K+qrGea4hMuNrKxZhKuC+R91gO49RWNf4ka0vhJo7JnVntVIOQdjtkOuOvsaoJp0T6gb2ZjMVTbHGTt8npnd656ZrXt5CGMcAI3L5isy42t7Hofxqs3m+QXkihMgkVc5+8M1g0nodFOcoO6Ob1SM6tqyxtE8kVrH50pBG1OnX6Z6U7Vre51CVtP091jghI87aPmJPY+1dC9vF/aTB4vN8xfungNk/d/SobXTbH7aZbVXimeTMgZtrtj+A+vt3rJ07nbDFxSTa1RgW2kXNncNFGzzIoBMrjCj6etbNqkty6QMNsP8R5G4dwD61cuo0SYOWkC+acI/KuuOfxHof1qxaxRxWyRx2/mW3zSIUboc56VcYqIq2LU17oTQSSRW6DAjRsqGbBC7cHDDp24qOG2QLLGXkjcL8oYYMZH8R9QfXoeKsQmORw4hKPKmSZDkMo6qff3qGC8Lz3c007GFABCGXG0dwW6nPrTucQpl22sSxF5nLkhDypHfn0qzGqzosaLnrvyDnGM4PqPpVW1AaBZbhWUmTKjbkqT096nj2yyOUYyLIFVXGVwcZxj8TQmDG+TIB5qOpt+PLEaA4OeuQc8DgiliMIklSbLTKcOxI69Qcdj1GahmuY2jWMRyo5JLCPnLDADfQ1NtMYYxormNPOcEck5HSj0F6jY52kvfmgXDx70VW+83rn+H+uaiMajYVkmgkUbmckEbf4lIPcVLBLG0cwMZiu3ZiDIMIo7AAdfSrEexlZZwkl28gAjThdp+7gn8+aNw1GO6LgCNrhXUtlkyAeo4/L9adIbc28hlV4NxIVE5IJx0HoaYtv9ng3FUhUndtDElmP8Q9qciFpC2SSy7ijDcVAPI/lTEKZQQ6uqlm6ZPGMDJ9icU9Niu28TSL5Qy237/qT264plrdxPtgxFI+w/fO7C9eT6+xpNil2hhUr5hKu5JT5Rk9e38qAJSQY1laIkh1OxR145wPzqu26TbLslaNXLAq2cqfX2x29aWBfLngkRZhjqd2Vcdj+PWnTy7GVpWETIDvH3eM9x34x+VADmlmSdYhgwuxAI6KD296sQx3AhDXC5JU8qeeOMHpzjvVdyqMDA6yrGCUTOck+n09aaJB5o/1nmuMNvJYZ4A4+nNGwCTSeY/ksD5mGaMDqe+eevNPN2soYpcNtZQFV1BJGQCQevJ9OlRSpLGjJHeQ+cqBhGRyM8fXnBpsf2hxNtUPs+VUbK5yP4f8AGkMlgxHK0keTuBwGzwSec0yKFVZ4WIkkhO3ai8c9zTmtppIUQSpGjIEYvISSc+v4daS1aMebGivK7NzsflducjHrnvTFYdCQ00oZWUphWQk4Hodp/L6VZkMlvAImlWdSdu1U4Zcc4P5VCZ2FzGHZ1MmA7ONwywPB7+2KrySGx00YufLEYzvIPyDIAGOtF2FjRmVBG0wEyeWPliX16g49cgUksca5kMNxufDFhkMHPTr1HOKZC13cx4khEnmnkq+1j8udwHp2psMonCTLc7Iiu19x3c54PseOaYkSQkrH5qfM+d0m07Qn+zg807dFLIRCgO8lywYA5I5601PO8uV5NqOz7yV53Hp+tVnWXEvmeV5bqAVxt9Bznoe2KL2C1ydVRZA0Q6tgZblj79unpXwHX320sTW7S/vI0XjfGwIYDGOO/WvgSumg73Maq2CukLs8ZYyZiOAwT5zyB8ox0965uunKO7ed5IiIwC8gLDb04YeldBzshZQVYQMEwTuDYLygfXnpV3TJUiudqvubo6gnCegGe1VD5JPJlA6JKNvzZ7ZAzj6e9RoxSbMxlaZDhY4wSPqc1NSPPFxLpT9nNSPUdEnUont2rqLaXC8civPfDlwXZPTHWu3t2Kx568V4E42Z797o0Z5D5PynJK8ivYvB+raUNEjdJ40CwqoHfhQMH9a8UVy/txUMpLKScc1dOp7N3JcOZWZ2ms/EkW3jyGLR7b7dpdtA6XE5O0GVjn5D3wBj8fasj4jeLbzxlYjTYkFjYSFTO3V5AOiD0HrXMvh8A4H04GKTeI8jPHTrSdeT0Q1FBtjs4IoYFCxxrtA9K5XWllu7qKxgR5JruQRhYxljk44/Ct2+nCqcD5j0HtXmnjDUZo7+D7PK8U0Z8wOjEMp7EEdO9VQpupKy3JqTVOLkz1u40rT76BFsrtjq9vD5GyVdjiJeNrpwSPWs+P7PevLLHG0UgP2PUbYHIRv+Wcg9s459D7V5zceKtSnhWLU3W5uY1/dXcmUmhb/ZcHn8at6R4vmsr2W7ntWYTW6QymOTBkYHIbgEc1i8sxEU7a9tf+G/LRkRxtF9bG1APM8OWFs0rRJHbNcXD+pyQifif0FXvD04khRzwwFcrqfilbq2ht7awMSKQ3zSg5xnC4xng/yrS8I3ong5I6nOOxzXQqFSEXKatdlKtTqPlg76Ho1lIsQAGSM81dMmRlcc1jWzZVCMnB5xWgm76c1mNouBj26Z61NEcqcZBqpGcZOPl6DmrS8Ac8fyqWxFlsH74z6ZqOXYikqApPHA5pXbCgVUuXIXC9feobHYzb9toY9K4bxHeiKOR2PyICSa6vVJtqOWPTvmvKvGl/vCwK3Lnc30H/162w9PnmkFSfs4ORz8Be4unlZPMZjuI9u+KtR4wmJP3hICx8Adehx1PvSxQKtsikDAzuZATu4zkHPNOjEYChP3kw5JY42n0OOa99KyseBJ3dyxsDEI6DC5Yg5OW5IGcjOKz9X3GO3LAgEHA3Z9OelXlCnIZS4jGdkoIOT2BPQdaztWGJEzOJc5ICnhRxxjtSBHU/BNEk+J2ipJ5mw+dnYMn/UyV9USSILpHk8yPjbHNGvy/Rs8CvlP4OSLF8R9Idm2qPOyfbyXr6ogBciN7gfZGiBBPAHtn1rkrv3kdVLYmthPA8pOLlJBuyCTkY6+x5qXymkuPsMMTqyQ7ywGQ65yCffP8qihtg2EgNstsRvJ8wpt9Pz9amBSMMYWaFo14DEEHHoRzWBqR20aQ3E0dzIxQBfkB6E85X0p94rssjThrhXwxIBxgevYH3pjeXcXUxH7qR9jRvjDgDtnv1/WppptsMywlFm2nEgJ4b+62f6d6QxtpItyisF/c7wxaRt7DjAwfz60KW82XyQz+ZJgIW5Q+uOuDRpuLcu6OGuCBvhZQMDPJ+vPWpY/NkvZA828yAiNtn3O/XuccD6UugdRwikhW6PmGCOUhlVmwdwHIOexxmoZX8xC0IjaNlG2NOM4b07gHmphjALyjcu5d2OHAYYz7jmnyoDOJIYoWboVAGcf0qhA4ieOdjNGFKAq+PkbPT8ar5EFuy73lmDBkY8KB6DH/wCrmn2Lrc2xgQrE8h3bWAyAD6duKmefkKYomj6NtOMAjj61Olrj8ijM8crQpIGijZMOACRv5OAR2qvcXu1Y0eJRtYgvHxnBweM+tXGkmjnaKQCSFWDZU7i3OQBj2pFS1j+z3N35aBQYwp+8c/d49eg/GhBsJazSzRFZVWRy25EdO/bbnp061fdPLjW5hUyzKuGUtgg9SMe1ViztIp8iYxj7kocAox6gg9h61LazRyI8T5Ry52Mw+Q9lyfcg/lTQiSJbeG4tn+efZlAhfdweSOfcVF5QCqw80QEsXKvlj6D14qIu0SMUhRZmJ3fNy49Qex7Vat5c3ILllIAADqA3frjv0/KgY3yEQFoEgjJAQrtAJB7/AFIz+NN8iNSYcyywohjJ3HOAOvHcetIvnSRqkrxz724AGGAPbI646+9SmRGdcMIFKEgt0IBwQR9eaZJCitDA+7kj7isNrMOgHqO3tTJhO1sqKvnkgArwV5xkHPP5UsnmC/Hno5EoCsyEHbgYznsOlT2jyRrN5pIRmKLn1xjj3xzSXYbK8iL5yG2/0eVJBlD1wOMfSliWZIN4IMRnJwv9zJwf16UFiroyTRHf0RTww75HXt/OoSGghmSJuW27iSQuN2Sf6UDJZPIurhZiZbeWNvKUOO+eOT9aVYmigMSzETeYw3svPcj8skVKwmSPyluEWIsRkc4II4IqNC6tGVREj+9IpbBGOvXqD6UWFckgiYxJFdr5r7mbzBnafyqK08/EqwQrHIMHzGIzwTnn9OlSygqW2KLeJQBswSpGeue3tTW8xDcSWwRbdCqhs5bkjv65zTC4stqReQRCaZTzOPMXPOenHHf8MVNdRrPNArrFIEbcWOeDng/hinWqZn3HeZFY4D9AOnWoyF3qzbvNlYOQuT8p7YpiuXLUOZSWkQbTsSNQcjkk1RxdOJGNvHH5r7grD5iAcEn35/WrBk+0xoT5lq4Y7WA5bA+X8Pao1VJJVhaaV0KqVwDkDOefzxTfYF3JzHGXZ4igVT9wjnOM4FMX/SInWeNgk2VkLdOB6+vT8qrFncGTZhUJJIOGHocY54HSnyo8cqRx3STiTB8hsdck7l/rSbBIkit45IzcRRvFtf5QDx04O018CV98Mpa9nlh2sSQE3tjYemcZ6c9K+B66MP1Ma3QKKKK6TEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stage II lymphedema. A) Left upper extremity. B) Right lower extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tammy Mondry, DPT, MSRS, CLT-LANA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29942=[""].join("\n");
var outline_f29_15_29942=null;
var title_f29_15_29943="Sliding hernia repair";
var content_f29_15_29943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Sliding hernia repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 619px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The hernia sac is opened, exposing the intraperitoneal serosa-covered surface of the sliding sigmoid colon.",
"    <br>",
"     B) The peritoneal portion of the sac is trimmed, leaving a cuff of peritoneum attached to the sigmoid colon, which can be everted for approximation across the extraperitoneal mesenteric area.",
"     <br>",
"      C) The opposing leaves of the peritoneal cuff are sutured together from apex to internal ring.",
"      <br>",
"       D) The newly peritonealized sigmoid colon is returned to the abdominal cavity allowing for closure of the neck of the peritoneal component of the sac.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29943=[""].join("\n");
var outline_f29_15_29943=null;
var title_f29_15_29944="Optic neuritis: Prognosis and treatment";
var content_f29_15_29944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Optic neuritis: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Benjamin Osborne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Laura J Balcer, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29944/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/15/29944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is an inflammatory, demyelinating condition that causes acute, usually monocular, visual loss. It is highly associated with multiple sclerosis (MS), occurring in 50 percent of individuals at some time during the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Optic neuritis is the presenting feature of MS in 15 to 20 percent of patients.",
"   </p>",
"   <p>",
"    The prognosis and treatment of demyelinating optic neuritis will be reviewed in this topic. The epidemiology, pathophysiology, clinical features, and diagnosis of optic neuritis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term optic neuritis is sometimes applied to other inflammatory and infectious conditions affecting the optic nerve. These and other causes of optic neuropathy and the management of multiple sclerosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37112?source=see_link\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic concerns in patients with optic neuritis are visual recovery, recurrence of optic neuritis, and risk of multiple sclerosis (MS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recovery of vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without treatment, vision begins to improve after a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/5\">",
"     5",
"    </a>",
"    ]. Improvement can continue over many months; 90 percent have",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better vision at one year. Some patients may have a more or less favorable prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower visual acuity at the time of presentation is associated with less complete recovery; however, even those who have no light perception at presentation can recover normal vision [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. In the Optic Neuritis Treatment Trial (ONTT), 64 percent of patients whose vision at presentation was no better than light perception achieved a final visual acuity of",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      or better [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/8\">",
"       8",
"      </a>",
"      ]. Severe vision loss at one month, however, is less likely to be associated with good visual recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer lesions in the optic nerve, as demonstrated on magnetic resonance imaging (MRI), particularly those extending into the optic canal, are associated with poorer visual outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Two studies have found that reduced axial diffusivity on diffusion tensor MRI (DTI) correlates with worse visual outcome on follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data on 86 patients from one center suggests that African Americans may have a worse prognosis for visual recovery in comparison with Caucasian Americans, with more severe visual loss both at presentation (worse than",
"      <span class=\"nowrap\">",
"       20/200",
"      </span>",
"      in 93 versus 39 percent) and at one year (worse than",
"      <span class=\"nowrap\">",
"       20/200",
"      </span>",
"      in 17 versus 5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/14\">",
"       14",
"      </a>",
"      ]. At one year, only 61 percent of African Americans had better than",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      acuity compared with 92 percent of Caucasians. A worse visual prognosis has also been described in black South Africans [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While most children with optic neuritis have a good visual outcome, approximately 20 percent will have persistent functional visual impairment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/16-20\">",
"       16-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with multiple sclerosis may have a somewhat less favorable prognosis than those without [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Visual recovery is typically measured by acuity. However, one study found that patients with recovery of full visual acuity after optic neuritis may have persistent deficits in tasks that require visual motion perception [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ONTT, there was a 35 percent recurrence of optic neuritis at 10 years: 14 percent in the original eye, 12 percent in the other eye, and 9 percent in both eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with recurrent optic neuritis have a greater risk of developing MS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/19,23-26\">",
"     19,23-26",
"    </a>",
"    ]. Seropositivity for the aquaporin-4-specific serum autoantibody was predictive of subsequent NMO among patients with recurrent optic neuritis in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk of multiple sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ONTT, the five-year incidence of clinically definite MS was 30 percent following a first episode of idiopathic demyelinating optic neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/27\">",
"     27",
"    </a>",
"    ]. The cumulative incidence increased to 40 percent at 12 years and 50 percent at 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23,28\">",
"     23,28",
"    </a>",
"    ]. The median time to diagnosis of MS was three years. Other series have reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,29,30\">",
"     24,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demographic characteristics associated with risk of MS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age. In many series, the risk of MS appears to be lower if the initial attack of optic neuritis occurs in childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/17,19\">",
"       17,19",
"      </a>",
"      ]. In one investigation, MS occurred in 13 percent of 94 children at 10 years and in 19 percent at 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/19\">",
"       19",
"      </a>",
"      ]. However, in two other case series, the cumulative two-year risk of MS in children with optic neuritis was much higher, 36 to 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Among adults, patients who present with optic neuritis at an older age (greater than 35 to 40 years) may be somewhat less likely to develop MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,33,34\">",
"       24,33,34",
"      </a>",
"      ]. Optic neuritis itself is relatively uncommon in individuals over 40 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link&amp;anchor=H2#H2\">",
"       \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gender. Women may be somewhat more likely to develop MS after optic neuritis than men. In one prospective investigation of patients with optic neuritis followed for 15 years, MS developed in 74 percent of women and 34 percent of men [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/35\">",
"       35",
"      </a>",
"      ]. A higher risk in women was also reported by the Optic Neuritis Study Group and others [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23,24,28\">",
"       23,24,28",
"      </a>",
"      ]. Others have not found that gender influences MS risk in multivariate analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnic and regional influences. In the United States, Asians appear to be less likely to develop MS after optic neuritis than are Caucasians. In one case series, African Americans appeared to be particularly susceptible to the neuromyelitis optica (Devic's disease) form of multiple sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The lower incidence rates of MS after optic neuritis in Mexican and South American populations are consistent with the regional variation seen in MS overall [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. Similarly, the reported risks are also lower in Asian countries, while in Australia and Western Europe, incidence rates are similar to those reported in the ONTT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,34,39,40\">",
"       24,34,39,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Geographic factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical and laboratory features at the time of presentation with optic neuritis are also helpful in determining prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI abnormalities. The presence of characteristic demyelinating lesions on MRI is a strong predictor of developing MS. In the ONTT, the risk of MS after 15 years was 72 percent among those with one or more lesions on MRI versus 25 percent among those with no lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23,28\">",
"       23,28",
"      </a>",
"      ]. The risk did not significantly differ between those with single versus multiple lesions. Other studies report similar results, including two in pediatric populations [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/32,33,41,42\">",
"       32,33,41,42",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      In the ONTT, an abnormal brain MRI dominated other clinical and demographic risk factors, which were useful in prognosis only among those with a normal brain MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23\">",
"       23",
"      </a>",
"      ]. No patient developed MS after 10 years of follow-up if they had no white matter lesions on brain MRI along with any one of the following clinical features considered atypical for optic neuritis: no pain, no light perception vision at presentation, severe disc swelling, peripapillary hemorrhage, or retinal exudates.",
"      <br/>",
"      <br/>",
"      MRI findings also predict future MS-related disability. In one prospective series of 106 patients with optic neuritis, the presence of baseline gadolinium-enhancing lesions, and the presence and number of infratentorial and spinal cord lesions were predictive of disability among those who developed MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recurrent episode of optic neuritis. Recurrent optic neuritis is more common among those destined to develop MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23,24,29\">",
"       23,24,29",
"      </a>",
"      ]. Patients with recurrent optic neuritis may be particularly at risk for the variant of MS known as neuromyelitis optica or Devic's disease. This is particularly true for patients with a normal brain MRI and those with optic neuritis events in rapid succession [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/43\">",
"       43",
"      </a>",
"      ]. In one study, seropositivity for the aquaporin-4-specific serum autoantibody was predictive of subsequent NMO among patients with recurrent optic neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Simultaneous bilateral involvement of the optic nerves at the initial presentation, however, is associated with a lower risk of MS in most but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/19,31\">",
"       19,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Funduscopic examination &mdash; The presence of papillitis, especially if it is severe, is associated with a lower risk of MS, particularly among those with normal brain MRI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/23,28\">",
"       23,28",
"      </a>",
"      ]. Retinal perivenous sheathing is not a common finding in optic neuritis but when present does suggest a higher risk of MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebrospinal fluid &mdash; Studies have had somewhat conflicting results regarding the association between abnormal cerebrospinal fluid (CSF) findings (eg, oligoclonal bands [OCB], pleocytosis, myelin basic protein, IgG synthesis) and subsequent risk of MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,33,41,44,45\">",
"       24,33,41,44,45",
"      </a>",
"      ]. Most studies find that individuals who have OCB in the CSF at the time of the optic neuritis event are at higher risk of developing MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,33\">",
"       24,33",
"      </a>",
"      ]. However, OCB are also associated with the presence of white matter lesions on MRI and may not represent an independent risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/44-49\">",
"       44-49",
"      </a>",
"      ]. The combination of a normal brain MRI and absent OCB identifies individuals at very low risk of MS.",
"     </li>",
"     <li>",
"      Human leukocyte antigen &mdash; The human leukocyte antigen (HLA) type has been reported to affect the relationship between optic neuritis and MS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/50\">",
"       50",
"      </a>",
"      ]. One prospective study of patients with optic neuritis found a higher risk for conversion to MS among those with HLA-DR2 alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/34\">",
"       34",
"      </a>",
"      ]. Some investigations have corroborated this association, but others have not [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/24,33,50,51\">",
"       24,33,50,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum antibodies &mdash; Investigators have sought a specific serum marker for multiple sclerosis. In one case series of 103 individuals with clinically isolated syndromes (40 were optic neuritis), seropositivity for antibodies against myelin basic protein and myelin oligodendrocyte glycoprotein identified patients at high risk for MS in adjusted multivariate analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/49\">",
"       49",
"      </a>",
"      ]. However, a subsequent study did not find this association in a patient population with optic neuritis only [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for patients with optic neuritis are focused on improving vision and preventing or ameliorating the development of multiple sclerosis (MS).",
"   </p>",
"   <p>",
"    Other topics discuss the treatment of multiple sclerosis and the treatment of neuromyelitis optica. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=see_link\">",
"     \"Treatment of progressive multiple sclerosis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37112?source=see_link\">",
"     \"Clinically isolated syndromes suggestive of multiple sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis of multiple sclerosis in adults\", section on 'Neuromyelitis optica and optic-spinal MS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in the Optic Neuritis Treatment Trial (ONTT) were randomly assigned to either oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for 14 days with a four-day taper; intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (250 mg four times per day for three days) followed by oral prednisone (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for 11 days with a four-day taper; or oral placebo for 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients were treated within eight days of symptom onset. The primary visual outcomes were visual acuity and contrast sensitivity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      accelerated the recovery of visual function; however one-year visual outcomes were similar among treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      also reduced the risk of conversion to MS within the first two years in comparison with either placebo or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (7.5 versus 14.7 and 16.7 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"       53",
"      </a>",
"      ]. Among patients with two or more white matter lesions on MRI, incidence rates for MS were 16.2 versus 32.4 and 35.9 percent. At five years, however, there were no differences in the rates of MS between treatment groups [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      arm of the study was found to have a higher two-year risk of recurrent optic neuritis in both eyes, when compared with intravenous steroid therapy or with placebo (30 versus 13 and 16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"       53",
"      </a>",
"      ]. At 10 years, the risk of recurrent optic neuritis remained higher in the oral prednisone group when compared with the intravenous-treated group (44 versus 29 percent), but there was no longer a significant difference between the oral prednisone and placebo groups [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/7,23\">",
"       7,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A small randomized trial found that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    500 mg for five days had a beneficial effect on visual function at one and three weeks compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/54\">",
"     54",
"    </a>",
"    ]. There were no differences between treatment groups with regard to visual outcome at eight weeks or to the risk of developing additional demyelinating events at one year.",
"   </p>",
"   <p>",
"    Many patients can now be treated with home intravenous infusions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for episodes of optic neuritis. The side effects of treatment are minimal when given for a brief time course. The most common side effects in the ONTT were mood changes, facial flushing, sleep perturbations, weight gain, and dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decision to treat with intravenous steroids should be made after considering all potential benefits and risks, with the understanding that long-term visual outcome is not affected by this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. We use intravenous corticosteroid treatment in patients with abnormal high signal abnormalities on their brain MRI, since this treatment may delay the onset of MS. We also use intravenous corticosteroid therapy in those patients with either severe or bilateral vision loss, as this may hasten the speed of visual recovery. In the rare circumstance when intravenous corticosteroids are not available, we suggest the administration of high-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/54\">",
"     54",
"    </a>",
"    ]. The observed risks associated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    were seen in just one trial, were unexpected, and their pathologic basis is not understood. However, we do not use oral prednisone for treatment of optic neuritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other acute immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative treatments used for acute neuroimmunologic disease include intravenous immunoglobulin (IVIG) and plasma exchange. These do not have established efficacy in the treatment of optic neuritis.",
"   </p>",
"   <p>",
"    Two randomized trials studied the potential benefit of IVIG in 55 and 68 patients with optic neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Neither study found a difference in visual outcomes at six months. MRI outcomes and the incidence of subsequent demyelinating events at six months were also similar between treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/58\">",
"     58",
"    </a>",
"    ]. Another report of IVIG treatment in 23 patients with corticosteroid refractory optic neuritis found that 78 percent achieved vision",
"    <span class=\"nowrap\">",
"     20/30",
"    </span>",
"    or better, compared with 12.5 percent in a nonrandomized, matched control group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/59\">",
"     59",
"    </a>",
"    ]. The benefit appeared sustained at one year.",
"   </p>",
"   <p>",
"    Ten patients with severe optic neuritis underwent plasma exchange between 11 to 73 days after presentation and after failing to respond to intravenous corticosteroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/60\">",
"     60",
"    </a>",
"    ]. Seven patients appeared to respond with improvements in visual acuity; however, improvement was not sustained in two of these.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic immunomodulatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important clinical decision in patients with optic neuritis is whether or not to begin chronic immunomodulatory therapy in order to prevent, delay, or ameliorate subsequent MS. The results from three randomized trials support the use of treatment in high-risk patients, as defined by MRI findings.",
"   </p>",
"   <p>",
"    The Controlled High-Risk Avonex MS Prevention Study (CHAMPS) was a randomized, placebo-controlled trial of 383 patients with clinically isolated syndromes (192 with optic neuritis), comparing early treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex), 30 &micro;g intramuscularly each week versus placebo. Eligible patients were between 18 and 50 years, with two or more demyelinating lesions on their brain MRI. All patients had received treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    within 14 days after symptom onset and began study therapy within four weeks (median time to therapy was 20 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      significantly reduced the three-year cumulative risk of developing MS (35 versus 50 percent).",
"     </li>",
"     <li>",
"      There were a smaller number of T2-weighted and T1-gadolinium enhancing lesions on brain MRI in the treated versus placebo group at 18 months. The total volume of T2 lesions on MRI was also smaller in the treated group.",
"     </li>",
"     <li>",
"      Follow-up was extended to five years in a subset of willing CHAMPS participants (53 percent of the original study population). At five years, the cumulative risk of MS was lower among those originally assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (immediate treatment) compared with those originally assigned to placebo (delayed treatment) (36 versus 49 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the Early Treatment of Multiple Sclerosis Study (ETOMS), 308 patients with a first clinical demyelinating event (98 optic neuritis) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Rebif), 22 &micro;g subcutaneously each week or to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/63\">",
"     63",
"    </a>",
"    ]. Patients had either at least four white matter lesions or three lesions with at least one demonstrating gadolinium enhancement. Treatment began within three months of symptom onset. Seventy percent of the patients received treatment with corticosteroids before starting interferon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years, a lower proportion of the interferon-treated patients developed MS in comparison with placebo (34 versus 45 percent)",
"     </li>",
"     <li>",
"      The time to occurrence of the next demyelinating event was longer in the treated versus placebo group (569 versus 252 days)",
"     </li>",
"     <li>",
"      Fewer treated patients had new T2-weighted lesions on brain MRI compared with placebo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the BENEFIT trial, 487 patients presenting with a clinically isolated syndrome (80 with optic neuritis) and at least two lesions on brain MRI were assigned to receive 250 &micro;g interferon-1b (Betaseron) subcutaneously or placebo every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years, the risk of developing clinically definite MS was 45 percent in the placebo group versus 28 percent in the treatment group. The time for 25 percent of patients to develop clinically definite MS was delayed by about one year in the treated group.",
"     </li>",
"     <li>",
"      Treated patients had a lower cumulative number of new T2-weighted lesions on brain MRI compared with the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the PreCISe study trial, 481 patients presenting with a unifocal clinically isolated syndrome and two or more lesions on brain MRI were randomized to receive either 20 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    subcutaneously or placebo each day [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At three years, there was a relative 45 percent reduction in risk of conversion to clinically definite MS.",
"     </li>",
"     <li>",
"      At two years, treated patients had a lower cumulative number of new T2-weighted lesions on brain MRI compared with the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data from these studies indicate that early treatment in patients with clinically isolated syndromes, including optic neuritis, reduces the rate of MS development.",
"   </p>",
"   <p>",
"    Common side effects of beta interferon treatment in these trials included depression, injection site reactions, and flu-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/61,63,64\">",
"     61,63,64",
"    </a>",
"    ]. A significant number of patients on interferon therapy also develop elevated liver enzymes. Therefore, liver function and other laboratory tests should be checked prior to starting therapy and repeated every three and six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Side effects of interferons'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We offer treatment with beta interferon or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"     glatiramer acetate",
"    </a>",
"    to patients with optic neuritis and abnormal brain MRIs. If the patient can tolerate treatment, potential benefits include a longer attack-free interval, reduced number of demyelinating attacks, and a delay to MS-associated disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the clinical trials of treatment discussed above were limited to adults. No clinical trial data are available to guide the treatment of children with optic neuritis. Given their lower risk of MS, some modifications in the treatment approach seem reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    can be considered for acute treatment for severe debilitating bilateral vision loss in hopes of hastening recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/1,66,67\">",
"     1,66,67",
"    </a>",
"    ]. The risk of short-term treatment is low in children. Some clinicians recommend a longer taper rate (four to eight weeks) than is used in adults because of anecdotal reports of relapses of vision loss occurring with a shorter taper in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. As with adults, case series suggest that the final visual outcome is not altered by this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, immunomodulatory treatments with interferons are not used in younger children, although older children (&gt;15 years) are probably appropriately treated under the same guidelines as adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29944/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of multiple sclerosis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21000?source=see_link\">",
"     \"Treatment and prognosis of pediatric multiple sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/30/10722?source=see_link\">",
"       \"Patient information: Optic neuritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is an acute inflammatory demyelinating injury to the optic nerve.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual recovery begins within a few weeks. Most achieve",
"      <span class=\"nowrap\">",
"       20/40",
"      </span>",
"      vision or better at one year. When vision is more severely affected at onset, a good prognosis is less certain. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recovery of vision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In adults, 30 percent of individuals will develop multiple sclerosis (MS) at five years. The risk is higher, 56 percent, in those with two or more typical white matter lesions on magnetic resonance imaging (MRI). Younger children may be less likely than adults to develop MS. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk of multiple sclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      for children and adults with either severe vision loss or two or more white matter lesions on MRI (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Treatment is associated with a more rapid recovery of vision and with delayed onset of MS, but does not impact long-term visual function. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We recommend NOT using oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , which does not affect short or long-term visual outcomes in acute optic neuritis and may be associated with an increased risk of recurrent optic neuritis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treating individuals older than 15 years in age who present with acute optic neuritis and who have two or more white matter lesions on brain MRI with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"       interferon beta-1a",
"      </a>",
"      (Avonex), interferon beta-1a (Rebif),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/13/16597?source=see_link\">",
"       interferon beta-1b",
"      </a>",
"      (Betaseron), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/3/16437?source=see_link\">",
"       glatiramer acetate",
"      </a>",
"      (Copaxone) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If treatment is tolerated, potential benefits include a delay to the development of clinical multiple sclerosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic immunomodulatory therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/1\">",
"      Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/2\">",
"      Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/3\">",
"      Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/4\">",
"      Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005; 139:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/5\">",
"      The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/6\">",
"      Celesia GG, Kaufman DI, Brigell M, et al. Optic neuritis: a prospective study. Neurology 1990; 40:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/7\">",
"      Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004; 137:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/8\">",
"      Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol 1997; 115:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/9\">",
"      Kupersmith MJ, Gal RL, Beck RW, et al. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007; 69:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/10\">",
"      Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/11\">",
"      Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/12\">",
"      Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009; 72:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/13\">",
"      Naismith RT, Xu J, Tutlam NT, et al. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010; 74:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/14\">",
"      Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/15\">",
"      Pokroy R, Modi G, Saffer D. Optic neuritis in an urban black African community. Eye (Lond) 2001; 15:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/16\">",
"      Brady KM, Brar AS, Lee AG, et al. Optic neuritis in children: clinical features and visual outcome. J AAPOS 1999; 3:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/17\">",
"      Kriss A, Francis DA, Cuendet F, et al. Recovery after optic neuritis in childhood. J Neurol Neurosurg Psychiatry 1988; 51:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/18\">",
"      KENNEDY C, CARROLL FD. Optic neuritis in children. Arch Ophthalmol 1960; 63:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/19\">",
"      Lucchinetti CF, Kiers L, O'Duffy A, et al. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997; 49:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/20\">",
"      Riikonen R, Donner M, Erkkil&auml; H. Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children. Dev Med Child Neurol 1988; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/21\">",
"      Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008; 115:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/22\">",
"      Raz N, Dotan S, Benoliel T, et al. Sustained motion perception deficit following optic neuritis: Behavioral and cortical evidence. Neurology 2011; 76:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/23\">",
"      Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003; 121:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/24\">",
"      Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up. J Neurol 2005; 252:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/25\">",
"      Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/26\">",
"      Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/27\">",
"      The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 1997; 49:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/28\">",
"      Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/29\">",
"      Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/30\">",
"      Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. Neurology 2009; 72:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/31\">",
"      Wilejto M, Shroff M, Buncic JR, et al. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/32\">",
"      Absoud M, Cummins C, Desai N, et al. Childhood optic neuritis clinical features and outcome. Arch Dis Child 2011; 96:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/33\">",
"      Jin YP, de Pedro-Cuesta J, Huang YH, S&ouml;derstr&ouml;m M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/34\">",
"      Hely MA, McManis PG, Doran TJ, et al. Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry 1986; 49:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/35\">",
"      Rizzo JF 3rd, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988; 38:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/36\">",
"      Corona-Vazquez T, Ruiz-Sandoval J, Arriada-Mendicoa N. Optic neuritis progressing to multiple sclerosis. Acta Neurol Scand 1997; 95:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/37\">",
"      Alvarez G, C&aacute;rdenas M. Multiple sclerosis following optic neuritis in Chile. J Neurol Neurosurg Psychiatry 1989; 52:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/38\">",
"      Lana-Peixoto MA, Lana-Peixoto MI. The risk of multiple sclerosis developing in patients with isolated idiopathic optic neuritis in Brazil. Arq Neuropsiquiatr 1991; 49:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/39\">",
"      Wang JC, Tow S, Aung T, et al. The presentation, aetiology, management and outcome of optic neuritis in an Asian population. Clin Experiment Ophthalmol 2001; 29:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/40\">",
"      Wakakura M, Minei-Higa R, Oono S, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Jpn J Ophthalmol 1999; 43:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/41\">",
"      Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997; 41:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/42\">",
"      Alper G, Wang L. Demyelinating optic neuritis in children. J Child Neurol 2009; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/43\">",
"      Pirko I, Blauwet LA, Blauwet LK, et al. The natural history of recurrent optic neuritis. Arch Neurol 2004; 61:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/44\">",
"      Rolak LA, Beck RW, Paty DW, et al. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996; 46:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/45\">",
"      Cole SR, Beck RW, Moke PS, et al. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998; 51:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/46\">",
"      S&ouml;derstr&ouml;m M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/47\">",
"      Frederiksen JL, Madsen HO, Ryder LP, et al. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch Neurol 1997; 54:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/48\">",
"      Frederiksen JL, Larsson HB, Olesen J. Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 1992; 86:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/49\">",
"      Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/50\">",
"      Francis DA, Compston DA, Batchelor JR, McDonald WI. A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up. J Neurol Neurosurg Psychiatry 1987; 50:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/51\">",
"      Kheradvar A, Tabassi AR, Nikbin B, et al. Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four-year follow-up study. Mult Scler 2004; 10:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/52\">",
"      Lim ET, Berger T, Reindl M, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/53\">",
"      Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/54\">",
"      Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999; 52:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/55\">",
"      Vedula SS, Brodney-Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2007; :CD001430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/56\">",
"      Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/57\">",
"      Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/58\">",
"      Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/59\">",
"      Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/60\">",
"      Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/61\">",
"      CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/62\">",
"      Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/63\">",
"      Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/64\">",
"      Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/65\">",
"      Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/66\">",
"      Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29944/abstract/67\">",
"      Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. Ophthalmology 1990; 97:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5252 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29944=[""].join("\n");
var outline_f29_15_29944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recovery of vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk of multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other acute immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic immunomodulatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37112?source=related_link\">",
"      Clinically isolated syndromes suggestive of multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/30/10722?source=related_link\">",
"      Patient information: Optic neuritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/21000?source=related_link\">",
"      Treatment and prognosis of pediatric multiple sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26265?source=related_link\">",
"      Treatment of progressive multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29945="Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology";
var content_f29_15_29945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Mark D Siegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29945/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/15/29945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distinct type of hypoxemic respiratory failure characterized by acute abnormality of both lungs was first recognized during the 1960s. Military clinicians working in surgical hospitals in Vietnam called it shock lung, while civilian clinicians referred to it as adult respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent recognition that individuals of any age could be afflicted led to the current term, acute respiratory distress syndrome (ARDS).",
"   </p>",
"   <p>",
"    The Berlin Definition of ARDS (published in 2012) has replaced the American-European Consensus Conference&rsquo;s definition of ARDS (published in 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, it should be recognized that most evidence is based upon prior definitions. The current diagnostic criteria for ARDS are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, pathologic stages, and etiologies of ARDS will be reviewed here. Other issues related to ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link\">",
"     \"Novel therapies for the acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ARDS was determined in a multicenter, population-based, prospective cohort study in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/4\">",
"     4",
"    </a>",
"    ]. The study followed 1113 patients with ARDS for 15 months beginning in 1999 or 2000:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age-adjusted incidence was 86 per 100,000 person-years for individuals with an arterial oxygen tension to fraction of inspired oxygen ratio",
"      <span class=\"nowrap\">",
"       (PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      &le;300 mmHg and 64 per 100,000 person-years for individuals with a",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &le;200 mmHg.",
"     </li>",
"     <li>",
"      The incidence increased with patient age from 16 per 100,000 person-years among individuals 15 to 19 years of age to 306 per 100,000 person-years among individuals 75 to 84 years of age.",
"     </li>",
"     <li>",
"      Extrapolation of the data suggested that there are approximately 190,000 cases of ARDS in the United States each year [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within intensive care units, approximately 10 to 15 percent of admitted patients and up to 20 percent of mechanically ventilated patients meet criteria for ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The incidence of ARDS may be somewhat higher in the United States than in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of ARDS may be decreasing. A prospective cohort study from a single institution reported that the incidence of ARDS decreased from 82.4 cases per 100,000 person-years in 2001 to 38.9 cases per 100,000 person-years in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/10\">",
"     10",
"    </a>",
"    ]. This was attributable to a decline in hospital-acquired ARDS, since the incidence of ARDS at hospital presentation did not change. Those who developed ARDS had more severe disease, more comorbidities, and more predisposing conditions. These findings may reflect changes in the delivery of care at this institution only; studies from other institutions are necessary before it can be concluded that the incidence of ARDS is declining in general.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy lungs regulate the movement of fluid to maintain a small amount of interstitial fluid and dry alveoli. This is interrupted by lung injury, causing excess fluid in both the interstitium and alveoli. Consequences include impaired gas exchange, decreased compliance, and increased pulmonary arterial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Baseline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal lung function requires that dry, patent alveoli be closely situated to appropriately perfused capillaries (",
"    <a class=\"graphic graphic_picture graphicRef80140 \" href=\"UTD.htm?39/27/40373\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/11\">",
"     11",
"    </a>",
"    ]. The normal pulmonary capillary endothelium is selectively permeable: fluid crosses the membranes under the control of hydrostatic and oncotic forces, while serum proteins remain intravascular.",
"   </p>",
"   <p>",
"    The Starling equation describes the forces that direct fluid movement between the vessels and the interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/12\">",
"     12",
"    </a>",
"    ]. A simplified version of the equation is:",
"   </p>",
"   <p>",
"    &nbsp;Q &nbsp;= &nbsp;K &nbsp;x &nbsp;[(Pmv &nbsp;- &nbsp;Ppmv) &nbsp;- rc (&pi;mv &nbsp;- &nbsp;&pi;pmv)]",
"   </p>",
"   <p>",
"    where Q represents the net transvascular flow of fluid, K the permeability of the endothelial membrane, Pmv the hydrostatic pressure within the lumen of the microvessels, Ppmv the hydrostatic pressure in the perimicrovascular space, rc represents the reflection coefficient of the capillary barrier, &pi;mv the oncotic pressure in the circulation, and &pi;pmv the oncotic pressure in the perimicrovascular compartment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The balance of hydrostatic and oncotic forces normally allows small quantities of fluid into the interstitium, but three mechanisms prevent alveolar edema (",
"    <a class=\"graphic graphic_figure graphicRef73684 graphicRef69933 graphicRef73443 graphicRef61194 \" href=\"UTD.htm?38/12/39111\">",
"     figure 1A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Retained intravascular protein maintains an oncotic gradient favoring reabsorption",
"     </li>",
"     <li>",
"      The interstitial lymphatics can return large quantities of fluid to the circulation",
"     </li>",
"     <li>",
"      Tight junctions between alveolar epithelial cells prevent leakage into the air spaces",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS is a consequence of an alveolar injury producing diffuse alveolar damage (",
"    <a class=\"graphic graphic_picture graphicRef57964 \" href=\"UTD.htm?30/4/30793\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65804 \" href=\"UTD.htm?40/11/41145\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/13\">",
"     13",
"    </a>",
"    ]. The injury causes release of pro-inflammatory cytokines such as tumor necrosis factor, interleukin (IL)-1, IL-6, and IL-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. These cytokines recruit neutrophils to the lungs, where they become activated and release toxic mediators (eg, reactive oxygen species and proteases) that damage the capillary endothelium and alveolar epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/13,20-24\">",
"     13,20-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Damage to the capillary endothelium and alveolar epithelium allows protein to escape from the vascular space. The oncotic gradient that favors resorption of fluid is lost and fluid pours into the interstitium, overwhelming the lymphatics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/25\">",
"     25",
"    </a>",
"    ]. The ability to upregulate alveolar fluid clearance may also be lost [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/26\">",
"     26",
"    </a>",
"    ]. The result is that the air spaces fill with bloody, proteinaceous edema fluid and debris from degenerating cells. In addition, functional surfactant is lost, resulting in alveolar collapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung injury has numerous consequences including impairment of gas exchange, decreased lung compliance, and increased pulmonary arterial pressure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired gas exchange &ndash; Impaired gas exchange in ARDS is primarily due to ventilation-perfusion mismatching: physiologic shunting causes hypoxemia, while increased physiologic dead space impairs carbon dioxide elimination [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. A high minute volume is generally needed to maintain a normal arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      ), although hypercapnia is uncommon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=see_link\">",
"       \"Oxygenation and mechanisms of hypoxemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased lung compliance &ndash; Decreased pulmonary compliance is one of the hallmarks of ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/29\">",
"       29",
"      </a>",
"      ]. It is a consequence of the stiffness of poorly or non-aerated lung, rather than the pressure-volume characteristics of residual functioning lung units [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/30\">",
"       30",
"      </a>",
"      ]. Even small tidal volumes can exceed the lung's inspiratory capacity and cause a dramatic rise in airway pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary hypertension &ndash; Pulmonary hypertension (PH) occurs in up to 25 percent of patients with ARDS who undergo mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/31-33\">",
"       31-33",
"      </a>",
"      ]. Causes include hypoxic vasoconstriction, vascular compression by positive airway pressure, parenchymal destruction, airway collapse, hypercarbia, and pulmonary vasoconstrictors [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/34\">",
"       34",
"      </a>",
"      ]. The clinical importance of PH in most patients with ARDS is uncertain. PH severe enough to cor pulmonale is rare, but it is associated with an increased risk of death [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased airways resistance (Raw) is also a feature of ARDS, although its clinical significance is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGIC STAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ARDS tend to progress through three relatively discrete pathologic stages (",
"    <a class=\"graphic graphic_figure graphicRef77051 \" href=\"UTD.htm?38/41/39582\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/39\">",
"     39",
"    </a>",
"    ]. The initial stage is the exudative stage, characterized by diffuse alveolar damage. After approximately seven to ten days, a proliferative stage develops, characterized by resolution of pulmonary edema, proliferation of type II alveolar cells, squamous metaplasia, interstitial infiltration by myofibroblasts, and early deposition of collagen. Some patients progress to a fibrotic stage, characterized by obliteration of normal lung architecture, diffuse fibrosis, and cyst formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ETIOLOGIES AND PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS has traditionally been conceptualized as a pattern of lung injury and clinical manifestations that can be caused by a variety of insults. However, the validity of the assumption that different inciting events cause a similar pattern of lung injury and similar clinical features has been questioned because numerous studies have found more severe reductions in lung compliance and less responsiveness to positive end-expiratory pressure (PEEP) when the ARDS was due to a pulmonary process than when it was due to an extrapulmonary precipitant, such as sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More than 60 possible causes of ARDS have been identified and other potential causes continue to emerge as adverse pulmonary reactions to new therapies are observed (",
"    <a class=\"graphic graphic_table graphicRef58759 \" href=\"UTD.htm?39/41/40603\">",
"     table 1",
"    </a>",
"    ). However, only a few common causes account for most cases of ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/8,44-47\">",
"     8,44-47",
"    </a>",
"    ]. Factors that may predispose a patient to develop ARDS, but probably can't cause ARDS, have also been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is the most common cause of ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/44,45,48,49\">",
"     44,45,48,49",
"    </a>",
"    ]. It should be the first etiology considered whenever ARDS develops in a patient who is predisposed to serious infection or in association with a new fever or hypotension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of developing ARDS may be particularly high among septic patients with a history of alcoholism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. This was illustrated by a prospective cohort study that determined the incidence of ARDS in 220 patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/51\">",
"     51",
"    </a>",
"    ]. The incidence of ARDS among patients who chronically abuse alcohol was 70 percent, compared to 31 percent among patients who did not chronically abuse alcohol. A possible explanation for these findings is that alcoholism may decrease the concentration of glutathione in the epithelial lining fluid, predisposing the lung to oxidative injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/50,53,54\">",
"     50,53,54",
"    </a>",
"    ]. Alternatively, chronic alcohol abuse may increase the risk of ARDS by enhancing inappropriate leukocyte adhesion to endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational evidence indicates that ARDS will develop in approximately one-third of hospitalized patients who have a recognized episode of aspiration of gastric contents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/44,46,56\">",
"     44,46,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was initially suggested that aspirated contents had to have a pH less than 2.5 to cause severe lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/57\">",
"     57",
"    </a>",
"    ]; however, more recent animal studies have shown that aspiration of non-acidic gastric contents can also cause widespread damage to the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/58\">",
"     58",
"    </a>",
"    ]. This suggests that gastric enzymes and small food particles also contribute to the lung injury.",
"   </p>",
"   <p>",
"    The unexpected development of ARDS may be the only indication that an intubated patient has developed a tracheoesophageal fistula. This is a rare complication of intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community acquired pneumonia is probably the most common cause of ARDS that develops outside of the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/59\">",
"     59",
"    </a>",
"    ]. Common pathogens include Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/60\">",
"     60",
"    </a>",
"    ], Legionella pneumophila, Pneumocystis jirovecii (formerly called Pneumocystis carinii), Staphylococcus aureus, enteric gram negative organisms, and a variety of respiratory viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nosocomial pneumonias can also progress to ARDS. Staphylococcus aureus, Pseudomonas aeruginosa, and other enteric gram negative bacteria are the most commonly implicated pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Severe trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS is a complication of severe trauma. There are several situations during which ARDS seems to be particularly common following trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral lung contusion following blunt trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fat embolism after long bone fractures. In this situation, ARDS typically appears 12 to 48 hours after the trauma. This complication has decreased since immobilization for transport to the hospital became routine [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=see_link\">",
"       \"Fat embolism syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sepsis may be the most common cause of ARDS that develops several days or more after severe trauma or burns.",
"     </li>",
"     <li>",
"      Massive traumatic tissue injury may directly precipitate or predispose a patient to ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/63,66\">",
"       63,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although ARDS can contribute to the length of critical illness following severe trauma, it does not appear to independently increase the risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/67\">",
"     67",
"    </a>",
"    ]. Trauma-related ARDS has a significantly better prognosis than ARDS that is not related to trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Massive transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of more than 15 units of red blood cells is a risk factor for the development of ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/45\">",
"     45",
"    </a>",
"    ]. It is unknown whether the transfusion injures the lungs or the need for massive transfusion identifies patients who are at high risk for ARDS from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/69\">",
"     69",
"    </a>",
"    ]. Transfusion of smaller volumes of packed red blood cells may also increase the risk of developing ARDS, as well as increasing the risk of mortality among patients with established ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link\">",
"     \"Massive blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Transfusion-related acute lung injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of even one unit of a plasma-containing blood product sometimes causes ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Fresh frozen plasma, platelet, and packed red blood cell transfusions have all been implicated. By definition, respiratory distress becomes apparent within six hours of completion of the transfusion. The mechanism in incompletely understood and may be multifactorial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lung and hematopoietic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first two or three days after surgery, lung transplant recipients are prone to primary graft failure. This devastating form of ARDS is attributed to imperfect preservation of the transplanted lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36057?source=see_link\">",
"     \"Primary lung graft dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hematopoietic stem cell transplant patients are at risk for ARDS due to a variety of infectious and noninfectious causes. Noninfectious insults include idiopathic pneumonia syndrome, engraftment syndrome, and diffuse alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/73\">",
"     73",
"    </a>",
"    ]. The lung injury appears to be partly related to the inflammation associated with chemoradiation conditioning regimens, as well as T cell alloreactivity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"     \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=see_link\">",
"     \"Pulmonary complications after autologous hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Drugs and alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARDS can occur following an overdose. Drugs that have been implicated include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , cocaine, opioids, phenothiazines, and tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Idiosyncratic reactions to other drugs (eg, protamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    ), including certain chemotherapeutic agents, occasionally precipitate ARDS after therapeutic doses. Radiologic contrast media can also provoke ARDS in susceptible individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/76\">",
"     76",
"    </a>",
"    ]. Alcohol abuse increases the risk of ARDS due to other causes (eg, sepsis, trauma), but does not cause ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetic determinants",
"    </span>",
"    &nbsp;&mdash;&nbsp;It seems likely that there are genetic determinants that increase an individual's risk of developing ARDS, since only a small proportion of the patients who are exposed to typical insults actually develop ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/78\">",
"     78",
"    </a>",
"    ]. Studies that link mutations in the surfactant protein B (SP-B) gene to an increased risk of ARDS support this notion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Insertion-deletion polymorphisms associated with the angiotensin converting enzyme (ACE) gene have also been suggested as a possible risk factor for ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/81\">",
"     81",
"    </a>",
"    ], although not all studies support this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other possible risk factors for ARDS include cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/85,86\">",
"     85,86",
"    </a>",
"    ], pneumonectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/87\">",
"     87",
"    </a>",
"    ], acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/88\">",
"     88",
"    </a>",
"    ], obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], and near drowning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/56,91,92\">",
"     56,91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=see_link\">",
"     \"Drowning (submersion injuries)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous air embolism can occasionally cause ARDS. Outside of the operating room, the most common portal of entry for the air is a central venous catheter left open to the air [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5933039\">",
"    <span class=\"h2\">",
"     Lung injury prediction score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung injury prediction score (LIPS) identifies patients who are unlikely to develop ARDS. This was demonstrated by a prospective cohort study of 5584 patients, in which seven percent of the cohort developed ARDS, resulting in a negative predictive value (ie, the percent of patients with a LIPS &lt;4 who will not develop ARDS) of 97 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/94\">",
"     94",
"    </a>",
"    ]. A LIPS &gt;4 predicted ARDS with a sensitivity and specificity of 69 and 78 percent, respectively. A smaller study, using a retrospective derivation and prospective validation cohorts reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29945/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LIPS is the sum of the points assigned for each of the following predisposing conditions: shock (2 points), aspiration (2 points), sepsis (1 point), pneumonia (1.5 points), orthopedic spine surgery (1.5 points), acute abdominal surgery (2 points), cardiac surgery (2.5 points), aortic vascular surgery (3.5 points), traumatic brain injury (2 points), smoke inhalation (2 points), near drowning (2 points), lung contusion (1.5 points), multiple fractures (1.5 points), alcohol abuse (1 point), obesity (BMI &gt;30, 1 point), hypoalbuminemia (1 point), chemotherapy (1 point), fraction of inspired oxygen &gt;0.35 or &gt;4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    (2 points), tachypnea &gt;30",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    (1.5 points), oxyhemoglobin saturation &lt;95 percent (1 point), acidosis (pH &lt;7.35, 1.5 points), and diabetes mellitus (-1 point).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       \"Patient information: Adult respiratory distress syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the acute onset of bilateral alveolar infiltrates and hypoxemia. The diagnostic criteria for ARDS are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Healthy lungs regulate the movement of fluid to maintain a small amount of interstitial fluid and dry alveoli. In patients with ARDS, this regulation is interrupted by lung injury, causing excess fluid in both the interstitium and alveoli. Consequences include impaired gas exchange, decreased compliance, and increased pulmonary arterial pressure.(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ARDS tend to progress through three relatively discrete pathologic stages: the exudative stage, proliferative stage, and fibrotic stage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathologic stages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 60 possible causes of ARDS have been identified and other potential causes continue to emerge as adverse pulmonary reactions to new therapies are observed. However, only a few common causes account for most cases of ARDS. Factors that may predispose a patient to develop ARDS have also been identified. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Etiologies and predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/1\">",
"      Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967; 2:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/2\">",
"      Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/3\">",
"      Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/4\">",
"      Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/5\">",
"      Frutos-Vivar F, Nin N, Esteban A. Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr Opin Crit Care 2004; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/6\">",
"      Estenssoro E, Dubin A, Laffaire E, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med 2002; 30:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/7\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/8\">",
"      Zaccardelli DS, Pattishall EN. Clinical diagnostic criteria of the adult respiratory distress syndrome in the intensive care unit. Crit Care Med 1996; 24:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/9\">",
"      MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care 2005; 11:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/10\">",
"      Li G, Malinchoc M, Cartin-Ceba R, et al. Eight-year trend of acute respiratory distress syndrome: a population-based study in Olmsted County, Minnesota. Am J Respir Crit Care Med 2011; 183:59.",
"     </a>",
"    </li>",
"    <li>",
"     George RB, Chesson AL, Rennard SI. Functional anatomy of the respiratory system. In: Chest Medicine. Essentials of Pulmonary and Critical Care Medicine, 3rd ed, George RB, Light RW, Matthay MA, et al (Eds), Williams &amp; Wilkins, Baltimore 1995. p.3.",
"    </li>",
"    <li>",
"     Matthay MA. Acute hypoxemic respiratory failure: Pulmonary edema and ARDS. In: Chest Medicine. Essentials of Pulmonary and Critical Care Medicine, 3rd ed, George RB, Light RW, Matthay MA, et al (Eds), Williams &amp; Wilkins, Baltimore 1995. p.593.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/13\">",
"      Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med 2004; 141:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/14\">",
"      Parsons PE, Eisner MD, Thompson BT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med 2005; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/15\">",
"      Martin TR. Lung cytokines and ARDS: Roger S. Mitchell Lecture. Chest 1999; 116:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/16\">",
"      Colletti LM, Remick DG, Burtch GD, et al. Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 1990; 85:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/17\">",
"      Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/18\">",
"      Miller EJ, Cohen AB, Matthay MA. Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis. Crit Care Med 1996; 24:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/19\">",
"      Chollet-Martin S, Gatecel C, Kermarrec N, et al. Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996; 153:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/20\">",
"      Windsor AC, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993; 80:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/21\">",
"      Hogg JC. Felix Fleischner Lecture. The traffic of polymorphonuclear leukocytes through pulmonary microvessels in health and disease. AJR Am J Roentgenol 1994; 163:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/22\">",
"      Roumen RM, Hendriks T, de Man BM, Goris RJ. Serum lipofuscin as a prognostic indicator of adult respiratory distress syndrome and multiple organ failure. Br J Surg 1994; 81:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/23\">",
"      Gadek JE, Pacht ER. The interdependence of lung antioxidants and antiprotease defense in ARDS. Chest 1996; 110:273S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/24\">",
"      Donnelly SC, MacGregor I, Zamani A, et al. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/25\">",
"      Calandrino FS Jr, Anderson DJ, Mintun MA, Schuster DP. Pulmonary vascular permeability during the adult respiratory distress syndrome: a positron emission tomographic study. Am Rev Respir Dis 1988; 138:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/26\">",
"      Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/27\">",
"      Dantzker DR, Brook CJ, Dehart P, et al. Ventilation-perfusion distributions in the adult respiratory distress syndrome. Am Rev Respir Dis 1979; 120:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/28\">",
"      Kiiski R, Takala J, Kari A, Milic-Emili J. Effect of tidal volume on gas exchange and oxygen transport in the adult respiratory distress syndrome. Am Rev Respir Dis 1992; 146:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/29\">",
"      Roupie E, Dambrosio M, Servillo G, et al. Titration of tidal volume and induced hypercapnia in acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 152:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/30\">",
"      Gattinoni L, Pesenti A, Avalli L, et al. Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. Am Rev Respir Dis 1987; 136:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/31\">",
"      Vieillard-Baron A, Schmitt JM, Augarde R, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med 2001; 29:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/32\">",
"      Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989; 17:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/33\">",
"      Steltzer H, Krafft P, Fridrich P, et al. Right ventricular function and oxygen transport patterns in patients with acute respiratory distress syndrome. Anaesthesia 1994; 49:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/34\">",
"      Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006; 34:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/35\">",
"      Melot C, Naeije R, Mols P, et al. Pulmonary vascular tone improves pulmonary gas exchange in the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 136:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/36\">",
"      Monchi M, Bellenfant F, Cariou A, et al. Early predictive factors of survival in the acute respiratory distress syndrome. A multivariate analysis. Am J Respir Crit Care Med 1998; 158:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/37\">",
"      Wright PE, Bernard GR. The role of airflow resistance in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/38\">",
"      Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994; 106:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/39\">",
"      Tomashefski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med 1990; 11:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/40\">",
"      Gattinoni L, Pelosi P, Suter PM, et al. Acute respiratory distress syndrome caused by pulmonary and extrapulmonary disease. Different syndromes? Am J Respir Crit Care Med 1998; 158:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/41\">",
"      Lim CM, Jung H, Koh Y, et al. Effect of alveolar recruitment maneuver in early acute respiratory distress syndrome according to antiderecruitment strategy, etiological category of diffuse lung injury, and body position of the patient. Crit Care Med 2003; 31:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/42\">",
"      Tugrul S, Akinci O, Ozcan PE, et al. Effects of sustained inflation and postinflation positive end-expiratory pressure in acute respiratory distress syndrome: focusing on pulmonary and extrapulmonary forms. Crit Care Med 2003; 31:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/43\">",
"      Rocco PR, Zin WA. Pulmonary and extrapulmonary acute respiratory distress syndrome: are they different? Curr Opin Crit Care 2005; 11:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/44\">",
"      Pepe PE, Potkin RT, Reus DH, et al. Clinical predictors of the adult respiratory distress syndrome. Am J Surg 1982; 144:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/45\">",
"      Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/46\">",
"      Fowler AA, Hamman RF, Good JT, et al. Adult respiratory distress syndrome: risk with common predispositions. Ann Intern Med 1983; 98:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/47\">",
"      Villar J, Blanco J, A&ntilde;&oacute;n JM, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011; 37:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/48\">",
"      Doyle RL, Szaflarski N, Modin GW, et al. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 1995; 152:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/49\">",
"      Fein AM, Lippmann M, Holtzman H, et al. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 1983; 83:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/50\">",
"      Moss M, Bucher B, Moore FA, et al. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. JAMA 1996; 275:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/51\">",
"      Moss M, Parsons PE, Steinberg KP, et al. Chronic alcohol abuse is associated with an increased incidence of acute respiratory distress syndrome and severity of multiple organ dysfunction in patients with septic shock. Crit Care Med 2003; 31:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/52\">",
"      Iscimen R, Cartin-Ceba R, Yilmaz M, et al. Risk factors for the development of acute lung injury in patients with septic shock: an observational cohort study. Crit Care Med 2008; 36:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/53\">",
"      Moss M, Guidot DM, Wong-Lambertina M, et al. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Am J Respir Crit Care Med 2000; 161:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/54\">",
"      Foreman MG, Hoor TT, Brown LA, Moss M. Effects of chronic hepatic dysfunction on pulmonary glutathione homeostasis. Alcohol Clin Exp Res 2002; 26:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/55\">",
"      Burnham EL, Moss M, Harris F, Brown LA. Elevated plasma and lung endothelial selectin levels in patients with acute respiratory distress syndrome and a history of chronic alcohol abuse. Crit Care Med 2004; 32:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/56\">",
"      Tietjen PA, Kaner RJ, Quinn CE. Aspiration emergencies. Clin Chest Med 1994; 15:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/57\">",
"      MENDELSON CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol 1946; 52:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/58\">",
"      Wynne JW. Aspiration pneumonitis. Correlation of experimental models with clinical disease. Clin Chest Med 1982; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/59\">",
"      Baumann WR, Jung RC, Koss M, et al. Incidence and mortality of adult respiratory distress syndrome: a prospective analysis from a large metropolitan hospital. Crit Care Med 1986; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/60\">",
"      Mannes GP, Boersma WG, Baur CH, Postmus PE. Adult respiratory distress syndrome (ARDS) due to bacteraemic pneumococcal pneumonia. Eur Respir J 1991; 4:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/61\">",
"      Pachon J, Prados MD, Capote F, et al. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990; 142:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/62\">",
"      Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/63\">",
"      Demling RH. Current concepts on the adult respiratory distress syndrome. Circ Shock 1990; 30:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/64\">",
"      Sutyak JP, Wohltmann CD, Larson J. Pulmonary contusions and critical care management in thoracic trauma. Thorac Surg Clin 2007; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/65\">",
"      Schonfeld SA, Ploysongsang Y, DiLisio R, et al. Fat embolism prophylaxis with corticosteroids. A prospective study in high-risk patients. Ann Intern Med 1983; 99:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/66\">",
"      Moore FA, Moore EE, Read RA. Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome. New Horiz 1993; 1:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/67\">",
"      Treggiari MM, Hudson LD, Martin DP, et al. Effect of acute lung injury and acute respiratory distress syndrome on outcome in critically ill trauma patients. Crit Care Med 2004; 32:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/68\">",
"      Calfee CS, Eisner MD, Ware LB, et al. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007; 35:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/69\">",
"      Ketai LH, Grum CM. C3a and adult respiratory distress syndrome after massive transfusion. Crit Care Med 1986; 14:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/70\">",
"      Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005; 33:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/71\">",
"      Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007; 136:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/72\">",
"      Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest 2007; 131:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/73\">",
"      Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/74\">",
"      Parsons PE. Respiratory failure as a result of drugs, overdoses, and poisonings. Clin Chest Med 1994; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/75\">",
"      Reed CR, Glauser FL. Drug-induced noncardiogenic pulmonary edema. Chest 1991; 100:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/76\">",
"      Borish L, Matloff SM, Findlay SR. Radiographic contrast media-induced noncardiogenic pulmonary edema: case report and review of the literature. J Allergy Clin Immunol 1984; 74:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/77\">",
"      Guidot DM, Hart CM. Alcohol abuse and acute lung injury: epidemiology and pathophysiology of a recently recognized association. J Investig Med 2005; 53:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/78\">",
"      Marshall RP, Webb S, Hill MR, et al. Genetic polymorphisms associated with susceptibility and outcome in ARDS. Chest 2002; 121:68S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/79\">",
"      Gong MN, Wei Z, Xu LL, et al. Polymorphism in the surfactant protein-B gene, gender, and the risk of direct pulmonary injury and ARDS. Chest 2004; 125:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/80\">",
"      Lin Z, Pearson C, Chinchilli V, et al. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet 2000; 58:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/81\">",
"      Marshall RP, Webb S, Bellingan GJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/82\">",
"      Villar J, Flores C, P&eacute;rez-M&eacute;ndez L, et al. Angiotensin-converting enzyme insertion/deletion polymorphism is not associated with susceptibility and outcome in sepsis and acute respiratory distress syndrome. Intensive Care Med 2008; 34:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/83\">",
"      Iribarren C, Jacobs DR Jr, Sidney S, et al. Cigarette smoking, alcohol consumption, and risk of ARDS: a 15-year cohort study in a managed care setting. Chest 2000; 117:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/84\">",
"      Calfee CS, Matthay MA, Eisner MD, et al. Active and passive cigarette smoking and acute lung injury after severe blunt trauma. Am J Respir Crit Care Med 2011; 183:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/85\">",
"      Messent M, Sullivan K, Keogh BF, et al. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence and prediction. Anaesthesia 1992; 47:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/86\">",
"      Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999; 68:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/87\">",
"      Dulu A, Pastores SM, Park B, et al. Prevalence and mortality of acute lung injury and ARDS after lung resection. Chest 2006; 130:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/88\">",
"      De Campos T, Deree J, Coimbra R. From acute pancreatitis to end-organ injury: mechanisms of acute lung injury. Surg Infect (Larchmt) 2007; 8:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/89\">",
"      Anzueto A, Frutos-Vivar F, Esteban A, et al. Influence of body mass index on outcome of the mechanically ventilated patients. Thorax 2011; 66:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/90\">",
"      Gong MN, Bajwa EK, Thompson BT, Christiani DC. Body mass index is associated with the development of acute respiratory distress syndrome. Thorax 2010; 65:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/91\">",
"      Cohen DS, Matthay MA, Cogan MG, Murray JF. Pulmonary edema associated with salt water near-drowning: new insights. Am Rev Respir Dis 1992; 146:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/92\">",
"      Modell JH. Drowning. N Engl J Med 1993; 328:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/93\">",
"      Clark MC, Flick MR. Permeability pulmonary edema caused by venous air embolism. Am Rev Respir Dis 1984; 129:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/94\">",
"      Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med 2011; 183:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29945/abstract/95\">",
"      Trillo-Alvarez C, Cartin-Ceba R, Kor DJ, et al. Acute lung injury prediction score: derivation and validation in a population-based sample. Eur Respir J 2011; 37:604.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1609 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29945=[""].join("\n");
var outline_f29_15_29945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Baseline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGIC STAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ETIOLOGIES AND PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Severe trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Massive transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Transfusion-related acute lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lung and hematopoietic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Drugs and alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetic determinants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5933039\">",
"      Lung injury prediction score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1609|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/42/35502\" title=\"figure 1A\">",
"      Protective mechanisms in edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/15/8447\" title=\"figure 1B\">",
"      Early development edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/43/23231\" title=\"figure 1C\">",
"      Late development edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/20/44367\" title=\"figure 1D\">",
"      Alveolar edema development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/41/39582\" title=\"figure 2\">",
"      Time course of ARDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1609|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/27/40373\" title=\"picture 1\">",
"      Normal lung High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/4/30793\" title=\"picture 2\">",
"      Early DAD micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/11/41145\" title=\"picture 3\">",
"      Late DAD micrograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/41/40603\" title=\"table 1\">",
"      Conditions associated with ARDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=related_link\">",
"      Acute respiratory distress syndrome: Prognosis and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=related_link\">",
"      Drowning (submersion injuries)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36057?source=related_link\">",
"      Primary lung graft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/25/14745?source=related_link\">",
"      Pulmonary complications after autologous hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29946="Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy";
var content_f29_15_29946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Everett E Vokes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/15/29946/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/15/29946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H281026240\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive local therapy (surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy [RT]) is the key component of the initial treatment of locally advanced squamous cell head and neck cancer but is associated with high rates of locoregional and distant recurrence. In addition, treatment can cause considerable morbidity, including loss of swallowing, tongue and larynx function.",
"   </p>",
"   <p>",
"    In an effort to improve cure rates and functional outcomes, chemotherapy has been integrated into various multimodality approaches. These approaches have been applied for both inoperable patients and those who are operable but prefer an organ preservation technique.",
"   </p>",
"   <p>",
"    Combined modality functional organ preservation approaches that have been studied in patients with locoregionally advanced head and neck cancer in addition to definitive RT alone include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction (neoadjuvant) chemotherapy (chemotherapy prior to surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT)",
"     </li>",
"     <li>",
"      Concurrent chemoradiotherapy, in which chemotherapy is administered at the same time as RT. This approach has included variant schedules in which cycles of induction chemotherapy are alternated with RT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/1\">",
"       1",
"      </a>",
"      ]. Newer targeted therapies can also be combined with concurrent radiation.",
"     </li>",
"     <li>",
"      Combined induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general application of these approaches to patients with locoregionally advanced head and neck cancer arising in the oral cavity, oropharynx, hypopharynx, and larynx will be reviewed here. More detailed discussions for locoregionally advanced cancer of each of these sites, plus a review of the management of advanced nasopharyngeal carcinoma, are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1321?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=see_link\">",
"       \"Treatment of early and locoregionally advanced nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1049946212\">",
"    <span class=\"h1\">",
"     SELECTION OF AN ORGAN-SPARING TREATMENT APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026294\">",
"    <span class=\"h2\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key postulated advantages of integrating chemotherapy with radiation therapy (RT) in a functional organ preservation approach include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction chemotherapy prior to RT may reduce tumor volume and improve function prior to concurrent chemoradiotherapy, thereby permitting more effective and less toxic local therapy. Even with significant tumor volume reduction, the target volume should be based upon the anatomic compartments that encompass the pretreatment sites of gross disease.",
"     </li>",
"     <li>",
"      Induction chemotherapy could treat subclinical distant metastatic disease without delay",
"     </li>",
"     <li>",
"      The administration of chemotherapy concurrently with RT may sensitize tumor cells to the effects of radiation and thus overcome radiation resistance. Reduction of repopulation between radiation treatment fractions may also contribute to the benefits of concurrent chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=see_link\">",
"       \"Methods to overcome radiation resistance in head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Induction chemotherapy can provide prognostic information to select chemoradiotherapy treatment intensity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sequential therapy, the combination of induction chemotherapy followed by concurrent chemoradiotherapy, may combine the benefits of both induction chemotherapy and concurrent chemoradiotherapy.",
"   </p>",
"   <p>",
"    However, the addition of chemotherapy to RT can be associated with increased toxicity, which may limit patient compliance and delay or prevent the completion of definitive local therapy. Furthermore, the use of induction chemotherapy, either alone or followed by concurrent chemoradiotherapy, may induce cross-resistance to subsequent RT or chemoradiotherapy.",
"   </p>",
"   <p>",
"    Functional organ preservation approaches may not be appropriate and surgery may be preferred when the tumor has already destroyed the organ. This situation occurs most frequently in patients with far advanced laryngeal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link&amp;anchor=H349830938#H349830938\">",
"     \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\", section on 'Total laryngectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026429\">",
"    <span class=\"h2\">",
"     Definitive locoregional therapy alone vs chemotherapy plus definitive locoregional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Veterans Affairs Laryngeal Cancer Study Group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] trial established the feasibility of combining chemotherapy and RT for functional organ preservation compared with a primary surgical approach. Subsequently, multiple additional randomized trials have been conducted comparing the addition of chemotherapy to definitive locoregional therapy alone in patients with squamous cell head and neck cancer in general and in tumors of specific anatomic sites.",
"   </p>",
"   <p>",
"    The Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC), which was updated in 2009, pooled individual patient data from 93 trials and 16,485 patients with resectable or unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/4\">",
"     4",
"    </a>",
"    ]. In all trials, patients were randomly assigned to definitive locoregional therapy alone (surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT) or definitive locoregional therapy in combination with chemotherapy (induction, concurrent, or adjuvant). The trials included patients with oral cavity, oropharyngeal, hypopharyngeal and laryngeal cancers; trials that were limited to patients with primary nasopharyngeal tumors were excluded. The primary endpoint of the MACH-NC meta-analysis was overall survival.",
"   </p>",
"   <p>",
"    Results from this meta-analysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent chemotherapy &ndash; Concurrent chemotherapy was assessed in 50 trials that included 9605 patients. Mean follow-up was 5.6 years. Concurrent chemotherapy significantly decreased the risk of death compared with definitive local therapy alone (hazard ratio [HR] 0.81, 95% CI 0.78-0.86); this correlated with a 6.5 percent absolute decrease in mortality at five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The benefit was due to a decrease in cancer-related deaths, and no increase in non-cancer deaths was observed with concurrent chemotherapy. &nbsp;",
"     </li>",
"     <li>",
"      No statistically significant differences were observed with different RT schedules (once daily versus altered fractionation).",
"     </li>",
"     <li>",
"      There was a statistically significant decrease in effect from concurrent chemotherapy with increasing patient age, and no benefit was observed in those over age 70 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction chemotherapy &ndash; In 31 trials with 5311 patients, there was no statistically significant effect on overall survival from induction chemotherapy compared with surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT alone (HR 0.96, 95% CI 0.90-1.02). When results were analyzed based upon the induction chemotherapy regimen, results with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus 5-fluorouracil were significantly better than with other regimens.",
"     </li>",
"     <li>",
"      Concurrent chemoradiotherapy versus induction chemotherapy &ndash; Only six trials, involving 861 patients, directly compared concurrent chemoradiotherapy with various induction chemotherapy regimens followed by definitive locoregional therapy. Analysis of these trials did not demonstrate a statistically significant improvement in overall survival with concurrent therapy compared with induction therapy (HR 0.90, p = 0.15). Secondary analyses suggested that concurrent chemoradiotherapy was more effective at preventing locoregional failure, while induction chemotherapy provided a relatively more pronounced effect on distant metastases.",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy &ndash; In six trials with 2567 patients that assessed the impact of adjuvant chemotherapy, there was no improvement in overall survival compared with definitive local therapy alone (HR 1.06, 95% CI 0.95-1.16).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1049946399\">",
"    <span class=\"h2\">",
"     Sequential versus concurrent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of induction chemotherapy prior to concurrent chemoradiotherapy remains controversial. [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II trial, 101 patients with stages III and IV head and neck cancers were randomly assigned to either sequential or concurrent chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/7\">",
"       7",
"      </a>",
"      ]. Sequential therapy consisted of three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and 5-fluoruracil, which was followed by two cycles of concurrent cisplatin plus 5-fluorouracil during RT, or to the same concurrent therapy alone. Sequential therapy significantly improved the radiologic complete response rate compared with concurrent chemoradiotherapy (the primary endpoint of the trial, 50 versus 21 percent). There was a statistically nonsignificant increase in both progression-free and overall survival with sequential therapy (medians 30 versus 20 months and 40 versus 33 months, respectively).",
"     </li>",
"     <li>",
"      In the DeCIDE trial, 280 patients were randomly assigned to induction with two cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , and 5-fluorouracil followed by chemoradiotherapy or chemoradiotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/8\">",
"       8",
"      </a>",
"      ]. Chemoradiotherapy consisted of docetaxel, 5-fluorouracil, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (given as five &ldquo;cycles&rdquo; in combination with RT at 150cGy bid, repeated every other week).",
"      <br/>",
"      <br/>",
"      An analysis of the trial was presented at the 2012 American Society of Clinical Oncology (ASCO) meeting. There was no statistically significant difference in overall survival, the primary endpoint of the study (hazard ratio 0.91, 95% CI 0.59-1.41). Differences in relapse-free survival and distant metastasis free survival with induction chemoradiotherapy were not statistically significant.",
"     </li>",
"     <li>",
"      In the PARADIGM trial, 145 patients were randomly assigned to concurrent chemoradiotherapy (with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      on weeks 1 and 4) or to sequential chemotherapy using three cycles of a standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , 5-fluorouracil plus cisplatin regimen for induction, followed by concurrent chemoradiotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/9\">",
"       9",
"      </a>",
"      ]. In the sequential chemoradiotherapy arm, the chemoradiotherapy regimen varied and was based upon the response to induction chemotherapy (docetaxel 20",
"      <span class=\"nowrap\">",
"       mg/m2/week",
"      </span>",
"      with accelerated concomitant boost RT for &ldquo;poor responders&rdquo; to induction, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      AUC 1.5 with standard fraction RT for &ldquo;good&rdquo; responders). The original statistical plan called for enrollment of 300 patients but the trial was terminated early because of poor accrual.",
"      <br/>",
"      <br/>",
"      At a median follow-up of 49 months, there was no statistically significant difference in three-year overall survival, the primary endpoint of the trial (sequential therapy 73 percent versus concurrent chemoradiotherapy alone 78 percent, hazard ratio for death 1.09, 95% CI 0.59-2.03) and no clear benefit in any subset. Sequential therapy was associated with a higher frequency of febrile neutropenia compared with concurrent chemoradiotherapy alone (16 of 70 [23 percent] versus 1 of 75 [1 percent]). Notably, dilution of the already small patient numbers by biologically and prognostically distinct HPV positive patients further hinders the ability to make any statistical conclusions from this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of sequential therapy based upon the DECIDE and PARADIGM trials remains inconclusive due to early termination, low patient numbers, and the probable inclusion of a large number of biologically distinct HPV positive patients. Further studies addressing this issue have been completed and await reporting and might contribute to conclusions about sequential therapy. In the meantime, the use of sequential therapy should be an individual",
"    <span class=\"nowrap\">",
"     physician/patient",
"    </span>",
"    decision but generally reserved for those healthy patients at high risk for both distant and locoregional recurrence (N2c or N3 nodal stage and at least T2 primary stage).",
"   </p>",
"   <p>",
"    In the TAX 324 trial, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , plus 5-fluorouracil (TPF) regimen followed by concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus RT was superior to induction cisplatin plus 5-fluorouracil (PF) followed by the same chemoradiotherapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The MACH-NC meta-analysis found that induction PF had a positive effect on survival; thus, the superiority of TPF induction compared with PF in the TAX 324 trial provides further indirect evidence of the benefit of a sequential approach using this three drug regimen compared to a two drug regimen. (See",
"    <a class=\"local\" href=\"#H281026593\">",
"     'Induction chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1049946406\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined approaches using chemotherapy and definitive radiotherapy are used in patients with both resectable and unresectable disease. The definitions of resectable and unresectable disease vary among practitioners and a large fraction of resectable patients can be treated non-surgically in an effort to preserve organ anatomy and function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose disease is considered resectable, concurrent chemoradiotherapy with or without induction chemotherapy may be useful as an approach for functional organ preservation.",
"     </li>",
"     <li>",
"      If the disease is unresectable then the addition of chemotherapy to radiation therapy or (in patients not considered to be candidates for multimodality therapy) radiation therapy alone are the only treatment options. Such treatment may render the patient free of disease and may result in functional organ preservation. In some cases with persistent disease following completion of chemoradiotherapy, salvage surgery can be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemoradiotherapy for locally advanced head and neck cancer is associated with significant toxicity that can result in treatment delays or interruptions. Appropriate patient selection is critical to successfully complete therapy. The patient&rsquo;s performance status, comorbidities, age, and psychosocial support network are important factors that need to be considered prior to proceeding with a combined modality approach.",
"   </p>",
"   <p>",
"    Key factors to consider in selecting appropriate treatment for an individual patient include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most randomized clinical trials limited enrollment to patients with minimal comorbidities and a good performance status (ECOG 0 and 1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      )).",
"     </li>",
"     <li>",
"      Although the elderly have been successfully treated, the MACH-NC meta-analysis found that older patients are less likely to benefit from the addition of chemotherapy to definitive locoregional treatment and the meta-analysis could not demonstrate a benefit in those over 70 years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/4\">",
"       4",
"      </a>",
"      ]. Age alone should not be used as a criterion in selecting treatment approaches; rather comorbidities and performance status should be critically assessed in all patients, especially in the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"       \"Comprehensive geriatric assessment for patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"       \"Systemic chemotherapy for cancer in elderly persons\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a poor performance status or significant comorbidities may be best managed with definitive RT alone or laryngectomy for larynx cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link&amp;anchor=H349830938#H349830938\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\", section on 'Total laryngectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026585\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents with proven activity in squamous cell head and neck cancer that are most commonly included in either induction or concurrent chemotherapy regimens include the platinum compounds (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ), 5-fluorouracil, and taxanes (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026593\">",
"    <span class=\"h2\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early clinical trials found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-fluorouracil (PF, cisplatin, 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and 5-fluorouracil, 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    continuous 24-hour infusion for five days) given every three weeks as induction chemotherapy induced higher rates of complete response and better survival compared with earlier cisplatin and bleomycin-based regimens and regimens using shorter infusions of 5-fluorouracil and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent randomized trials found that the addition of a taxane (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) to PF induction chemotherapy enhanced the effectiveness of induction chemotherapy used with RT alone or with RT plus concurrent chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/10,11,14-16\">",
"     10,11,14-16",
"    </a>",
"    ]. The TAX 324 and EORTC",
"    <span class=\"nowrap\">",
"     24971/TAX",
"    </span>",
"    323 trials illustrate the potential benefits of adding a taxane to the induction chemotherapy regimen with locoregionally advanced cancer of the oral cavity, oropharynx, hypopharynx, and larynx:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most extensive data come from the TAX 324 trial, in which 501 patients were randomly assigned to induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , plus 5-fluorouracil (TPF) or cisplatin plus 5-fluorouracil (PF) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Both induction regimens were given every three weeks for three cycles. The TPF induction regimen administered docetaxel 75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1, cisplatin 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1, and 5-fluorouracil 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      by continuous infusion on days 1 to 4. This was followed by concurrent chemoradiotherapy using weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (dosed at an area under the concentration x time curve [AUC] of 1.5). With a median follow-up of 72 months, overall survival was significantly better with TPF compared with PF (hazard ratio 0.74, five-year survival 52 versus 42 percent, (95% CI 0.58-0.94). Similar improvement in progression-free survival was observed.",
"      <br/>",
"      <br/>",
"      Acute toxicity associated with TPF induction chemotherapy in the TAX 324 trial was substantial. Severe myelosuppression was manifested by grade 3 or 4 neutropenia, febrile neutropenia, and neutropenic infection in 83, 12, and 12 percent of cases, respectively, during induction chemotherapy. Severe nonhematologic toxicities included stomatitis (mucositis), nausea, esophagitis, and anorexia in 21, 14, 13, and 12 percent of cases, respectively. Treatment delays due to toxicity occurred in 29 percent of patients during induction chemotherapy and were less frequent on the TPF arm.",
"     </li>",
"     <li>",
"      The EORTC",
"      <span class=\"nowrap\">",
"       24971/TAX",
"      </span>",
"      323 trial randomly assigned 358 patients to four cycles of a slightly different TPF induction regimen or the same PF regimen used in the TAX 324 trial [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/16\">",
"       16",
"      </a>",
"      ]. The TPF regimen consisted of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      and 5-fluorouracil (750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      by continuous intravenous infusion for five days). Chemotherapy was not administered concurrently with RT. Overall survival was significantly improved with this TPF regimen compared with PF (median 18.8 versus 14.5 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protocols for these chemotherapy regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25473?source=see_link\">",
"     \"Treatment protocols for squamous cell carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027161\">",
"    <span class=\"h2\">",
"     Concurrent chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although multiple clinical trials and the MACH-NC meta-analysis demonstrated a survival benefit from chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/4\">",
"     4",
"    </a>",
"    ], the optimal concurrent regimen has not been defined. The MACH-NC meta-analysis found a greater benefit for platinum-based as compared with other chemotherapy regimens. The various regimens have not been directly compared with each other in adequately powered, randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026895\">",
"    <span class=\"h3\">",
"     Cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose bolus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, and 43) is often considered the preferred regimen, although it is associated with severe acute and late toxicities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The toxicity associated with concurrent cisplatin on this schedule is illustrated by results from the RTOG 91-11 trial in patients with advanced laryngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/19\">",
"     19",
"    </a>",
"    ]. Frequent severe (grade 3 and 4) adverse events were hematologic side effects, stomatitis, dysphagia or odynophagia, and",
"    <sup>",
"    </sup>",
"    nausea or vomiting (47, 43, 35,",
"    <sup>",
"    </sup>",
"    and 20 percent, respectively). Only 120 of 172 patients (70 percent) treated with this regimen completed all three cycles of cisplatin, although another 40 of the remaining 52 were able to receive two cycles. High-dose bolus cisplatin is typically reserved for patients with excellent performance status and minimal comorbidities.",
"   </p>",
"   <p>",
"    Whether three cycles of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is necessary is uncertain. In the RTOG 0129 trial, once daily fractionation RT for seven weeks, in combination with three cycles of cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 22, and 43), was compared with accelerated boost RT (42 fractions given over six weeks) with two cycles of cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 22) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no statistically significant difference in overall survival when those receiving two cycles of cisplatin with once daily fractionation were compared with those receiving three cycles plus once daily fractionation.",
"   </p>",
"   <p>",
"    We generally reserve concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) for patients with an excellent performance status (ECOG 0 or 1, (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"     table 1",
"    </a>",
"    )). Alternative cisplatin dosing schedules (eg, 30 to 40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, 6",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, or 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days on weeks 1 and 5) are sometimes used because of improved patient tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/21-27\">",
"     21-27",
"    </a>",
"    ]. These alternative schedules have not been directly compared to high-dose bolus cisplatin, but they are considered reasonable options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281026902\">",
"    <span class=\"h3\">",
"     Carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    is more myelosuppressive than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    but causes less neurotoxicity, nephrotoxicity, and nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Carboplatin is not as effective as cisplatin for its direct antitumor effect. Whether carboplatin is as effective as cisplatin as a radiation sensitizer is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least one trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is not as effective as high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/28\">",
"     28",
"    </a>",
"    ]. Nonetheless, weekly carboplatin (AUC of 1.5 to 2) is an option as an alternative to cisplatin, especially in patients with renal disease, poorer performance status, or those who may have difficulty tolerating the fluid volume associated with bolus cisplatin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/33\">",
"     33",
"    </a>",
"    ]. The combination of carboplatin plus 5-fluorouracil may also represent another option when cisplatin is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/34\">",
"     34",
"    </a>",
"    ]. Carboplatin has also been combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent chemoradiotherapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    demonstrated comparable efficacy and better tolerability when compared to concurrent chemoradiotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in one randomized study in patients with locally advanced nasopharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/36\">",
"     36",
"    </a>",
"    ]. There was no significant difference in three-year disease-free survival (61 versus 63 percent for carboplatin and cisplatin regimens, respectively) or overall survival (79 versus 78 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027372\">",
"    <span class=\"h3\">",
"     Epidermal growth factor inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal growth factor receptor (EGFR) is highly overexpressed in head and neck squamous cell carcinoma and is associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. EGFR activation facilitates tumor growth by promoting angiogenesis and proliferation and metastasis by increasing motility and adhesion of tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    are monoclonal antibodies that bind to and inhibit the EGFR receptor.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    is an inhibitor of the EGFR tyrosine kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168427307\">",
"    <span class=\"h4\">",
"     Cetuximab alone plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    was evaluated in a multinational trial in which 424 patients with locoregionally advanced cancers of the oropharynx, hypopharynx, or larynx were randomly assigned to RT with or without concurrent weekly cetuximab [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/40\">",
"     40",
"    </a>",
"    ]. Cetuximab was administered at a dose of 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours one week prior to RT, followed by 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over one hour weekly during RT.",
"   </p>",
"   <p>",
"    With a median follow-up of 54 months, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    -treated group had significantly better overall survival compared to those receiving RT alone (three-year survival 55 versus 45 percent, hazard ratio 0.73). Locoregional control rates were also significantly better (50 versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/41\">",
"     41",
"    </a>",
"    ]. An underpowered subset analysis showed the benefit of cetuximab plus RT was restricted to patients under the age of 65 years and with a Karnofsky performance score (KPS) 90 to 100 (",
"    <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"     table 2",
"    </a>",
"    ) and those with oropharyngeal cancer. Patients 65 years of age and older and those with KPS 60 to 80 had an overall survival that favored radiotherapy alone, although the difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    had a greater incidence of Grade 3 or 4 radiation dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/41\">",
"     41",
"    </a>",
"    ]. Guidelines for the management of radiation dermatitis in patients receiving concurrent cetuximab have recently been published (",
"    <a class=\"graphic graphic_table graphicRef79344 \" href=\"UTD.htm?26/58/27566\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe infusion reactions occurred in about 3 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , 90 percent of which were in the first cycle. In certain southeastern parts of the United States, the risk of severe infusion reactions is much higher [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In addition, one retrospective study found that concurrent cetuximab caused significantly more mucositis, dermatitis, weight loss, and requirements for enteral feeding than concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , although concurrent cetuximab did not increase the frequency of treatment interruptions or delay [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=see_link&amp;anchor=H2#H2\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'EGFR signal transduction inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H48#H48\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus RT with RT alone, which is no longer considered a standard approach for patients with locoregionally advanced disease. Therefore it failed to identify the relative position of cetuximab-based radiation-enhancement versus the most frequently investigated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based approach. How concurrent cetuximab plus RT compares with concurrent cisplatin-based chemoradiotherapy has so far not been prospectively addressed in a randomized trial.",
"   </p>",
"   <p>",
"    The currently available data do NOT support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    with RT as an alternative to RT alone in elderly patients and those with significant comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168427314\">",
"    <span class=\"h4\">",
"     Cetuximab plus cisplatin plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined concurrent treatment with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    does not appear to offer any advantages compared with concurrent cisplatin alone as reported in an early analysis of the randomized RTOG 0522 phase III trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/46\">",
"     46",
"    </a>",
"    ]. In this trial, 940 patients with locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were treated with concurrent cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 22) plus accelerated RT (70 Gy in 42 fractions over six weeks) with or without concurrent cetuximab. Patients receiving cetuximab were to receive a loading dose of 400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    followed by weekly treatment with 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    during RT.",
"   </p>",
"   <p>",
"    Results of the planned third interim analysis with a median follow-up of 2.4 years were presented at the 2011 American Society of Clinical Oncology (ASCO) meeting. There was no improvement in progression-free survival, the primary endpoint of the trial, with concurrent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    compared to cisplatin alone (63 versus 64 percent, HR 1.05, 95%CI 0.84-1.29). Similarly, there was no statistically significant improvement in overall survival (83 versus 80 percent, HR 0.87, 95% CI 0.66-1.15). Toxicity was similar on both arms of the trial except for increases in grade 3 to 4 mucositis and skin reaction in patients receiving cetuximab (45 versus 35 and 40 versus 17 percent, respectively). There may changes in the results with longer follow up and with further analysis. Currently these data do not support combining cetuximab with bolus cisplatin and standard radiotherapy outside of a clinical trial.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    should not be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    during RT outside the context of a formal clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175776412\">",
"    <span class=\"h4\">",
"     Panitumumab plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    is another monoclonal antibody targeting the EGFR receptor. Panitumumab was studied in the randomized, phase II Concert trial, in which 150 patients were randomly assigned to panitumumab plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    given concurrently with RT or to cisplatin alone plus RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/47\">",
"     47",
"    </a>",
"    ]. In a preliminary report at the 2012 ASCO meeting, there was no improvement in locoregional control associated with the addition of panitumumab, and there was a trend toward poorer survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175776446\">",
"    <span class=\"h4\">",
"     Erlotinib plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    is a small molecule inhibitor of the EGFR tyrosine kinase. Erlotinib was combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in a phase II trial in which 205 patients with locally advanced squamous cell carcinoma of the head and neck were randomly assigned to either cisplatin alone or cisplatin plus erlotinib, both given concurrently with definitive RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/48\">",
"     48",
"    </a>",
"    ]. The addition of erlotinib did not significantly improve either the complete response rate or progression-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027704\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY PLANNING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027844\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy and concurrent chemoradiotherapy are intensive and require multidisciplinary input to be successful. A multidisciplinary team is needed to coordinate care, prevent treatment delays, and provide optimal RT planning. Planning should begin prior to initiation of the induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation for distant metastases should include chest imaging, as well as any other studies indicated by symptoms.",
"     </li>",
"     <li>",
"      A nutritional evaluation should be carried out prior to initial treatment, and nutritional support should be provided as needed during and after treatment. We avoid prophylactic gastric feeding tubes in patients without an immediate need, as many patients can be supported through treatment without the need for a tube. However, some centers routinely insert prophylactic feeding tubes to supplement nutrition support throughout chemoradiotherapy.",
"     </li>",
"     <li>",
"      Dental issues should be considered and treated if necessary, so that the RT component of therapy does not have to be delayed.",
"     </li>",
"     <li>",
"      Speech and swallowing should be assessed prior to treatment for most patients.",
"     </li>",
"     <li>",
"      Comorbid medical issues should be addressed prior to treatment, since four to six months of rigorous treatment may exacerbate underlying illnesses. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027852\">",
"    <span class=\"h2\">",
"     RT treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT uses a treatment plan based upon the tumor&rsquo;s initial size, location, and relation to normal organs. Contrast-enhanced CT or MRI should be obtained prior to induction chemotherapy to serve as a reference for post-induction RT planning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Changes in body weight, neck contours, and tumor volumes may necessitate replanning following completion of induction chemotherapy. Pretreatment primary tumor and gross nodal tumor volumes should be used for treatment planning even though tumor shrinkage may have occurred. All structures involved by tumor prior to induction chemotherapy should be included in the final treatment plan, even if gross tumor is no longer identifiable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027860\">",
"    <span class=\"h2\">",
"     RT schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered RT fractionation schedules used without concurrent chemotherapy have been extensively investigated to improve locoregional control and overall survival.",
"   </p>",
"   <p>",
"    Hyperfractionation results in better locoregional control and overall survival when compared to once-daily RT as single modality treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/50\">",
"     50",
"    </a>",
"    ]. Accelerated fractionation using continuous schedules without radiation dose reduction improves local control but the impact on overall survival is unclear. However, the added cost and logistical challenges of multiple fractions per day RT have limited the widespread utilization of these techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, at least two randomized trials have not observed a benefit from altered RT fractionation schedules when the RT is given in combination with concurrent chemotherapy. One of these trials also strongly suggests that standard fractionation concurrent chemoradiation is superior to accelerated fractionation RT alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the RTOG 0129 trial, 721 patients with locoregionally advanced head and neck cancer were randomly assigned to once daily fractionation RT (70 Gy in 35 fractions over seven weeks) or to accelerated boost RT (70 Gy in 42 fractions over six weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients receiving once daily fractionation RT were to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      on days 1, 22, and 43, while those receiving accelerated boost RT were to receive the same dose of cisplatin on days 1 and 22. There was no statistically significant difference in overall survival (the primary endpoint of the trial) when the two radiation schedules were compared, nor was a difference observed in progression-free survival, locoregional relapse rate, or the incidence of distant metastases.",
"     </li>",
"     <li>",
"      In the GORTEC 99-02 trial, 840 patients were randomly assigned to one of three regimens: conventional chemoradiotherapy (70 Gy in 7 weeks with three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      5-fluorouracil), accelerated chemoradiotherapy (70 Gy in 6 weeks with two cycles of carboplatin 5-fluorouracil), or very accelerated RT alone (64.8 Gy in 3.5 weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/51\">",
"       51",
"      </a>",
"      ]. With a median follow-up of five years, there was no benefit from accelerated chemoradiotherapy compared with conventional chemoradiotherapy (three-year progression-free survival 34 versus 38 percent, p = 0.88). There was a trend for conventional chemoradiotherapy to do better than very accelerated RT alone (three-year progression-free survival 38 versus 32 percent, p = 0.06). Similar results were observed for overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027712\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of induction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemotherapy may delay or prevent the delivery of a full course of RT. Although the benefits of induction chemotherapy or concurrent chemotherapy have been demonstrated in randomized clinical trials, breaks in therapy and the transition between induction and concurrent therapy should be minimized whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027720\">",
"    <span class=\"h3\">",
"     Interval between induction chemotherapy and RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mathematical modeling and retrospective studies indicate that delays in instituting RT may be associated with poorer tumor control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Time is required for the mucosa and bone marrow to recover from induction chemotherapy, but concurrent chemoradiotherapy should be initiated whenever possible within three to five weeks after the last dose of induction chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/49\">",
"     49",
"    </a>",
"    ]. Delays beyond this period of time will increase the risk of locoregional failure. Additional chemotherapy should not be used as a &ldquo;holding plan\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281027727\">",
"    <span class=\"h3\">",
"     RT delivery time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RT component of treatment should be completed without unnecessary delay. A post hoc analysis of the TAX 324 trial analyzed outcome as a function of the duration required to complete the entire course of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/55\">",
"     55",
"    </a>",
"    ]. A multivariate analysis of outcomes in the 333 patients who completed all three cycles of induction chemotherapy and received a full course of radiation found that prolonging the duration of RT beyond eight weeks was an independent predictor of inferior survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028065\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for surgery to treat persistent or recurrent primary tumor and regional lymph node disease depend upon the extent of pretreatment disease and subsequent response to therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery should be considered for resectable patients with poor responses in the primary site or neck after induction chemotherapy and for patients with residual disease after concurrent chemoradiotherapy.",
"     </li>",
"     <li>",
"      Neck dissection, if feasible, is generally planned for patients with residual disease in the neck following concurrent chemoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical examination is critical for the assessment of residual disease after concurrent chemoradiotherapy and sequential therapy. Computed tomography (CT) and positron emission tomography (PET) scans augment the clinical evaluation but can be difficult to interpret if they are performed too soon after the completion of concurrent chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028072\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for the primary tumor provides good locoregional control and prolonged survival for some patients with residual disease after concurrent chemoradiotherapy, although it is associated with considerable morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Residual or recurrent disease often contains multiple foci of tumor rather than a concentric tumor mass [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/58\">",
"     58",
"    </a>",
"    ]. Thus, the salvage operation is typically the procedure that would have been performed prior to chemoradiotherapy even for tumors that showed some response to therapy.",
"   </p>",
"   <p>",
"    Overall complication rates of 30 to 50 percent and pharyngocutaneous fistula rates of 30 percent are common in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/56,59\">",
"     56,59",
"    </a>",
"    ]. Many of these complications occur because of the poor tissue quality at the surgery site which results in poor wound healing and postoperative function. The use of free flap reconstruction brings nonirradiated, well vascularized tissue into the site and results in a decreased incidence of wound complications.",
"   </p>",
"   <p>",
"    Although it is preferable to wait 10 to 12 weeks to assess for residual tumor after concurrent chemoradiotherapy, some surgeons prefer to perform salvage surgery at four to six weeks when residual tumor is clearly present, because of concerns of operating in tissue with radiation fibrosis. (See",
"    <a class=\"local\" href=\"#H281028107\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028079\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neck dissection following chemoradiotherapy for locoregionally advanced head and neck cancer is generally indicated for patients with clinically evident cervical lymph nodes who have an incomplete clinical response to therapy.",
"   </p>",
"   <p>",
"    The role of neck dissection in patients with a complete response in the neck to chemoradiotherapy is evolving. Although elective neck dissection was previously recommended for patients with bulky disease prior to treatment, more recent retrospective studies and at least one prospective study suggest that a neck dissection can be deferred in patients with a negative PET scan at 12 weeks after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. High quality CT imaging is an alternative when PET is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the prospective study, 112 consecutive patients who achieved a complete response following chemoradiotherapy underwent a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    at 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/60\">",
"     60",
"    </a>",
"    ]. Of these, 50 (45 percent) had residual abnormalities on CT, but only nine of the 50 were PET positive. All 41 patients with a CT abnormality and a negative PET were followed for a median 28 months without isolated recurrence in the neck nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028086\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications associated the treatment of locoregionally advanced head and neck cancer are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"       \"Management of late complications of head and neck cancer and its treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"       \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topics that require particular consideration when chemotherapy and RT are combined include the prevention of infection due to severe myelosuppression and the maintenance of adequate nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028520\">",
"    <span class=\"h2\">",
"     Prevention of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive chemotherapy results in severe myelosuppression in the majority of patients. As an example, in the TAX 324 trial, induction chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and 5-fluorouracil resulted in grade 3 or 4 neutropenia, febrile neutropenia, and neutropenic infection in 83, 12, and 12 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H281026593\">",
"     'Induction chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028093\">",
"    <span class=\"h3\">",
"     Granulocyte colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observed incidence of febrile neutropenia observed in the TAX 324 trial meets the criterion for considering the use of granulocyte colony-stimulating factors to prevent febrile neutropenia according to guidelines from a variety of expert groups including the American Society of Clinical Oncology (ASCO),the European Organization for Research and Treatment of Cancer (EORTC) and the Infectious Disease Society of America, all of which recommend the use of primary prophylaxis if the risk of febrile neutropenia with a specific regimen is &ge; 20 percent. However, primary prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) was not permitted in the TAX 324 trial evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , plus 5-fluorouracil (TPF) induction chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774219#H523774219\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Indications, benefits, and guidelines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774275#H523774275\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, the use of granulocyte colony-stimulating factors as primary prophylaxis during induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemoradiotherapy may adversely affect outcomes. In one trial of concurrent chemoradiotherapy with hyperfractionated accelerated radiotherapy, patients randomized to prophylactic G-CSF experienced significantly reduced locoregional tumor control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/63\">",
"     63",
"    </a>",
"    ]. These findings suggest that G-CSF should be used cautiously during RT and imply that G-CSF may have a possible protective tumor effect in head and neck cancer. Because of the increasing frequency of HPV associated tumors, it is unclear if this is disease specific or a generalization for all squamous cancers of the head and neck. We recommend caution when using G-CSF in this setting. There are no data on granulocyte-macrophage-CSF (GM-CSF).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028100\">",
"    <span class=\"h3\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , have been routinely used during induction chemotherapy; these typically are initiated on day 5 of each cycle and continued for 10 days. The merits of antibiotic prophylaxis to prevent infection and infection-related complications in cancer patients at risk because of severe neutropenia remain controversial. Nevertheless, fluoroquinolone prophylaxis, in particular, has been shown to reduce the risk of febrile episodes in neutropenic outpatients with solid tumors and potentially decrease mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H247552642#H247552642\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Antibacterial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028543\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic medication has become routine to minimize the consequences of myelosuppression. Our approach is to use a fluoroquinolone antibiotic during induction chemotherapy because of the myelotoxicity of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-fluorouracil (TPF) regimen. We avoid the use of hematopoietic colony-stimulating factors in general since the data suggest a negative impact, at least when G-CSF is given during radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702831617\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional status should be monitored throughout the course of therapy, and feeding tubes or gastrostomy tubes are frequently required (",
"    <a class=\"graphic graphic_table graphicRef86568 \" href=\"UTD.htm?12/50/13100\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/15/29946/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link&amp;anchor=H14#H14\">",
"     \"The role of parenteral and enteral/oral nutritional support in patients with cancer\", section on 'Head and neck cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastrostomy or percutaneous endoscopic gastrostomy (PEG) tubes preferably should not be placed prior to induction chemotherapy due to complications that may occur during this phase of therapy. If the nutritional status is such that the patient requires a prophylactic gastrostomy or PEG tube prior to or during induction therapy, then such individuals may not be candidates for aggressive induction chemotherapy. If a prophylactic gastrostomy or PEG tube is placed prior to induction chemotherapy, then initiation of chemotherapy should be delayed for two weeks to allow the tract to mature, and proton pump inhibitors may be prescribed during induction chemotherapy therapy to prevent wound problems.",
"   </p>",
"   <p>",
"    Gastrostomy or PEG tube placement prior to concurrent chemoradiotherapy is less problematic than insertion prior to induction chemotherapy. However, aggressive analgesic use, nutritional counseling and support, intravenous fluid support, and optimal nursing care can prevent the need for tubes in many patients undergoing functional organ preservation therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028107\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences will occur within this timeframe. Continued follow-up beyond five years is generally suggested since the risk of recurrence remains elevated beyond the first five years, especially for cancers of the hypopharynx, larynx, nasopharynx, and salivary glands and there is a high rate of development of second primary malignancies. Because of the higher risk of recurrence and second primary malignancy in those who continue tobacco use, many schedule more frequent surveillance visits for these patients and continue for longer duration (ie, beyond five years).",
"   </p>",
"   <p>",
"    Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281028114\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of chemotherapy in combination with definitive local therapy using radiation therapy (RT) achieves improved results compared with RT alone and potentially can achieve equivalent or improved overall survival while preserving organ function compared with surgery plus RT alone. Approaches include administering chemotherapy with RT (concurrent chemoradiotherapy), chemotherapy prior to RT (induction chemotherapy), or by combining induction chemotherapy prior to concurrent chemoradiotherapy (sequential therapy). (See",
"    <a class=\"local\" href=\"#H281026294\">",
"     'Rationale'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H281026429\">",
"     'Definitive locoregional therapy alone vs chemotherapy plus definitive locoregional therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment regimens combining chemotherapy and RT for locally advanced head and neck cancer are associated with significant toxicity. Appropriate patient selection is critical to successfully complete therapy. The patient&rsquo;s performance status, comorbidities, age, and psychosocial support network are important factors that need to be considered. (See",
"      <a class=\"local\" href=\"#H1049946406\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with locoregionally advanced head and neck cancer who are treated with a functional organ preservation approach (ie, chemotherapy plus RT rather than surgery), we recommend concurrent chemoradiotherapy rather than induction chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The use of induction therapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) may offer additional advantages in select situations. Concurrent chemoradiotherapy is preferable for patients less likely to have distant metastases (N0 and N1 presentations) and for preservation of the larynx and sequential therapy may be preferable for select patients with high risk of distant metastases (more extensive lymph node disease including bulky N2b, N2c, and N3) and may provide a long term survival advantage for larynx cancer patients. (See",
"      <a class=\"local\" href=\"#H1049946212\">",
"       'Selection of an organ-sparing treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients treated with induction chemotherapy prior to concurrent chemoradiotherapy, we recommend the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , plus 5-fluorouracil (TPF) chemotherapy rather than cisplatin plus 5-fluorouracil (PF) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This approach significantly improved local control and overall survival compared to PF. &nbsp;It remains unclear however if the sequential approach provides a survival advantage over concurrent chemoradiotherapy alone. Decisions should be individualized, but generally sequential therapy should be reserved for healthy patients with high risk of distant and locoregional failure (especially the combination of N2C, N3 nodal stage plus T2 or greater primary stage). (See",
"      <a class=\"local\" href=\"#H281026593\">",
"       'Induction chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25473?source=see_link\">",
"       \"Treatment protocols for squamous cell carcinoma of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the high frequency of severe neutropenia during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , plus 5-fluoruracil (TPF) induction chemotherapy, we recommend primary prophylaxis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Our approach is to use a fluoroquinolone antibiotic during induction chemotherapy, and to avoid hematopoietic colony-stimulating factors in general. (See",
"      <a class=\"local\" href=\"#H281028520\">",
"       'Prevention of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients being treated with concurrent chemoradiation alone or after induction chemotherapy, we recommend the use of platinum-based chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H281027161\">",
"       'Concurrent chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with a good performance status who did not receive induction chemotherapy with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -containing regimen, cisplatin (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks given concurrently with conventional RT) has the best established efficacy. Cisplatin (30 to 40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly given concurrently with RT) is an alternative that may be more tolerable, particularly for patients with a diminished performance status.",
"     </li>",
"     <li>",
"      For patients who received induction chemotherapy with TPF or another",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -containing regimen, we suggest concurrent chemotherapy with low-dose weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (dosed at an area under the concentration x time curve [AUC] of 1.5), as was done in the TAX 324 trial (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who are not candidates for treatment with a platinum-based regimen due to specific contraindication (eg, nephrotoxicity, ototoxicity, or neuropathy), we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the effectiveness of cetuximab in patients over the age of 65, with comorbidities, or with a poor performance status was not confirmed in subset analysis, and age and poor performance status alone should not be considered an indication for cetuximab. (See",
"      <a class=\"local\" href=\"#H281027372\">",
"       'Epidermal growth factor inhibition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful RT planning is required to ensure that an adequate course of definitive RT is administered in a timely fashion; delays or an incomplete course of treatment may lead to an increased risk of locoregional recurrence. We suggest once daily fractionation of RT in combination with concurrent chemotherapy rather that a hyperfractionated and accelerated regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Although alternative RT schedules improve outcomes when administered without concurrent chemotherapy, altered fractionation does not compensate for the lack of concurrent chemotherapy. (See",
"      <a class=\"local\" href=\"#H281027704\">",
"       'Radiation therapy planning'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"       \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgery should be considered for patients with poor responses in the primary site or neck after induction chemotherapy and for patients with residual disease after radiotherapy or concurrent chemoradiotherapy. Neck dissection is indicated for patients with clinically detectable residual disease or a positive PET scan 12 weeks after concurrent chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H281028065\">",
"       'Role of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The application of these combined modality approaches to cancers of specific sites in the head and neck is discussed separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1321?source=see_link\">",
"       \"Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/1\">",
"      Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009; 101:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/2\">",
"      Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/3\">",
"      Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 1994; 12:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/4\">",
"      Pignon JP, le Ma&icirc;tre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/5\">",
"      Rapidis AD, Trichas M, Stavrinidis E, et al. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Oral Oncol 2006; 42:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/6\">",
"      Urba SG, Moon J, Giri PG, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 2005; 23:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/7\">",
"      Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21:1515.",
"     </a>",
"    </li>",
"    <li>",
"     Cohen EEW et al. Docetaxel Based Chemoradiotherapy Plus or Minus Indicution Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE). J Clin Oncol 2012; (suppl: abstract #5500).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/9\">",
"      Haddad R, O'Neill A, Rabinowitz G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/10\">",
"      Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/11\">",
"      Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/12\">",
"      Michal SA, Adelstein DJ, Rybicki LA, et al. Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head Neck 2012; 34:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/13\">",
"      Rooney M, Kish J, Jacobs J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985; 55:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/14\">",
"      Hitt R, L&oacute;pez-Pousa A, Mart&iacute;nez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/15\">",
"      Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/16\">",
"      Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/17\">",
"      Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92.",
"     </a>",
"    </li>",
"    <li>",
"     Forastiere AA, Maor M, Weber RS, et al. Long-term results of Intergroug RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy (abstract). J Clin Oncol 2006; 24:284s. (Abstract available online at www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD, accessed August 23, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/19\">",
"      Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/20\">",
"      Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome (abstract #5507). J Clin Oncol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/21\">",
"      Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997; 43:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/22\">",
"      Bachaud JM, Cohen-Jonathan E, Alzieu C, et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys 1996; 36:999.",
"     </a>",
"    </li>",
"    <li>",
"     Limaye SA, Nissel-Horowitz S, Caramalis A, et al. Concurrent chemoradiotherapy with weekly platinum for patients with unresectable/locally advanced SCCHN and comorbidities. J Clin Oncol 2008; 26:17033. (Available online at file://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=34222, accessed April 15, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/24\">",
"      Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/25\">",
"      Traynor AM, Richards GM, Hartig GK, et al. Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: the University of Wisconsin experience. Head Neck 2010; 32:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/26\">",
"      Newlin HE, Amdur RJ, Riggs CE, et al. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. Cancer 2010; 116:4533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/27\">",
"      Sharma A, Mohanti BK, Thakar A, et al. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial. Ann Oncol 2010; 21:2272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/28\">",
"      Fountzilas G, Ciuleanu E, Dafni U, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 2004; 21:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/29\">",
"      Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/30\">",
"      Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/31\">",
"      Douple EB, Richmond RC, O'Hara JA, Coughlin CT. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985; 12 Suppl A:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/32\">",
"      Yang LX, Douple E, Wang HJ. Irradiation-enhanced binding of carboplatin to DNA. Int J Radiat Biol 1995; 68:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/33\">",
"      Posner MR, Norris CM, Wirth LJ, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 2009; 20:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/34\">",
"      Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/35\">",
"      Haddad R, Sonis S, Posner M, et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 2009; 115:4514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/36\">",
"      Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 2007; 43:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/37\">",
"      Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53:3579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/38\">",
"      Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/39\">",
"      Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/40\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/41\">",
"      Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/42\">",
"      Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/43\">",
"      Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/44\">",
"      O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/45\">",
"      Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 2011; 98:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/46\">",
"      Ang KK, et AL. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (abstract #5500). J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     Giralt J, et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012; (suppl abstract #5502).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/48\">",
"      Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. J Clin Oncol 2013; 31:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/49\">",
"      Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 75:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/50\">",
"      Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/51\">",
"      Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012; 13:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/52\">",
"      Wyatt RM, Jones BJ, Dale RG. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. Br J Radiol 2008; 81:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/53\">",
"      El Sharouni SY, Kal HB, Battermann JJ. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 2003; 89:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/54\">",
"      Wyatt RM, Beddoe AH, Dale RG. The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol 2003; 48:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/55\">",
"      Sher DJ, Posner MR, Tishler RB, et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys 2011; 81:e813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/56\">",
"      Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003; 129:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/57\">",
"      Richey LM, Shores CG, George J, et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 2007; 136:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/58\">",
"      Zb&auml;ren P, Nuyens M, Curschmann J, Stauffer E. Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 2007; 29:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/59\">",
"      Lee SC, Shores CG, Weissler MC. Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg 2008; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/60\">",
"      Porceddu SV, Pryor DI, Burmeister E, et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/61\">",
"      Ong SC, Sch&ouml;der H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008; 49:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/62\">",
"      Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope 2007; 117:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/63\">",
"      Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/64\">",
"      Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/65\">",
"      Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/15/29946/abstract/66\">",
"      Tulunay-Ugur OE, McClinton C, Young Z, et al. Functional outcomes of chemoradiation in patients with head and neck cancer. Otolaryngol Head Neck Surg 2013; 148:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3392 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29946=[""].join("\n");
var outline_f29_15_29946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H281028114\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281026240\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1049946212\">",
"      SELECTION OF AN ORGAN-SPARING TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281026294\">",
"      Rationale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281026429\">",
"      Definitive locoregional therapy alone vs chemotherapy plus definitive locoregional therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1049946399\">",
"      Sequential versus concurrent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1049946406\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281026585\">",
"      CHEMOTHERAPY REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281026593\">",
"      Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281027161\">",
"      Concurrent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281026895\">",
"      - Cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281026902\">",
"      - Carboplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281027372\">",
"      - Epidermal growth factor inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H168427307\">",
"      Cetuximab alone plus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H168427314\">",
"      Cetuximab plus cisplatin plus RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H175776412\">",
"      Panitumumab plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H175776446\">",
"      Erlotinib plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281027704\">",
"      RADIATION THERAPY PLANNING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281027844\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281027852\">",
"      RT treatment plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281027860\">",
"      RT schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281027712\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281027720\">",
"      - Interval between induction chemotherapy and RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281027727\">",
"      - RT delivery time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281028065\">",
"      ROLE OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281028072\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281028079\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281028086\">",
"      COMPLICATIONS AND SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H281028520\">",
"      Prevention of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281028093\">",
"      - Granulocyte colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281028100\">",
"      - Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H281028543\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702831617\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281028107\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281028114\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/58/27566\" title=\"table 3\">",
"      Modified NCI CTCAE v4 grading radiation dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/50/13100\" title=\"table 4\">",
"      Risks and benefits of enteral feeding tubes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28649?source=related_link\">",
"      Methods to overcome radiation resistance in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/3/8250?source=related_link\">",
"      Treatment of early and locoregionally advanced nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/45/41689?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1321?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oral cavity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15224?source=related_link\">",
"      Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25473?source=related_link\">",
"      Treatment protocols for squamous cell carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_15_29947="WHO Classification of anovulation";
var content_f29_15_29947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    World Health Organization classification of anovulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        WHO class 1: Hypogonadotropic hypogonadal anovulation (hypothalamic amenorrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These women have low or low-normal serum follicle-stimulating hormone (FSH) concentrations and low serum estradiol concentrations due to decreased hypothalamic secretion of gonadotropin-releasing hormone (GnRH) or pituitary unresponsiveness to GnRH.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        WHO class 2: Normogonadotropic normoestrogenic anovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These women may secrete normal amounts of gonadotropins and estrogens. However, FSH secretion during the follicular phase of the cycle is subnormal. This group includes women with polycystic ovary syndrome (PCOS). Some ovulate occasionally, especially those with oligomenorrhea.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        WHO class 3: Hypergonadotropic hypoestrogenic anovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The primary causes are premature ovarian failure (absence of ovarian follicles due to early menopause) and ovarian resistance (follicular form).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hyperprolactinemic anovulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        These women are anovulatory because hyperprolactinemia inhibits gonadotropin and therefore estrogen secretion; they may have regular anovulatory cycles, but most have oligomenorrhea or amenorrhea. Their serum gonadotropin concentrations are usually normal.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29947=[""].join("\n");
var outline_f29_15_29947=null;
var title_f29_15_29948="Antithrombotic Rx in MVP";
var content_f29_15_29948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Antithrombotic therapy in symptomatic patients with mitral valve prolapse (MVP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that antithrombotic therapy with aspirin or warfarin is indicated in patients with MVP in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Aspirin (75 to 325 mg/day) for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Cerebral transient ischemic attacks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. In patients under age 65 for atrial fibrillation in the absence of mitral regurgitation, hypertension, or heart failure, all of which are risk factors for thromboembolism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Warfarin for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Atrial fibrillation in patients &ge;65 years of age or those with a murmur of mitral regurgitation, hypertension, or a history of heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. In patients with a history of stroke who have mitral regurgitation, atrial fibrillation, or left atrial thrombus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of aspirin or warfarin in patients with MVP in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Aspirin (75 to 325 mg/day) for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. A history of stroke in the absence of mitral regurgitation, atrial fibrillation, left atrial thrombus, or, on echocardiography, thickening (&ge;5 mm) or redundancy of the mitral valve leaflets.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. A history of stroke if there are contraindications to warfarin therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Warfarin for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. A history of stroke in the absence of mitral regurgitation, atrial fibrillation, or left atrial thrombus if echocardiography shows thickening (&ge;5 mm) and/or redundancy of the mitral valve leaflets.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Cerebral transient ischemic attacks despite aspirin therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of aspirin in patients with MS in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Aspirin (75 to 325 mg/day) in patients in sinus rhythm who have high risk findings of mitral valve prolapse on echocardiography.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29948=[""].join("\n");
var outline_f29_15_29948=null;
var title_f29_15_29949="Age-specific odds ratios for suicidal ideation and behavior";
var content_f29_15_29949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F63706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F63706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Age-specific odds ratios for suicidal ideation and behavior",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 472px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Odds ratios &gt;1.0 indicate that the risk of suicidality while receiving antidepressants is elevated relative to placebo; odds ratios &lt;1.0 indicate a protective effect of antidepressants.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the American Journal of Psychiatry (Copyright &copy; 2007). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29949=[""].join("\n");
var outline_f29_15_29949=null;
var title_f29_15_29950="Gram stain CSF 1";
var content_f29_15_29950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain CSF 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDhVkxViNifeqyoT1FTx8Y7V8PI+oLMZNWoiCeetV1IwCKfE7bzlQMHjnqKxYy+hGB/KnkjbVFLkCQqR9KuIdyg4rKUbDTuPRuamBzxUUac5qVRzms2MehA4pwxnmmKpzzUm33/AEqWAoOQadgGgKOMD8akxgc9agZF1UccilxkCpAuORyDSgdcCgRGq0EfN7UqtltvenEZ7UBcUYCgd/WpByen0qMLn3qReKGA4YwaaYwTuzT15NG2pWg9x4ABFOUHO0Dg9T6VleJNVXRNFuL90LiFc7QetQ+CvEA8RaWL3yvKySNpOav2U3T9rb3b2+Ycy5uS+u5vovOefzp792zyBTMnGevPQVV1GVljZFBDHvWFrmkFd2OM1qe6udUkWP5McDBrOaxljm/0gkk9wa1irNdMWGSDV0WhlGWB6V6irezSSPWi4xRU0OxJvFdpHKD3rtAFeMKQCBzzXOW0bWatICduKptrU9vdxu7gQk8g1zVIzryvE5alP2mqOuIOBgHNWYlATknI96ZDJHcRJJEQysM5FTMBt+lcd7nFJOOhXnfIUDkd6o+Zucc/Lmrsy5GB3qBIc84qlYm5JB8zHPBFTlFI4zzTo4wgzinsvTipuFyr5fzsxJ5GMU0oRjPWrGMAdqbtz+dUmK5ERxzUcnA3KpOOlTheoJprL0p3FcgKbgNy/gTTdvOelTMo96QjtzTuFyHbkimsvP0qVjk4HahhQmBTkXd1GQfxpoTrxx2qyV6Co5EO3iruK5C6FULDk1GY8nI7dasBWUdf/rUnGdufm6mmmMr+XRU+0en6UU+ZgcYOuaeMk05F7mnha9BsgWMEd6nQY7k1EOAafECW5qJDTJ0Vc5wMmrMTE9iPrUK5zxU4yeDjNYsomRueOtToQTVVCanGFNZNAWE4Ip5qEHJFPdhtyc8HORU2FclHNOA4qOKVGJwecVLuHAqWAnOO9Ko7E0qc80o9x+NAXG7BndSkYqQZPPpQUz65FILjFGTTiMMOKEwM+tPIPGeaGFxAOvFPA4Hc0gAyKdt5znFIZyvxPa4/4RC7S1j8x2wCNueM81H8L4pIvCtqJYjFJjkYx3rr3jEqlXGR7063hCLhQBj0rf6x/s/sLdb3Gvi579LDoxwQK5rUdbjtbx7a8yCT8pxXVIMNjHBry/4ks1trUMjDMZHHtSwlKNar7OR2YWKk9To1e3mUGDhjyfepzPtChTz3rg7O/LBShK54rZs528whjketdVTCOO7PRnh+x0moSxixIBycVwmqz7lwTgjtXSSzYXa3KsaZF4VXUJfOMhEZ9KMPKFDWoyY2prU6LwPdedokYIOV4zXRHkHuKp6VYx2NqkEQ4Wr+3GK8yo1KbktmeVXkpS0K7Jz+HNY2t+I9N0Jok1CYRmQ4XNdDt5PPNcf4+8DweKYUcs0dzEPkYVpQVJ1Eq7aj1sYvmafJv5nS2l1DdQJLbyK6OMgip8n2xXg1h/wk/hLWrfTZIZJrPzAqcZGM9QR0r3HTTI9tE03DEA4rbF4P6s04yUovZoSnz30aa7ksikj3+lBHGT25qQr1FRlecVyokZwRmkzngUpXHFI6lRx6UwuNfOeB9aj53nPSpckYpMcdMc0gIsdelIASeOBUvVsYPTOe1IR0ApgQvwajd0RSWOKsuuee9Z0tizybmcnnOKuNnuxN9ickED0qMjB9KmVcKKRhkfN9BQBHn/OKKXb7UUFXOLTqM1OB6VCAamTLDFeiyB3bBp6fSmquKnRDmobGSLjipFbnpTdv1yaeqYJyDis2MkTrUw5qJRyPSpVyfoazYDlz17VOuCOeexqED0qaPg1LEAiVWyo5p4PzCnZwRxSMQPmbgDk0guKEkM8bLJtjUEMmAd3pz7VZYCol6ZpwbJwRipYDwoOOTS9jTOvT9aUHApAKmQeelSH1qE8inbwTtPWhjTHAdOaeccVGGAHvTkOTk1I7kqkEn0qT8cGokYCkJDDDdKAuTqT3Ncp8Q9Am1exiktF3SxZyoHJrqIgAAFqZXIOadOpKlNVIbo1pVfZu54zBYXFtabLiFo3T1WrGnqSCxc4FeqX+nW9+m2Ve3WuFfw3Pb6o0Ubgwk5FenTx0aqfPoz2KeMjNCWsctyECqc+tdnpFsYI1Rmzx1qCzsY7eMKAN4HU1dilEZAfArzq1X2mi2OHEVXPSJoqMHjmnHkfj0qCCYPyvSph69D1rA4XoKF5NNkDMMKdtPycZ70A57c0CuQvbxSEGRFZgOCwzSxKFT3zUvvxSHheKLA5N6MQNg8ioyn7zPYjrUh6E0owcZqkRciZOc4/SmlfyqV22qTzioreVZ1JThc45p20uF9RpXqcU3acdKmAXvgc8ZNDrgcjjFIdyvtNLt/CptvyjH400gd/xouBCw5PXFRNz04qdx8vAqErxjgkdDVIRGeOCetMcEgbTUhAJ6c+tAXbVDItvuaKm+X1opAcOi881V1nUU0qwluXUsEGcDvV6JSyZzSXVjHdWzxTKHUjGCM16UXFSXPsFrozfDutQ6za/aIl2nOCp6it+LI6iuH8N+GbzSdfmlWT/AENgcIO/4V3sa9+lXi4041P3TumTT5uVc61JETJzUqpSRj/9VTID9K4mU2Rbcdaeik/WnmPI6U9Y+BUthcRFyMGpUTB4pVjOcdMU9Vx1qWxCMOOacF604Lx0qRVIOM1IDGXHNIq4Ge9T7R1OeKAo6UrjREAexp3tmnqBzxQFyaLgRgcmkKAuDzkVMFz9KCvJ70XAjIB59KTotS7RimOvalcYmeM4JNSD9KjHDDIqwASBgUMEKBxmlQluxFCrxingHJxx9aljEAwPeopEBwxAyO9WcZ4HNJKvyZx0qbjiZ8vzcZ5AriPEutzWN55f8OeDXWareR2asztg+prybxLqgvLqTAJAOQc16OXYf2s7tXR62GpLl5pHoXhPXluXWJ3yTyDXaq+QOleC6BftBcKWYjuK9g8O34vbNHJ5HB5qcwwvsJ80dmZ4zDpLnibYzjjpS7uTxzTOOOKcOlcJ5Q/qMUFu1M6exo6getFhDiR608Y2571GR2zzSAEDGadiQOdw9O9KoAHy4BqPJLYqTqPSgAU9yB7UpYYphBHA6HrSOSOMdaQxwphAJ5py8r0+tIw544pDuROpGe9Rspxxj8anPtUZHpVoRAF9OoppHJBqbBzkGmgYNMZFn3oqX5vUflRTA4yIDg9vSrCDn+VV4m5qwp+ldjBEoXnGPxqaNfWogfXpU6MCKzYDlXmp1wKiVuanTtzUMA3YqVeRUe0FulSAACpYh68HrTiATUSA7jk5yePapgKlgSKAetPI4461GvBz2qTOKkYFT7U0qelPUnilHHXPNAxAOnHNB6YpwwTSMCeaQB0FA6GlxgDigjjimA0nkZoAFKcdMZpw7AUgGhealGOPem7Mj3pwB7AmgY8Dmnhc/wA6aB8vHWnjqOOlQxjtuBkVVvmaOLJOFNXeOBk/jTLmBZ4yCPwpXtuVHVo8r8U3ryyyIXBQZxXA3TDLc8muj8YW7w6pMpLKAx4rmQjMxwM19bgYRjTTR9E9KaikS2TCNgzHNex+BYVbSVkGMNzxXnnhTw5JqF2hIIh75r2LTbKKytEggGEUYFebm+IhK1OL1OTF1OSkoPctqo4IP507qR9Kci5P4UFa8U8RsTr9KbjPIJ6fjUiDFI/QgUySJVIYEkHinE4BOPypM8gDOakAAIPemIYmD2waeR83tTwCeeKYDz1zSAQ8njikYBj0px4UZoYfKD2pDGDjoKa45zTx8o+tI/TmgCM9PamdM56U8HnjpSOBVAMK9z1phCnIqTbx1NNIxyetMBu1fSil49aKYWODjft6VZiPTmqcdWIzkj0rvkhlsHCknpU0bADPUVXQ1KhFZsCyOcVOpwPeqyMKf1zjrWbQFiNievWplIwQO1VYXx9TU6ketQ0InVh+FODEfjUSnipFx3OTUgSK4HWpM5H1qEHHFOUgdakY7k4zSluRSE96QHn/AAoBDyfmHFOyDUbOqH5jSnDjpn60WC5J1AJpGPHf600NwMmpDg9aQDU54qUDHNNAx0FSL06UgBRzg09RycdKEAJHqakAGOfwoGNAI5pyr3J4pqswkwwG0dDShTIFAJAqChJWxxVLW9Zi0qwkmfG4L8qnjJqr4l12x0MQrelw0p2oEXNeW+KNak1PUCu8mLoB7V14XBzxEldWiduDoxqP0I21Ntb1N2nQDJ4NdNpHg+JHWa6KlW/hFZ3hvTIZcSFQqrg59a73SLmKRmiZgSvTNdmNxDp+5R0S3PSxFWdKHLEsadY29nH5dsgVV9BV7zDjgAkdqkKogz0BGKjjjQzbuteSnfVnhVJym7yJkbC7j3HegkkDmop1ZxtjO33qRFKoM4LetMyJFOSKRh7ZNAPrSg5PGKQhpXnoaXoOhpxPOBTU4fvTEUl1aB7gwAOsnuOKvFd3IpZI4mIcohYfxbeaQNxjmhtPYQmCAOvvRu4xih2AHH6UmQBzSGBx6U0gHjpz3p4xntTeNxwCPelcZGwyeCKbtOfX1qQ47U3IzVXEBHHNMYqOuMetSE4GO1QsQCQ2MU0AuP8AaFFN3H+8aKqwXOAUc471YTgYquvXmpA2K9BjLSsDT1ODweaqqxxweD3qRTjOKiwXLaGpgeKqRn5ql8zGBnrUNDLSe/WpckpgdaqRSAsParKEf/qqGhMlhJCjd1qZW5wRVcPzzUgb8qhiLOfaml/mqIyfKKCVYYYZz1pWC5YLfL7dabuzwOlR7sDFCHp15osBI4WQ7Xxkc4qVT1xnioRwvv605WwKQyYfjmlLYGV61Fu/Cnqc0rAInmCXOflPb0q2p79KrlgPehXLcA4FJ6gkXA23oM09MsuaW2jyR0NWHiIHTFSwuRhA3WnqAOlMwQevFOQnHvUlFXVrSK7tZIniSR9hKZGcH2rwa7sprW9kNwhGw9K+hQQTnAzXmfxSRIQ0gRQWHYV35bWdOr7P+Y9PL6qTsznbTWSIUigGNvBApklxdfaRKjsp9jXLW11tOQcGt7Trl7sBFXPbivbqYdU7ySPWvCorndaFrM1zEkLyFmHrXT6Ve/aBKCrKYjtOe9cz4Q0tkczSgg+hFdlFGqjCqBnrjvXz2IdPncYo+fxaip+6SK2fu9TVLWNVtNIshPeyEBm2qB3NXQQBmuP+IfhmfxNYRwW9yYWRtw4yKijGEqiVR2j1ZyataK7OuSZZI43Q7lkUMvrg0bwg+YjFeXeGfDPijSddikuNUkuLIDaVZicj6dq9B1NpEjEgyQvLADtV1qMac1GE1JPqhO9rtWNPO455p4yDkdKp2Fyl1bpNGGCsM4YYNWSwxisGraCHEjnPrTCPmBz+VI/3CM49KTOEGTmkA/gZA7Ugf3FNJ4681DKGZQFfafWiwFndyCKY7YHvTAzCPB6imsc+v40JDHZ6UikZ459qbzng0gOT6YNVYSH5JNMY7uMfnRnOeaZnaOaEhi7j6UUZFFMDhO2OKdjgCgLxzTsYNegxigcU5cmjuMCpF6elK4hycmne7HGKReBxzUmBjis2ULECDxVqM4bFQIBU8a81DESn0p6HnnjFIAcjJp+OcZqBCNxyelQRXtvLK0UUyNIvVQeR+FWHXIKnvXlWueDdV0nU5tZ0SdpHVjIEP3ueo9xXRhqNOs3Gc+V9OzYpOSV4q56v8xxntT+Ac+vauB+HvinU9XmnttUtwrRYw4Urz6GpPiB4p1Dw9Nbm0t0eFj87OD+VP6lV9v8AV9Ob1Dmjye06Hdj60uQvFYPhrXotdsEubXJzwwI6H0rcVcnJ6iuaUJU5OMlZoppWuhWLHlelPTJ60DBNSKvHSpYrjo1A+hqzFD6jioo1PsKsxPt4NQBNE2w/LxVoSgrzjNZ8XVstkZz9Kmz83FK4rEpYZwM0wEg0vOetIx5461JQ/PpxXP8AjfQxrGjSLAn+kKMD3rfGcc9KBlSSDxTjKUJKcd0aUqnI7nzrN4YvrRnE4ChT1PSu58I6FJYCN3QPvwfwr0a6s4bpGSaJXRhyGHWlt7aOKIRoAqKMAe1ehXzOrXhySR1vFRjG0FYitYlUYAwDT3Zg+BjBqcJjoMCo3ALZHX1FecjhlLmd2MlyqDYOay/EVzc2mnSy2a7pVGQDWo5YEHGa5/xv4jsvDultJefO8gISPHLGtKUZTnGMVdvoEXGL5pPQz/BXi+HXIZY2JF3AcSKP6V1qkyYPbGa82+E1hYXH2rVraKSKSdslGOQOe1emheK3xtOnSryhTVkhXbim/wABAcA+lKTkDFKB+NIoOetcqJYj8j0NNJ4p79evFMIBGO1MQpfg1HuBPWnFcLjHXmmbQB9PSiw7jmY49qbux0oJ465pDnpRYBd3PvTQ3zY5/wAKaQcnPahQR3GTVCJGb16+gFMxnk5z6UpBpuCOOc+tIYv50UbVopgccoyPenhc4z0pqDkY6VMF6mu1gN21IAOlKq04DipbGR7TmpUH6U9Rk0oXkVLYxyLg1YjHNRKDgVJwrE5PI/CoYD9yhuvzemafvH41i3mpwwzeWCDIxoW/AdQx5PSn7OVr2LdJpXZt5zgk04MCMEcVShkZxyauxqCORkVm0Q04siW2jSQmONVJ6kDGaj1TSbXU7Uw3kKSIeuRmr6AdD0p5XgdqSk07p6j52Zmi6PaaTAILKIRpknArTVeOlIPrUqDOMjpQ5OT5pO7JbuRMmDkVOq5HqKcQM47Uv3R1qWxCoB37VIADznFNFPGB1qRjiuT8hA9alAIpqgYHHNODdaLiJOuOaCPzqPnd7GpR7jk1LGJ1AoxjA6mlHWlAy3TmkA3bkkHrTD0walzlzxmhk4BPemAw88d6jI2njFSAeppcAnkUCIcDGaxfEnhyw1+JE1CJZAhyua3to9selIFBYAdBTjOUHzRdmO5m6bp0Gn2ywWsSxoowAoxV1AQCCcn1p+0qeetAA57mk23qwbuMxzwaQlgc7R1p6r6d6TackcYpokikY46UicDpx6VNtHemYHQUwGNycgdKbuBHTrUhHHpTHGBnHAoAZjr1oAwTntUmOKYepoAaRk9KMYPt3pCNv1p+3I+tMBpGT7UYB461XuYZvNV4n2qPvCrA4Hem1ZAmJtPp+lFSZ96Km5RxyLzzUqYPeoyMihUJI55z2ruYkWAOgxUiLweBSKufqKlXg8Vm2MRUx1pVTHJ6GnjP1FP6EdKm4XE24HsKo6pIYoSfWtB5FQZOAKzdZliNozsw2gZpxXvI1oWc0jjr12aYOTjFaFnqMQRFc5cVx13qLSyuqkqman06barE5Y9ia9yeFvD3j3HSjONj02ynWUDYeMVsQ8rmuJ8OXTyOFIK8V2tscjn0rw68PZy5Tx8TT5JEo6jinEbl70oWnKOxFYs5RqDANPTqOaCORjGKft4HNK4w75zTCG3dePrUuOfY+1AXC0XEAzingkDkdKaB82OgqQD8qQx27I471ICSP51EvTAp68rSAdkCpVYEAjPFREdM9KcowoGDUgSqw696bHwxzTTx0ppJA5NCQXLG4duooJz1qsjfMPrU5YHpQAoUZ6kg0hHp1pBnBxTd+XxjmkArNjAOPpR97nvSE9cmgdOuaADgnimLxn3pc4/rQcdOwoEABIpORn1p2cdajxk5HSmhDwDWfcXJjkCJ13cj1q8zEng4qLYC25lGRVRaW5LTew7BIBx17U11JyB9KkduOBUIZt3IoKHBeB9aTbhhinA8HIqNjg5oAVgGpCDkDmhSPSl6DimCGnByOaRwAOtSNjHHFMOOMnJpDI8D+8350VLhfX+VFO47HHoDjPepRxg1GnvUgUHFdjEiaPrx171Kv0piKB0qZR2rNsBeo6U4AkAHGaFxinr1zUXAgu7dpkwjbSK57xMClosW7B7+9daThTjNef8Aim4kF06k/LnAFdGFTnUS7HXgo3qXOXmtkwXcrirNiIVUZwKZPGkoXJwO4qe0tVuJlVPurxXuSl7urPfbsjovD8fm3AMZ+UV3NsNqjPNYGgaaLaJXVcZro06V8/iZqc7o8DF1OedkPBGelPbJjJU81yPjLxhF4aEQe3eZpCQMVzF78RNYM8A0/SH8uQA5dTk59K0pYCvWipxWj6to4+eMXZs6KbxFJb+Jo7CQgbuQCa7aM7kBPcZFcBb+E/7U12DXLoyJMoH7vPGf8mu+QbUVewFZYn2S5VT3tr6m077NEh4wAKfjjtSZHGRRuG3nvXMZXFI5GDz1p2SOOtRseaTd83HNAE2fzFLnimEj8aOOnegCUNu+lO3kDA61CcY96C9SMl3HAo6n2qHfnntShsjg0WES8Lz3pwYA+1RFvfihjtAp2uDJvM5PFIWHHBqLd60uemOlIBx65/SgsAabuz64pBhue9AEmTmq93eRWuPOyM96nyc1Vv7SK9i8uUHB96cbX97YmTdtCZJUljDo2VPQiqsWq2cl21rHcxtcL1QMMip4IUtrdYkUlFGK8b8d6Dd+HfEttrmixzSyyylpE6gH/A11YTDwxE3TcrPp6+ZMpSjG9r9/+Aezl23cYxSk5rE0/XLe5jgjnljju2QExE8g1rKxAGa5nFx0kaSjZkmStM+tIGJ6U1jyBQSOPWlZQTk4Apuc9MfSomdi23bxQkGxMcHPPFIWx0pM8e1A5xkcUAOPU9D70w45I6/yp+DnI7UwL8x6c0DQ3yn/AOeh/IUU/wCf3op3HY5FM5qZO1V1bmpk5HSutiRbjIFSLUEedvOalVeRyayYx46g1KuD3pmOKeg/OpYiRsgda4LxPbkXLuwPJ4rvscjJrn/F0C/ZFkCEkHsK3ws+SojqwdTkqK/U86dGL9DXQ+FNLkuZ97grGpz9arWVo17dxwoAATzmvRbG1S0t1SNQABXfjMVyx5Fuz0cXieSPKtyeJBHGFHGKcp5wDQKjKuLgEH5D7V5CPDb1C50+1vNv2qCOXbyN6g4NTx2sCgARIMdPlHFSDmpAMVLbta5Sm0IAAAKkHHbrURBz/SlyfwpWE2SMxppYEgfrUZJHIpN3FAEpbGB+tKp5zUO7jNOjbIznn0oGS596cGzUQ9DTxwKAB26Ugfnpml5amkENSAeCCM4xQrYOB1zTQMZoIx0HIoFcf/F1PPenE5A56UmOlBHGR3oAUc9D9adnHQ5NIABgcUYzxSAO3Jp2DjFJj2pcYz1pABJ/CgHj/GjGcgdO1IQRQAE+tMlRJFxIob6inHPGRxTcdcHinYE7bHlPjPwPqE/iSPVNLuCm5l3DkFcelem2u4W8YkOW2jNSuDjBORVK6vUtUzK2FFdNXEVK8YQnry6IcIJt8q1ZdLAY5pN35Vl2eow3ZYxODg1d35rBq2jKlTlHcnHB68UkmSODg1UkvEjbaepqeGZZGI3ZbHSjVEcrsT5z0604EDv17VESAePWmGQl/rQtRFouMe9MLbQWbtTFPPWorskRORycUhpXdhn2+H1NFY2Z/wC7RV8kTp9lLuUoyM81MjfN3FQKfSpo29ua6WcpaTkc1MgNV0IBAzVhT71kxkuOxpdwQFmpqt70pUOMNnmpAbZ3aXIJjzgHBzU80YkiKsOPeoFt1Vg0fy47Cq3iDUE07TZZJHCcHDE45o5eaSUOpULtnBa74qtNC8QJb2kPmvkeYf7ua9Gs5zcQJIcgOAcV4t4G8P3Os+ITf3g8y3Rixdud57V7ZCoTCoMADFejmdOlRcKUNZJasUalSpFzqfL0LC8in+3amqec07ocV5ZI4KN2QTmnk4PHNRtwwoY5HWgCO6l8mEvtJPtSQXHmRhj3FG0quGO6mhQOAMU9LBrckDZ5JpQxz1poGO1KDzSAfnpinhuM1Dux34p45xzxSGSq2RyalUjoelV1IC8VKD8ue9IBSWGNoxQhZmO5cAHg1nWWqi41K5tDBIjQgZdhw30rTyPSiScXZoN9RARjHpQAc0cdRS9+tIQvzYP6U5fcUmcHrS8kdeTRcB4C5BI56A04Lhs+tNUcdak4ABzzSuAbflJximkY56n60pb1pu7gjmkMdt4pp/lQxx170vGM0CGAZzz1pNhByakxSHIOSDjrTuI5XxP4y0jw9OtvfSuJm5CqpJA9a5bxnra3dhFLYSB4nXJPQ11viXwdpfiGZLq7hzKBwcEHHvXl3jHTn0q48qPIgAwB2r2Mvp4apKHLfnW99vkelgI6ynK1lt3INA1G4t71Wjc4J5FehDxLGkBLH5xxzXmWhrILgFFzkVsXttO7qXjZPbFd+Lw1OrUXMeoqUJwTktTR1jxNcdY9pJ/SrfhLxLM8zLKVkcjoOtcw2l3F1OqRBufUV0/hjw2tlfrLcb9w9uKxr08NTouL3Mq0IJPTQ761uTchSFINWfLOc0+FFUAIBinkZPoK+f5ux4c7X0Ij3GKjmDOp2nipynoc03aeDTuSjJ8qb/nm/wCdFa2P9pqKq5p7VnHxk4OamVhuAxyarxnHGamXmuxmJZjPTpzU24KCTkgAk4qCPip0OeRWTGRabfpfRu6I6BGwc1eRh+NQrjGB09uKeOD71MrN6ATIxAP9a80+L91NcLZ6fbsC0jksoPJ9K9HdsKe/FeK+IdP1G98eljDIUMqlGxwFGO9ejlNOLr+0k7cqbM6l+SyV76aHpfgPSv7I8PxROP3h+Zj7mulTpgcVRgBWJF9BVxCRivOqzdSbqS3ZtOy91bImUcDNPB/KoN5yOlPVqzsZkg6jBoDcnnFNyKhfqMc0WBEznJ9c00fqKZnHQ9KUGlYbHg4zzS59+tRluKQHnFOwEpPFEb5HTFR8+tIH54xSSAsg4p6scAg1XB3A571KOAMUWAmUDJbHPrS7uOKYOmB1p3GcVNguKr55HGKcD7cU3ilHA5NFhXHjJA5pc/NjvQp5pV4pAPXjrT2OBzTdxAJ/nUUjng9qQx2eM5prOahZzmkB5wTiiwFkPljmkLDnPSoScH2pGbIxRYRcSQFfU05T8vvVRXxgcc1MH4A70WAfknGa8/8Aifai4gXywCQvI/Gu3mysWxCc4wCTXhviabxNo+pySasPMsJZPvdQFz+lehltB1KylGSTXR9fQ6MPiI0Jc0k2utuhL4PljS8ELr83oa9QuNPiuI0IjB464rmdB8I287wajDcB4nAZdp9a9AjRUVVHQVWY4iNSqpU36nficTZJRZm2elW8ZDmMbxVqYIpHyjIq3kKhY549OTVS6BbnBHfB61593J3Z5s6spvVkkUoJxmpg+4nJrKVipPB5q1GzAcd+abiZlsn0FNG4Ag8D0pgkx1pu4HvilYZJg+v60VH8v+TRTsK5xiPyKsI4xVRRzVhD0rvkhFxHqZZMZqopye3SpB1+lZNAWUk9Kd5n+c1BGe/rT8jOT1qbDZYLZU1W+zxl9+1d3rinqW3YPSg+3X0pDUnHYmTGAMVKrenNQKcjI6U6PCj2pWJbuS7vbFLk55qMMcn0oZ8YzzSsImLYHBpN+TzUe7NKvNKwx5bvSqfWom56dKcrg/LnmiwEgPajjjmm9D2pM/5FKwCs35UKvz5A7UgHBp4bn1FAXJFPPHFTAjA5qBc46cmng45NFhXJSwxmlVsDrnFQOS3Q4xSq2frU2BlhXyM9fpTiegFQA/LijPaiwizu6np6UqsOOTn1qDccYB+tLvwQM0rDuWCeOtVbkyEAxY4POaeZCcd89zUbEkegoWgMcpBxnrSscmq6lgxOakZieQaGgJgT0zTS2ODnmog7ADJpd5Y5FFgJlINSK+CfWqynB4qTdkZ7UWEPc5IzXPePtIbWvDF1awjM5AKfUHNbxaonuY1uI4GOJJASox1x1q6cpU5qcd1qF9Gn1OW+GVnqGnaAtpqS7XQ/KM9BXYAnFQ9D6fSpFOADTrVHVqSqPdlKySS6D1YYOajYq+R1NKWyOelNUjP3cfWskDIDGA3XmkZSVwGwanciqxkOScdOvvVoQ9d3QnNLkgHAH0NRLKOuD+NJKWeNhH9/tk4FFhj98vrF+tFYfla7/fs//HqK29l5oVz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29950=[""].join("\n");
var outline_f29_15_29950=null;
var title_f29_15_29951="Epistaxis management algorithm";
var content_f29_15_29951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Flow diagram for management of epistaxis in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 557px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ENT: ears, nose, and throat.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_15_29951=[""].join("\n");
var outline_f29_15_29951=null;
